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The gastro-intestinal tract is the commonest site of internal malignancy and also 
susceptible to the chronic inflammatory bowel diseases, Crohn’s disease and 
ulcerative colitis. The intestinal epithelium represents a complex, immunologically 
active, barrier to the large number of antigens present in the gut. Intestinal epithelial 
cells can present antigens, take part in the sophisticated regulation of intestinal 
inflammation, as well as potentially undergoing malignant change.
Cyclo-oxygenase (COX) is the enzyme which synthesises prostaglandins and 
thromboxanes and COX-2 is its inducible isoform. COX-2 is up-regulated in the 
inflammatory bowel diseases as well as in the majority of colorectal carcinomas. 
There is increasing evidence that COX inhibition protects against colorectal 
carcinoma, although the role of COX-2 in inflammatory bowel disease is less clear. 
COX-2 is known to be an important enzyme in the context of inflammation and 
oncogenesis and is highly regulated.
This thesis aimed to explore the induction of COX-2, and its regulation, in intestinal 
epithelial cells. In particular, it concentrated on the intra-cellular signalling 
pathways involved in its regulation. To pursue these aims HT-29 cells were used as 
an experimental model of intestinal epithelial cells with supportive work being 
performed in the Caco-2 cell line.
In intestinal epithelial cells, COX-2 was induced by the Thl pro-inflammatory 
cytokines TNFa and IL-1. Cytokine induced COX-2 expression could be complexly 
regulated at the level of mRNA transcription and stability, COX-2 protein 
production, as well as the generation of COX-2 dependent products such as PGE2 . It 
could be regulated by its products such as PGE2 as well as cyclopentenone 
prostaglandins which are PPARy agonists. It was also regulated by IFNy in opposing 
ways at the level of COX-2 mRNA compared to downstream protein and PGE2 
production. The Th2 cytokines IL-4 and IL-13 inhibited COX-2 expression 
consistently at all points.
TNFa and IL-1 a  activated the PI 3-Kinase signalling pathway in intestinal epithelial 
cells, as well as activating the three major MAP Kinases. PI 3-Kinase activation 
appeared to inhibit COX-2 expression although conflicting evidence was obtained 
using two different PI 3-Kinase inhibitors. It is proposed that PI 3-Kinase mediates 
the inhibitory actions of IL-4 and IL-13 on COX-2, as it is shown that these 
cytokines also activate PI 3-Kinase in this system. The cytokine induction of COX-2 
expression and activity appears to be dependent on ERK1/2 and p38 MAP Kinase 
activation by TNFa and IL-1 a. It is also demonstrated that TNFa and IL-1 a  can 
phosphorylate and inactivate GSK-3a/p and that this process is dependent on both PI 
3-Kinase and ERK1/2 MAP Kinase which act synergistically in this context.
This thesis demonstrates the sophisticated mechanisms involved in regulating COX- 
2 in the intestinal epithelium. It also highlights the importance of the PI 3-Kinase 
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1.1.1 The Normal Intestine
The gastrointestinal tract provides a major interface between the body and the 
environment. It represents the largest collection of immune cells in the body and is 
exposed to an extremely diverse array of antigens and pathogens to which it must 
respond appropriately. Not only must this immunological response be tightly 
controlled, but so too must the high levels of cell turnover present throughout the 
length of the gastrointestinal tract.
Progressing from proximal to distal in the gastrointestinal tract one goes from the 
mouth and pharynx through the oesophagus to the stomach. At the distal end of the 
stomach, the pylorus marks the beginning of the duodenum which is the first part of 
the small bowel or small intestine. This is followed by the jejunum and ileum with 
the ileocaecal valve marking the junction between the small and the large intestine or 
colon whose distal margin is the anal verge.
Moving from a macroscopic to a microscopic viewpoint, there is general pattern 
shared by the length of the intestine with specialised differences between each area. 
Starting from the lumen of the bowel there is an initial epithelial layer consisting of a
1
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monolayer of intestinal epithelial cells (IECs) and scattered intraepithelial 
lymphocytes (IELs) with the basement membrane beneath. These form a membrane 
which is impermeable to all but the smallest molecules. This epithelial layer is 
replaced in its entirety every three to five days. Below this is the lamina propria, 
containing stromal cells and occasional lymphocytes as well as a rich vascular and 
lymphatic network, and delineated by the muscularis mucosa. These components 
make up the intestinal mucosa and are arranged architecturally into villi and crypts in 
the small intestine as opposed to straight tubular glands in the colon (see Figure 1.1). 
Below the mucosal layer is the submucosa, followed by an inner circular and outer 
longitudinal muscle layer. Finally there is the loose connective tissue of the serosal 
surface. Throughout the intestine there are occasional distinct lymphoid aggregates 
in the lamina propria such as Peyer’s patches.
The immunological function of the intestine as a whole represents a highly 
sophisticated interplay between the large number of lymphocytes present and the 
intestinal epithelial cells. Indeed the normal intestinal mucosa can be said to be 
chronically inflamed, with this state of “physiological” inflammation being highly 
regulated (Dwinell and Kagnoff, 1999). The intestinal epithelial cells play an 
integral role within this process, being in a position to always be the first cells 
exposed to any lumenal component, and being able to generate and transmit 
numerous signals.
The repertoire of known intestinal epithelial cell (IEC) responses is large and 
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C: Rectal D: Colorectal carcinoma
Crohn’s Disease
Figure 1.1: Histology o f the intestine in health and disease 
Photomicrographs of the normal small (A) and large (B) intestine. C. Crohn’s 
disease of the rectal mucosa showing massive infiltration by inflammatory cells 
and a characteristic granuloma. D. An adenocarcinoma of the colon showing 
epithelial proliferation, disruption of the normal architecture and invasion into 
deeper tissue. From Functional Histology by Wheater, P R., Burkitt, H.G., 
Daniels, V.G. Churchill Livingstone
Introduction
• Secreted epithelial products: Stimulated IECs have been shown to secrete a 
wide variety of C-X-C chemokines (e.g.: IL-8 , GROa-y and ENA-78) and C-C 
chemokines (e.g.: MCP-1, M IP-la and RANTES). They are also capable of 
releasing other pro-inflammatory cytokines such as TNFa and IL-1, and this 
seems to be in preference to immunoregulatory cytokines such as IL-4 and IFNy 
implying a function in inducing rather than regulating an immune response (Jung 
et al., 1995; Yang eta l., 1997).
• Antigen presentation: IECs are capable of expressing MHC class II as well as 
class I molecules on their cell surface and have been shown to act as antigen 
presenting cells to T-cells in vitro (Hoang et al., 1992).
• Cell surface receptor expression: IECs have receptors to several pro- 
inflammatory (e.g.: TNFa and IL-1), immunoregulatory (e.g.: IFNy, IL-2, IL-4) 
and chemotactic cytokines expressed on their surface (Kolios et al., 1999).
• Cell adhesion molecule expression: Stimulated IECs can up-regulate ICAM-1 
which acts as a receptor for the p2 integrins expressed on PMNs and 
lymphocytes (Huang et al., 1996).
• Expression o f enzymes involved in the inflammatory response: Enzymes such 
as iNOS and COX-2 have been shown to be induced in inflammation and iNOS 
can be induced in IECs (Kolios et al., 1998). This work will concentrate on the 
induction and regulation of COX-2 by intestinal epithelial cells.
3
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1.1.2 Inflammatory Bowel Disease
The inflammatory bowel diseases, comprising Crohn’s Disease (CD) and Ulcerative 
Colitis (UC), are chronic relapsing and remitting conditions of the gastrointestinal 
tract. These conditions are predominantly diseases of the western world whose 
aetiology is unknown. However there is increasing evidence of a genetic component 
to host susceptibility, an environmental component most clearly seen as an important 
role of host intestinal microflora, and an aberrant or inappropriate immune response 
which may be intrinsically related to an associated gene defect (Fiocchi, 1998). 
Such an inappropriate immune response can have extra-intestinal manifestations 







Figure 1.2: Aetiologicalfactors in Inflammatory Bowel Disease
Representation of the genetic, environmental and immunological components to the 
aetiology of IBD. There is no one clear agent and there is likely to be a complex 
interaction between many different factors
Although the precise aetiological mechanism is unknown the result is a chronic 
inflammatory process which commonly presents with bloody diarrhoea, can result in 
scarring and, if occurring in the colon for more than a decade can predispose to
4
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colorectal carcinoma (Bansal and Sonnenberg, 1996). These generally descriptive 
features are shared by the two conditions, and indeed Crohn’s Disease and 
Ulcerative Colitis may be indistinguishable in 10% of cases.
Also, from a historical point of view, the treatments for both Ulcerative Colitis and 
Crohn’s Disease have been very similar, based on the use of 5-aminosalicylic acid 
(5-ASA) or non-specific immunosuppression with steroids. 5-ASA was first used in 
the 1940’s and its precise mechanism of action remains unknown. However it has 
been shown, in vitro, to have a number of potentially beneficial effects in the context 
of IBD including inhibiting IL-1 release by intestinal epithelial cells, preventing 
lymphocyte recruitment, inhibiting platelet activating factor (PAF) and manipulating 
eicosanoid metabolism (Greenfield et al., 1993).
There are, however, important clinical, immunological and hence therapeutic 
differences between Crohn’s Disease and Ulcerative Colitis which are proving ever 
more important as our understanding of these conditions improves. These are 
outlined below and in Table 1.1.
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Feature Crohn’s Disease Ulcerative Colitis
Distribution Entire length of gut Limited to Colon
Thickness o f inflammation Full thickness Limited to mucosa and 
submucosa
Genetic associations Specific to CD Specific to UC
Pattern o f immune response Thl pattern Modified Th2
Effect o f smoking Associated Protective
Diversion o f faecal stream Relieves symptoms Exacerbates symptoms
Response to antibiotics Partial None
Response to Diet Partial None
Response to anti-TNFa therapy Partial None 1
Table 1.1: Differences between Crohn’s Disease and Ulcerative Colitis
1.1.2.1 Crohn’s Disease
Crohn’s Disease can affect any part of the entire length of the gastrointestinal tract, 
either in isolation or in combination. Furthermore the entire thickness of the bowel 
wall can be involved with an inflammatory reaction on the serosal surface, and the 
inflammatory process is characterised by the presence of granulomas. However 
despite this potential for variety there are classic patterns of disease such as:
• Ileo-caecal disease
• Peri-anal disease
• Stricturing and fistulising disease
• Crohn’s colitis
The reason that such clinical manifestations may be important, particularly in the 
absence of a unifying aetiological process, is that Crohn’s Disease may represent an 
agglomeration of related but different diseases with subtle differences in their
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genetic, immune and environmental profiles. There is evidence supporting this 
hypothesis with the finding that lymphocytes expressing the C-C chemokine receptor 
9, as well as secretion of the chemokine TECK, differentiate small bowel from 
colonic Crohn’s disease (Papadakis et al., 2001). Furthermore, recent genetic 
evidence demonstrates a link between the apoptosis regulator, and NFkB activator, 
NOD2 and susceptibility to Crohn’s disease (Hugot et al., 2001).
Generally Crohn’s Disease displays a classic Thl type pattern of immune response 
typified by increased IFNy, TNFa, IL-1 and IL-12 (Shanahan, 2001; Fiocchi, 1998). 
It is perhaps because it fits into this immunological pattern of response that there 
have been more recent advances in immunotherapies for Crohn’s Disease than there 
have for Ulcerative Colitis. The most striking of these has been using TNFa as a 
therapeutic target for the treatment of Crohn’s Disease. Using a variety of 
techniques to block the action of TNFa in Crohn’s Disease has resulted in dramatic 
therapeutic benefits. The most studied of these is a chimeric monoclonal antibody 
against TNFa (Infliximab or Remicaide®) which is widely used and, interestingly, is 
particularly effective in perianal and fistulising Crohn’s Disease implying that TNFa 
may be particularly important in these conditions (Present et al., 1999).
Following this lead there is now extensive research into immunotherapies in IBD 
(Shanahan, 2001), and Crohn’s Disease in particular, with many already at the trial 
stage as summarised in the table ( 1 .2 ) below.
7
Introduction
Potential Method of 
Action
Example Reference
1. Antibodies to Pro-
Inflammatory Molecules
• Anti TNF a  Antibody***
• Anti Integrin Antibody * *
(Targan etal., 1997) 
(Gordon et al., 2001)
2. Human Recombinant 




(Van Deventer et al., 1997) 
(Bank et al., 1997)
3. Antagonists to Receptors 
for Pro-Inflammatory 
Molecules
• Interleukin-1 receptor 
antagonist*
• TNFa receptor antagonist 
(Etanercept)**
(Cominelli etal., 1990) 
(D'Haens et al., 2000)
4. Antisense RNA to block 
translation of Pro- 
Inflammatory Molecules
• ICAM Antisense**
• Nuclear Factor kB 
Antisense*
(Yacyshyn etal., 1998) 
(Neurath et al., 1996)





• TNFa converting enzyme 
(TACE) antagonists*
(Hawkey et al., 1997) 
(Dekkers et al., 1999)
6 . Specific Antagonists of 
Pro-Inflammatory 
Molecules
• Platelet A ctivating Factor 
Antagonist**
(Stack etal., 1998)
Licensed for clinical use 
Clinical Trials 
Animal Work only
Table 1.2: Different molecular targets fo r  therapies in IBD
1.1.2.2 Ulcerative Colitis
From the point of view of the gastrointestinal tract, Ulcerative Colitis only affects the 
colon and always works proximally from the rectum in a continuous fashion. The
8
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chronic inflammatory process only involves the mucosa and submucosa sparing the 
muscularis layers of the bowel. Although often referred to as a disease with a Th2 
type immune response, in contrast to Crohn’s Disease, this is an oversimplification 
and cytokine patterns in Ulcerative Colitis are less clear (Shanahan, 2001). In 
particular it appears that the type of immune response alters in the acute and chronic 
phases of disease. In established disease there are features of a modified Th2 
response with a cytokine profile involving IL-5 and IL-10. This complexity in 
classifying the immune response reflects the generally poor results of immune based 
therapies in this condition. Indeed, the breakthroughs made with Crohn’s Disease 
have not worked in Ulcerative Colitis, exemplifying how these conditions are 
diverging as therapies progress.
1.1.3 Colorectal Carcinoma
The gastrointestinal tract is the commonest site of internal malignancies, with 
cancers most likely to develop in the colon. Colorectal cancer, like IBD, is 
predominantly a disease of the western world where it is the third most common 
cancer and the second most common cause of cancer related death. The World 
Health Organisation estimated that in 1996 there were 875,000 new cases of 
colorectal cancer worldwide and that there would 495,000 deaths attributable to the 
condition. Not only is this an important condition from the point of its high 




It is only the minority of colorectal carcinomas which are associated with an 
inherited genetic defect (Chung, 2000). The most important of these are hereditary 
non-polyposis colorectal cancer (HNPCC) or Lynch syndrome, which accounts for 
between 5-10% of cases, and the autosomal dominant condition familial 
adenomatous polyposis (FAP) accounting for approximately 1%. The majority of 
the remaining cases are termed sporadic.
FAP is associated with disruption of the tumour suppressor gene APC which was 
cloned in 1991 (Groden et al., 1991; Nishisho et al., 1991). The APC gene product 
is a large protein with multiple functional domains that mediate both oligomeristaion 
and binding to many intracellular proteins including P-catenin, y-catenin, glycogen 
synthase kinase (GSK)-3p, axin and tubulin. The most progress in understanding its 
function comes from studies of its interaction with GSK-3p and p-catenin, each an 
essential component of the Wingless/Wnt signalling pathway which was first 
characterised in Drosophila. In the normal physiological state there is a normal APC 
gene product and no Wnt signal. In these conditions, GSK-3p associated with APC 
phosphorylates p-catenin resulting in its degradation. In a tumourigenic state there is 
either a Wnt signal, or a mutant APC or p-catenin. The result of this is that p- 
catenin is not degraded, but accumulates in the cytoplasm and nucleus where it binds 
to T-cell factor (TCF) transcription factors resulting in the up-regulation of 
oncogenes such as c-Myc, cyclin D1 and, putatively, PPAR8 .
This work on APC combined with work on two other tumour suppressor gene 
pathways, K-ras and p53 which are mutated in approximately 50% of colorectal 
carcinomas, resulted in the proposal of a model of sporadic intestinal tumourigenesis
10
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by Fearon and Vogelstein. This model has proved to be very durable and able to 
accommodate the many new discoveries since its proposal in 1990 (Fearon and 
Vogelstein, 1990). It proposes a series of genetic mutations which allow the 
progression through the adenoma-carcinoma sequence. This progression occurs over 
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Figure 1.3: Model o f colorectal carcinoma progression
The clinical phenotype of HNPCC, and newly discovered information on the 
associated genotype, has added significant information to this model. HNPCC 
presents at a younger age than sporadic cases, predominantly affects the right colon, 
follows an autosomal dominant pattern, and appears to progress through the 
adenoma-carcinoma sequence much faster than the decade taken for sporadic cases. 
This phenotype is now explained by the discovery of the basic genetic defect which 
is an inactivating mutation in one of the DNA mismatch repair genes (MSH2, MLH1, 
PMS2, PMS1, MSH6). This inactivation may be due to a germline mutation, or
1 1
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epigenetic phenomena best illustrated by hypermethylation in the promoter causing 
inactivation, or a combination of both in a classic two hit model of tumour 
suppressor gene inactivation.
The resulting disruption of the ability to replicate DNA accurately is most noticeable 
in the short tandem repeats, known as microsatellites, and results in a high 
spontaneous rate of mutation. Subsequent microsatellite instability (MSI) in the 
associated tumours is also called replication error positivity (or RER+). An 
important gene which is particularly susceptible to mismatch repair mutations is that 
for the type II transforming growth factor (TGF)-P receptor. TGF-p is a potent 
inhibitor of colonic epithelial cell growth and an acquired disruption in its receptor 
has been shown to contribute to HNPCC.
1.1.4 Inflammatory Bowel Disease and colorectal carcinoma
It has become apparent that the presence of chronic colonic inflammation 
predisposes to colorectal carcinoma (Morson, 1985; Bansal and Sonnenberg, 1996). 
This increased risk is dependent on the extent of colonic involvement and the length 
of time since the onset of disease. As the predisoposition to colon cancer is highest 
in those with colonic inflammation involving the whole colon for at least eight years, 
it is unsurprising that the association between IBD and colorectal carcinoma is best 
seen in ulcerative colitis. However, chronic Crohn’s colitis also carries an increased 





Many immunologically active mediators have been proposed as playing a 
pathological role in IBD and colorectal carcinoma, and some of these have been 
targets for novel therapeutic strategies (see Table 1.2). This thesis will concentrate 
on the action of the enzyme Cyclo-oxygenase and its dependent products.
1.2.1 History
Cyclo-oxygenase is the name given to enzymes capable of converting arachidonic 
acid to prostanoids. Although the first cyclo-oxygenase enzyme (COX), also known 
as prostaglandin synthase (PGS) or prostaglandin G/H synthase (PGHS), was 
isolated in 1976 (Hemler et al., 1976), this was late in the history of prostaglandin 
production because the effects of inhibiting COX were described by Hippocrates. 
Indeed the whole field of cyclo-oxygenase research is intertwined with the existence 
of their inhibitors.
The use of powder from the dried bark of the willow tree {Cortex salicis) to treat 
fever in fifty patients was described in 1763 (Stone, 1763) with the active ingredient, 
salicylic acid, being commercially synthesised in 1859. However, although widely 
used as an anti-pyretic and analgesic, side effects of gastric irritation were 
troublesome. Felix Hoffman, an employee of Friedrich Bayer, tackled this problem 
in 1897 by synthesising a stable form of acetyl salicylic acid. He named this A- 
Spirin, the A representing the acetylation step and Spirin from Spirea ulmaria or
13
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meadowsweet, a plant rich in salicylates. Bayer patented Aspirin and started 
marketing it in 1899 with vast success, hence starting the modem pharmaceutical 
industry.
Aspirin was the first of a group of drugs, collectively known as non-steroidal anti­
inflammatory drugs (NSAIDs), whose use became widespread. However, their 
mechanism of action remained unknown until 1971 when Vane described their 
inhibition of prostaglandin synthesis for which he won the Nobel Prize for Medicine 
in 1982 (Vane, 1971). This was followed by the purification of the first cyclo- 
oxygenase enzyme in 1976 (Hemler et al., 1976) allowing the subsequent 
characterisation of the catalytic mechanisms and methods of NSAID induced 
inhibition.
At this point it was believed that there was only one COX enzyme which was 
constitutive in nature and that the rate limiting step for prostaglandin synthesis was 
the release of arachidonic acid substrate by the activation of phospholipases. This 
was shown not to be correct with the isolation of cDNA for the one known COX 
enzyme (PGS EC 1.14.99.1) (Yokoyama and Tanabe, 1989), and the concomitant 
demonstration that there was an inducible component to COX activity that was 
independent of both phospholipase induction and any increase in PGS EC 1.14.99.1 
message (Masferrer et al., 1990). The subsequent search for an inducible COX gene 
resulted in the isolation of an inducible cDNA encoding a novel COX enzyme by 
two groups simultaneously (Kujubu et al., 1991; Xie et al., 1991). These two 
isoforms of COX, the initially discovered classically constitutive component COX-1,
14
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and the second inducible component COX-2, remain the only COX enzymes 
currently identified.
1.2.2 Arachidonic Acid metabolism
COX enzymes catalyse the conversion of arachidonic acid to prostaglandins -  firstly 
by inserting two oxygen molecules to yield PGG2 (cyclo-oxygenase activity) and 
then reducing this intermediate to give PGH2 (peroxidase activity). PGH2 is 
subsequently converted to a variety of eicosanoids, arachidonate derivatives based 
around a 20 carbon structure (eicosa is Greek for twenty), that include the 
prostaglandins and thromboxane A2 . Which eicosanoids are produced is dependent 
on the environment, as well as the enzymatic machinery, of particular cells (Figure 
1.4).
To put the COX enzymes in the context of arachidonic acid metabolism as a whole, 
one needs to start at the level of stimulus initiated arachidonic acid liberation from 
phospholipid, a reaction catalysed by phospholipases A, C and D. The 
phospholipase A2 (PLA2) family of enzymes are the most important with respect to 
prostaglandin production, and can be split into secretory or SPLA2 (low MWt 14- 
18kDa), and cytoplasmic or CPLA2 (high MWt 80-110 kDa). They represent a 
potential point of regulation of eicosanoid production and respond to agonist 
stimulation. Indeed they have been shown to be up-regulated in both Crohn’s 
disease and Ulcerative Colitis (Minami et al., 1994; Haapamaki et al., 1999). 
Furthermore, there is evidence for some form of coupling between phospholipases 
and cyclo-oxygenases, although the mechanism for this is yet to be elucidated. It has
15
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Figure 1.4: Pathways o f Arachidonic Acid metabolism
Schematic representation of the pathways involved in arachidonic acid 
metabolism and generation of eicosanoids. PLA2 phospholipase A2; 
LOX lipoxygenase; COX cyclooxygenase; PG prostaglandin; HPETE 
hydroperoxyeicosatetraenoic acid; HETE hydroxyeicosatetraenoic 
acid; EET epoxyeicosatetraenoic acid; MDA malondialdehyde
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been hypothesised that different phospholipases selectively provide arachidonic acid 
to COX-1 or COX-2. Such a mechanism would probably depend on coincidental 
enzyme expression rather than a unique metabolic interaction (Herschman, 1996; 
Reddy and Herschman, 1997; Ueno et al., 2001).





Lipoxygenases insert an oxygen molecule into the twenty carbon ring of arachidonic 
acid and are numbered after the target carbon atom with 5-, 12-, and 15-lipoxygenase 
being the major enzymes relevant to gastrointestinal function. The ultimate products 
of lipoxygenase (LOX) activity are the leukotrienes, lipoxins and hydroxy fatty acids 
such as the hydroperoxyeicosatetraenoic (HPETEs) and hydroxyeicosatetraenoic 
(HETEs) acids. Of particular mechanistic interest is the finding that for 5-LOX, 
which catalyses leukotriene biosynthesis, there is an associated 5-LOX activating 
protein (FLAP) which is essential for functional 5-LOX activity. This 18kDa protein 
associates with 5-LOX at the nuclear membrane and acts as an arachidonic acid 
transfer protein which presents the substrate to the enzyme. Such a mechanism 
appears to be unique, although it has been hypothesised to exist for COX in order to 




The cytochrome p450 pathway of arachidonic acid metabolism represents a reaction 
where a single oxygen atom is inserted resulting in epoxy and (co/co'1) derivatives. 
Less is known about the functional importance of this pathway. Finally, and as an 
alternative to the above three pathways of arachidonic acid metabolism, arachidonic 
acid can be converted non-enzymatically to isoprostanes via free radical 
peroxidation, or be re-esterifled to give phospholipid. These pathways are 
represented in Figure 1.4
1.2.3 COX-1
COX-1 is encoded by a 24kb gene yielding a 2.8kb mRNA which in turn yields a 
71kDa protein. The gene does not have a TATA box in its promoter and contains 
multiple start sites of transcription. The only proven c/s-regulatory elements in the 
promoter are two SP1 sites at positions -111/-105 and -610/-604. Deletion of one or 
both of these sites results in a reduction of basal transcription of 50% or 75% 
respectively in human umbilical vein endothelial cells (Xu et al., 1997). It is 
classically regarded as being constitutive but is preferentially expressed at high 
levels in selected cells and tissues, including endothelial cells, platelets, renal 
collecting tubules and seminal vesicles demonstrating that it is developmentally 
regulated. In addition it is possible to induce modest increases in COX-1 mRNA 
when inducing a monocytic cell line, THP-1, to differentiate into a more 
macrophage-like cell line using TP A, again indicating a developmental regulation 
(Smith et al., 1993). In the gastrointestinal tract it has been shown that y-irradiation 
of crypt epithelial cells induces COX-1 (Cohn et al., 1997) but there are no other 




COX-2 is encoded by an 8 .8 kb gene which is transcribed into a 4kb mRNA which in 
turn produces a protein of 65kDa to 74kDa depending on its extent of glycosylation 
(Otto et al., 1993). This COX-2 protein demonstrates a 61% homology to COX-1 in 
humans with both enzymes displaying similar kinetics (Vane and Botting, 1996). Its 
main structural feature distinguishing it from COX-1 is an 18 amino acid sequence at 
the carboxy terminus whereas the COX-1 protein has a 17 amino acid sequence at 
the amino terminus. These features act as specific epitopes allowing the generation 
of specific antibodies to the two isoforms.
The gene structure for COX-2 is markedly different than that for COX-1. COX-2 is 
an immediate early (IE) gene (or primary response gene) which can be expressed in 
the absence of new protein synthesis. As with all IE genes it is relatively small but 
has functionally important regulatory regions at both the 5' and 3' ends of the gene. 
These allow regulation at the transcriptional and post-transcriptional levels. Indeed, 
in studies of cytokine induction of COX-2 in macrophages where cytokines caused a 
40 fold increase in COX-2 mRNA, there was only a 10-40% increase in transcription 
with alteration of mRNA stability causing the majority of the mRNA increase 
(Huang et al., 2000).
The promoter region at the 5' end of the COX-2 gene has been shown to have 
numerous putative elements regulating transcription although only five have been 
proven to regulate COX-2 transcription (See Figure 1.5):
18
- 4 4 5 / - 4 2 7  - 2 7 0 / - 2 6 5  - 2 2 3 / - 2 1 4  - 1 3 2 / - 1 2 4  - 5 8 / - 5 3  - 5 5 / 5 0  - 3 1 / - 2 5





Figure 1.5: Regulatory Elements in the COX1 and COX2 Promoter 
A schematic representation of the COX1 and COX2 promoters showing the 
binding sites for transcription factors in the 500bp prior to the start point of 
transcription. All elements shown have been proven to have a regulatory role.
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• Nuclear Factor k B (NFkB)
• SP1
• Nuclear Factor IL- 6  (NF-IL6 )
• ATF/cAMP response Element (CRE)
• E-Box
However deletion studies of promoter constructs have shown that regions up to 2300 
bases 5' of the TATA box do regulate TGFp induced COX-2 transcription (Yang et 
al., 1997). Such studies have shown varied results in different cell lines (Reddy et 
al., 2 0 0 0 ) and there appears to be cell type specificity in the promoter components 
which are essential to transcription.
At the 3' end of the COX-2 gene is an untranslated region (3'-UTR) which also plays 
a major role in COX-2 expression (Figure 1.6). This region contains multiple copies 
of adenylate and uridylate rich elements (AREs), composed of the sequence 5'- 
AUUA-3', which allow regulation of both mRNA stability and translational rate 
(Dixon et al., 2000). Inhibition of de novo protein synthesis with cycloheximide 
causes an up-regulation of COX-2 mRNA in numerous systems (Huang et al., 2000; 
Newton et al., 1997). It seems that, although transcription of COX-2 does not 
require protein synthesis, when it is induced proteins are made which will 
subsequently down regulate it at the level of mRNA stability and translational rate 
and these function by binding to the 3'-UTR. An example of such a protein is 
tristetraprolin (Taylor et al., 1996; Carballo et al., 2000).
The above regulatory elements indicate that COX-2 is an inducible gene which is 
highly regulated at many different points (Figure 1.7). Indeed, COX-2 can be
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Figure 1.6: Pathways from  COX2 gene to COX2 protein
A schematic representation of COX2 gene transcription, post-transcriptional 
processing and translation into COX2 protein. The position of the 3'
Untranslated Region (3'UTR), an important regulatory factor for mRNA stability 
and translational rate, is shown.
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Figure 1.7: The COX pathway and its potential points o f regulation
Schematic representation of the COX pathway including upstream and 
downstream components. Potential points of regulation are shown to the right of 
the figure.
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induced by a number of stimuli in a variety of systems. These include pro- 
inflammatory cytokines, bacterial products and bacterial invasion, oncogene 
expression, growth factors, serum, high osmolarity and ultraviolet radiation (Smith et 
al., 2000). Correspondingly, COX-2 has been shown to play an important role in 
physiological and pathophysiological processes throughout the body, and in 
inflammatory processes and cancer development particularly (DuBois et al., 1998).
1.2.5 Cvclo-oxvgenase Products and their Receptors
COX activity is the committed step to prostaglandin synthesis. However, COX is 
also capable of synthesising malondialdehye or peroxyl radicals, as well as 15-R- 
hydroxyeicosatetraenoic acid (HETE) (Shiff and Rigas, 2001) which is particularly 
important in the context of Aspirin use (Gronert et al., 1998). This 15-(R)-HETE 
compound enters the pathways downstream of lipoxygenase and acts as a precursor 
of 15-epi-lipoxin A4 biosynthesis which in turn inhibits IL- 8  release.
From the point of view of prostaglandins, which prostaglandin is synthesised as a 
result of COX activity depends on the specific downstream prostanoid synthase. 
There is also evidence that these prostanoid synthases can couple with either COX-1 
or COX-2. Such coupling of specific cyclo-oxygenase isoform and prostanoid 
synthase can either be due to co-ordinate induction, or potentially by direct 
interaction although there is no evidence of the latter (Smith et al., 2000). This 
coupling may explain the inverse regulation of PGD2 and PGE2 by TNFa activation 
of murine macrophages (Fournier et al., 1997). As well as producing thromboxane 
A2 by a specific synthase, the other prostaglandins that COX can potentially produce
20
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include PGE2 -  the major prostaglandin product in the gastrointestinal tract 
(Boughton-Smith et al., 1983), PGI2 or prostacyclin, PGF2« and finally PGD2 . The 
latter prostaglandin is metabolised into members of the cyclopentenone 
prostaglandin family (Willoughby et al., 2000).
Which prostaglandin is synthesised by specific cell types is dependent on the 
prostanoid synthases expressed. As examples of this: platelets mainly express TXA2 
and vascular endothelial cells mainly PGI2 ; mast cell synthesise PGD2 but not PGE2 . 
Despite this cell specialisation it has been demonstrated that the gastrointestinal tract 
can generate the entire range of eicosanoids (Bennett et al., 1981). Once 
synthesised, prostaglandins cannot be stored and act as local paracrine, autocrine or 
intracrine mediators. They are involved in a multiplicity of physiological responses 
and mediate the effects of COX expression.
Two classes of prostaglandin receptors exist to transduce signals upon ligand 
binding. Firstly, the G protein coupled cytoplasmic membrane class of receptor and 
secondly the peroxisome proliferator activated receptor (PPAR) class of nuclear 
receptors (Versteeg et al., 1999). All these types of eicosanoid receptors display 
considerable cell type specific expression allowing another point of extensive 
regulation of the physiological response to prostaglandins. These receptors, and the 
effects of ligand binding, are summarised in Table 1.3. PPAR receptors will be 














Table 1.3; The eicosanoid receptors and the effect o f  individual ligand binding 
1.2.6 Cvclo-oxygenases and the gastrointestinal tract
1.2.6.1 Normal epithelial function
COX-1 is expressed throughout the normal gut as shown by isolation of mRNA 
(ONeill and Ford-Hutchinson, 1993), protein (Kargman et al., 1996), and 
immunohistochemistry (Singer et al., 1998). It is expressed in the lower crypt 
epithelial cells corresponding to areas of proliferation in the small and large intestine 
(Cohn et al., 1997; Singer et al., 1998). Such a position implies a function in 
promoting normal, homeostatic proliferation and this is supported in studies of
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regeneration from irradiation induced injury. COX-1 knockout mice {COX-1-/-) 
have no gastrointestinal phenotype in the unstressed state although do show impaired 
response to injury (Cohn et al., 1997).
The action of prostaglandins in the normal functioning of the gastrointestinal tract is 
controversial. There is pharmacological evidence of a role for prostaglandins in 
physiological intestinal secretion and motility (Eberhart and DuBois, 1995). 
However, COX-1 {COX-1-/-) and COX-2 {COX-2-/-) deficient knockout mice have 
no appreciable intestinal phenotype apart from a mild predisposition to peritonitis in 
COX-2-/- mice (Morteau et al., 2000). This is despite a total inhibition of basal 
PGE2 production in COX-1-/- mice and either implies that compensatory 
mechanisms have developed in the mice or that COX activity is not needed for the 
normal gastrointestinal function in the unstressed gut.
COX-2 is not expressed in the normal gastrointestinal tract. However it is 
abundantly expressed in both cancers, and inflammatory processes of the gut.
1.2.6.2 NSAIDs and the upper gastrointestinal tract
Before concentrating on the colon it is important to briefly consider the actions of 
NSAIDs on the stomach. The ability of salicylates to cause gastric irritation was
threalised prior to the production of Aspirin at the end of the 19 century. Since then 
it has been widely appreciated that NSAIDs cause peptic ulceration. This, combined 
with the discovery of the two isoforms of COX, resulted in the paradigm that COX-1 
was crucial to gastric mucosal protection and COX-2 was related to inflammation. 
As it was only at the very end of the 20th century that COX selective inhibitors
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became available, it was assumed that the injurious effects of classical NSAIDs to 
the stomach were due to COX-1 inhibition and the beneficial effects as analgesics 
was due to their inhibition of COX-2.
However, although the above theory provided a good working model, it could not 
explain why COX-1-/- mice have no gastric ulceration (Morteau et al., 2000). 
Furthermore, it could not explain findings from experiments using both highly 
selective COX-1 and COX-2 inhibitors. A more complex interaction is emerging 
with evidence that COX-2 is required for ulcer healing (Mizuno et al., 1997), an 
important consideration for those developing ulceration on a COX-2 selective 
inhibitor. Also, in rats, specific pharmacological COX-1 inhibition does not cause 
gastric ulceration although a combination of specific COX-1 and COX-2 inhibitors 
was injurious (Wallace et al., 2000). In summary, the classical view of only COX-1 
contributing to mucosal defence is no longer tenable, although specific COX-2 
inhibition (or COX-1 sparing NSAIDs) is less injurious to the stomach than standard 
NSAIDs.
1.2.6.3 COX and colorectal carcinoma
The links between COX activity and colorectal carcinoma are strong and have been 
the focus of intense scientific research. Prior to the discovery of COX, human 
colorectal carcinomas had been demonstrated to produce more PGE2 than the 
surrounding normal mucosa (Bennett and Del Tacca, 1975). This was followed by 
the clinical observation that patients with familial adenomatous polyposis (FAP) had 
a regression of their polyps when placed on the NSAID sulindac (Waddell and 
Loughry, 1983). Epidemiological studies subsequently showed that long term
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NSAID use, and aspirin in particular, caused a significant reduction in mortality due 
to colorectal carcinoma (Giovannucci et al., 1994; Giovannucci et al., 1995). 
Having demonstrated that NSAIDs prevent colorectal carcinoma, the role of the 
isoforms of COX in the mechanism of this needed to be investigated.
With the discovery of the inducible isoform of COX it became apparent that, 
although COX-1 expression was unaltered in colorectal carcinoma, the expression of 
COX-2 was significantly increased (Eberhart et al., 1994). COX-2 has been shown 
to be expressed in 80-90% of colorectal carcinomas and 40-50% of premalignant 
adenomas. Furthermore, its specific inhibition causes a reduction in polyps in 
humans with FAP (Steinbach et al., 2000). In animal models, APCA716(+/-) mice, 
which develop hundreds of intestinal tumours mimicking FAP, develop far fewer 
tumours when crossed with COX-2-/- mice. This is further supported by animal 
models based on the injection of tumour cell lines into host animals. Injection of 
COX-2+ and COX-2’ xenografts into animals showed that the COX-2 expressing 
tumours grew far better, and that this was abrogated by COX-2 inhibition (Tsujii et 
al., 1998). This same study also showed that COX-1 had a role in regulating pro- 
angiogenic factors necessary for tumour development. This study was followed by 
performing a similar experimental protocol in reverse with COX-2 expressing 
tumour cell lines being injected into COX-1-/- or COX-2-/- mice. The tumours grew 
far slower in COX-2-/- mice compared to the COX-1-/- and wild type mice showing 
that host COX-2 as well as tumour COX-2 play a crucial role (Williams et al., 2000).
Thus COX activity generally is crucial to colorectal cancer development, with the 
particular importance of COX-2 probably being secondary to its inducibility and
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hence generation of a greater quantity of eicosanoid products. This effect of COX-2 
has been referred to as a landscaping or a field effect within the Vogelstein and 
Kinzler paradigm (Figure 1.3) (Kinzler and Vogelstein, 1998). Indeed, it may be the 
mechanism by which chronic IBD predisposes to colorectal carcinoma, another 
landscaping effect (Agoff et al., 2000; Kinzler and Vogelstein, 1998; Bansal and 
Sonnenberg, 1996). The expression of COX in epithelial cells, stromal cells and 
endothelial cells has been show to make a contribution to tumourigenesis in different 
models but the relative contributions of each cell type remain uncertain. Also, which 
COX products are most important in cancer development, and their mechanisms of 
action, needs further investigation.
As well as the undisputed importance of COX inhibition in the chemopreventive 
actions of NSAIDs, it is also apparent that NSAIDs can exert a number of COX 
independent effects. This is most clearly demonstrated by the fact that metabolites 
of certain NSAIDs, such as sulindac sulfone, which have no COX inhibiting 
properties, still cause decreased proliferation and increased apoptosis in models of 
colon cancer (Elder et al., 1996; Piazza et al., 1997). Secondly colonic cell lines, 
such as HCT-15 which completely lack COX activity and the ability to synthesise 
prostaglandins, still respond to NSAIDs in a similar manner to COX expressing cell 
lines (Hanif et al., 1996). Thus there is undoubtedly a COX independent component 
to the action of NSAIDs which is likely to be dose dependent and which may be seen 
predominantly at toxic doses (Williams et al., 1997).
26
Introduction
1.2.6.4 COX and Inflammatory Bowel Disease
The eicosanoid products of cyclo-oxygenase were known to be both produced by the 
colon (Boughton-Smith et al., 1983), and raised in IBD, prior to the discovery of an 
inducible isoform of COX (Donowitz, 1985; Lauritsen et al., 1988). Furthermore, 
these eicosanoid products were produced at times of active disease and returned to 
basal levels during remissions implying an inducible component (Sharon et al., 
1978). Hence, with the discovery of COX-2, it was hypothesised that it would be 
induced in IBD. This has now been demonstrated with the discovery of increased 
COX-2 mRNA in IBD which was shown to reflect disease activity (Hendel and 
Nielsen, 1997). This was followed by isolation of protein, along with 
immunohistochemistry, showing increased COX-2 expression in ulcerative colitis as 
well as in Crohn’s colitis and ileitis (Singer et al., 1998). The immunohistochemical 
staining showed that, although COX-2 was expressed in both epithelial cells and 
lamina propria mononuclear cells, the vast majority of the protein was in the 
epithelial cells.
Having confirmed the induction of COX-2 in IBD, the functional role of this 
expression needs to be assessed. It has been known for some time that NSAIDs 
cause exacerbation of IBD although it was not known whether this was a COX 
specific action (Kaufmann and Taubin, 1987). Three lines of evidence imply that 
this exacerbation of IBD is due to COX-2 inhibition.
1. The specific COX-2 inhibitor, L745,337, exacerbates a rat model of trinitro 
benzene sulphonic acid (TNBS) induced colitis resulting in higher rates of 
perforation and death (Reuter et al., 1996).
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2. Analogously, colitis induced in mice by oral Dextran Sodium Sulphate (DSS) 
administration is more aggressive and more lethal in COX-2-/- mice (Morteau et 
al., 2000). COX-1-/- mice were also more susceptible to induced colitis, 
although not as marked as the COX-2-/- animals, and this suggests a protective 
role for both COX-1 and COX-2 expression in the context of IBD.
3. Finally COX dependent products are protective in two animal models of colitis. 
Firstly, intra-rectal administration of PGE2 (lOOpg) in rats from one week after 
exposure to (DSS) resulted in histological amelioration of the colitis compared to 
controls (Sasaki et al., 2000). Also, myeloperoxidase activity around the lesions 
was less and there was decreased expression of the chemokines GRO and CINC- 
1 in the treated group. Secondly, using TNBS to induce colitis in rats, PGD2 was 
shown to be increased after the induction of colitis and that its action was to 
reverse the inflammatory process. Again colitis could be ameliorated by 
administration of PGD2 (Ajuebor et al., 2000).
Thus it seems that COX expression, and the induced COX-2 expression in particular, 
is beneficial in IBD and that this is dependent on the COX mediated production of 




1.3.1 Tumour Necrosis Factor a
The tumour necrosis factor protein was isolated in 1985 and named after its ability to 
kill tumour cells. It was subsequently found to refer to two closely related cytokines, 
TNFa and TNFp (or lymphotoxin-a) which share receptors and play a part in a wide 
variety of human diseases processes. TNFa is a member of a larger family of related 
ligands and is an immediate early gene which shares many of the characterisitic of 
the COX-2 gene: specifically-
• Multiple response elements in its promoter. These include binding sites for 
NFkB, AP-1, AP-2, SP1 and CRE and there is evidence of combinatorial 
activation as with COX-2.
• The presence of AREs in the 3'-UTR allowing post-transcriptional regulation 
via control of mRNA stability and translational rate.
• Expression in monocytes and macrophages, as well as B and T lymphocytes 
and also intestinal epithelial cells (Jung et al., 1995).
• Induced by a large number of diverse stimuli such as cytokines, growth 
factors, bacterial products and irradiation.
TNFa is first synthesised as a transmembrane (26kDa) precursor which can be 
biologically active in a juxtacrine manner. This precursor can then be cleaved by 
TNFa converting enzyme (TACE) into the 17kDa secreted form of TNFa which 
combine into homotrimers to bind to and activate its receptors.
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There are two distinct TNFa receptors which are also part of a larger family of 
related receptors. These receptors, TNFR1 (p55 or CD 120a) and TNFR2 (p75 or 
CD 120b), are expressed simultaneously on most cell types and it is therefore 
difficult to assign distinct signalling functions to each receptor (Natoli et al., 1998a; 
Orlinick and Chao, 1998). However experiments using TNFa-/- and TNFR1-/- 
knockout mice have similar phenotypes with markedly reduced sensitivity to LPS 
after D-galactosamine priming (Pfeffer et al., 1993; Pasparakis et al., 1996). 
Furthermore the TNFa-/- phenotype can be restored to that of wild type mice by the 
preparation of a transgenic mouse with human TNFa which can only bind TNFR1 
(Pasparakis et al., 1996). Such studies indicate a central role for TNFR1 in TNFa 
signaling. The role of TNFR2 appears to be more complex. Although there is 
evidence that it is capable of signalling independently of TNFR1, it is believed that 
its kinetics, having a rapid kon and &0fr, favour a ligand passing role increasing the 
local concentrations of TNFa for the TNFR1 (Tartaglia et al., 1993; Papadakis and 
Targan, 2000; Orlinick and Chao, 1998).
In the absence of ligand, TNFR1 is kept in the inactive monomeric state by the 
60kDa “silence of death domains” (SODD) (Jiang et al., 1999). Binding of TNFa 
homotrimers causes dissociation of SODD and trimerisation of TNFR1, allowing the 
death domains of the cytoplasmic tails to aggregate. These death domains recruit 
effector molecules to begin the signalling cascade as TNFR1 has no intrinsic kinase 
activity. These effector molecules include:
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• TRADD (TNFR associated death domain)
• FADD (Fas associated death domain)
• TRAF2 (TNFR associated factor 2)
• RIP (Receptor interacting protein)
- and constitute the TNFR1 signalling complex (Figure 1.8).
The TNFR2 does not have a death domain but interacts directly with TRAF1 and 
TRAF2 to mediate its effects.
The multiplicity of signals which results from TNFa ligand binding and activation of 
its receptor can be split into two parts. The first is the initiation of apoptotic cell 
death via FADD/MORT1 recruitment and subsequent activation of caspase 
proteases. The second is the initiation of cell protection events to prevent the cell 
undergoing apoptosis and promoting cell survival. These are believed to centre 
around activation of NFkB via activation of NFkB inducing kinase (NIK) by the 
TNFR1 (or indeed TNFR2) complexes. There is conflicting evidence of the role of 
TRAF2 in the activation of NFkB. Dominant negative TRAF2 inhibits in vitro 
NFkB activation by TNFa (Jobin et al., 1999; Natoli et al., 1998a) whereas 
TRAF2-/- knockout mice have normal TNFa induced NFkB activation (Yeh et al., 
1997). There is likely to be tissue specificity to these mechanisms as is seen with the 
activation of NFkB in the intestinal epithelium and the fact that it is partially 
dependent on TRAF2 (Jobin and Sartor, 2000).
Furthermore, there are NFkB independent mechanisms of cytoprotection. This is 









MAP Kinases NFkB Apoptosis
Figure 1.8: Signalling via the TNFa receptor 
Schematic representation showing the sequential, ligand induced, 
recruitment of different TNFRl associated proteins and their subsequent 
downstream consequences
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apoptosis than that caused by selective inhibition of NFkB (Natoli et al., 1998b). 
However overexpression of TRAF2 is not sufficient to protect cells from apoptosis 
induced by TNFa and the protein synthesis inhibitor cycloheximide. Thus, there are 
TNFa induced cytoprotective mechanisms involved independent of both NFkB and 
TRAF2 and the complete picture remains to be fully elucidated (see Figure 1.9) 















Figure 1.9: Consequences o f TNFRl activation
A schematic representation of the TNFRl dependent pathways promoting both
apoptosis and cytoprotection
1.3.1.1 TNFa and Inflammatory Bowel Disease
There is strong evidence that TNFa plays a pivotal role in Crohn’s disease, with its 
Thl pattern of immune response. Inhibition of TNFa, with monoclonal antibodies 
targeted against it, gives an excellent therapeutic response in Crohn’s disease which 
is not seen in ulcerative colitis (Targan et al., 1997; Papadakis and Targan, 2000).
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Furthermore, deletion of the 3'-UTR of the TNFa gene in mice resulting in an up- 
regulation of TNFa by stabilising its mRNA, results in an animal model showing 
enteritis with transmural inflammation and skip lesions very similar to Crohn’s 
disease (Kontoyiannis et al., 1999). This evidence of such a central role of TNFa in 
Crohn’s disease is also supported by in vitro studies using IECs, macrophages and T 
cells which are all activated by TNFa as well as all being able to secrete TNFa. 
However, such in vitro work could not predict the great success of TNFa as a 
therapeutic target in Crohn’s disease, compared to other possible targets such as 
IL-1.
1.3.1.2 TNFa and colorectal carcinoma
In contrast to the abundance of evidence of a role for TNFa in Crohn’s disease there 
is little evidence or literature concerning TNFa and colorectal carcinogenesis and 
deductions have to be drawn from other tumour models. There is evidence in 
clinical trials that TNFa, when injected into and around tumours, can destroy 
neovasculature and thus slow growth (Eggermont et al., 1996). In contrast to this, 
and perhaps more relevant, is evidence from an animal model of a different epithelial 
tumour. TNFa-/- knockout mice are resistant to the induction of skin tumours with 
DMBA (7,12-di-methylbenz[a]-anthracene), although there is no difference from the 
wild type in their subsequent malignant progression (Moore et ah, 1999). The 
malignant transformation occurring at sites chronic inflammation, seen in the skin 




Interleukin-1 (IL-1) is a highly inflammatory cytokine which can also upregulate 
host defences and act as an immunoadjuvant. It has two isoforms, IL -la  and IL-1 (3, 
which belong to a larger, evolutionarily conserved, family which includes fibroblast 
growth factor (FGF) and IL-18. Both forms of IL-1 are synthesised as 31kDa 
precursor forms which require processing by specific proteases to produce a mature 
17kDa secreted cytokine. Although the biological activities of IL -la  and p are 
effectively indistinguishable, there are important differences between the two 
molecules.
ProIL-la is secreted by cells when they die and is then cleaved by extracellular 
proteases (Kobayashi et al., 1988). It has been demonstrated that IL -la  can be 
secreted in the absence of cell death in vitro (Watanabe and Kobayashi, 1994). 
However, the fact that IL -la  is not commonly seen in the circulation or in body 
fluids, except during severe disease, means that release during cell death is likely to 
be the common mode of production (Watanabe and Kobayashi, 1994).
In contrast IL-1 p is released by living cells on stimulation and, like TNFa and COX- 
2 shares many features of an immediate early gene. The precursor form lacks 
biological activity and is converted to the mature form by the action of the cysteine 
protease (or caspase) IL-1 p converting enzyme (ICE), although other inflammatory 




The IL-1 cytokines are tightly regulated in a unique fashion (Figure 1.10). The first 
mechanism involves the soluble IL-1 receptor antagonist (sILIRa) which is 
structurally related to IL -la  and p. This molecule is released by the cell upon 
stimulation and, like IL -la  and p, is able to bind to the IL-1R1. However this ligand 
binding does not result in signal transduction, even at concentrations 1 0 6 times 
greater than those needed for IL -la  or p. The exact mechanism for this lack of 
response is not certain although the IL-1R accessory protein (IL-lRAcP), which is 
necessary for signal transduction, does not associate to the IL-1R1 bound to IL-IRa 
(Dinarello, 1997).
The second novel mechanism of regulation is the presence of a second IL-1R (IL- 
1RII) which acts as a decoy receptor or “IL-1 sink” in that it lacks the ability to 
transduce signals on ligand binding. This receptor, like IL-1R1, can also be released 
from the cell surface and bind to IL-1, again without producing a response. These 
sophisticated mechanisms at abrogating IL-1 responses, combined with the low 
numbers of IL-1R1 on primary as opposed to transformed cells, make the intense 
inflammatory response to IL-1 all the more surprising.
The IL-1R1 is the IL-1 receptor mediating functional responses and shares a 45% 
homology with the Drosophila Toll gene. When the membrane bound form binds to 
IL -la  or p it associates with the IL-lRAcP to form a signalling complex which lacks 
any intrinsic kinase activity. It does however have a binding site at amino acids 513- 
520 for IL-1R1 associated kinase (IRAK) which can phosphorylate a lOOkDa 
substrate and is partly responsible for downstream activation of NFkB, MAP 





No Signal Weak Signal Strong Signal No Signal
Figure 1.10: IL-1 Signalling
Schematic representation showing the necessary interaction of IL-1 R1 and 
the IL-RAcP to allow effective IL-1 signalling as a result of IL-1 binding. 
IL-1RII does not result in signal and neither does binding to either of the 
soluble forms of the two receptors. Finally IL-1 Receptor Antagonist (IL- 
lRa) never results in signal transduction.
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evidence that IL-1 can activate PI 3-Kinase and, as with TNFa, activation of NFkB 
may be PI 3-Kinase dependent (Reddy et al., 1997).
1.3.2.1 IL-1 and Inflammatory Bowel Disease
IL-1 is raised in intestinal tissue of both Crohn’s Disease and ulcerative colitis 
consistent with the chronic inflammatory process (Cominelli et al., 1992; Fiocchi, 
1998). Most interest has concentrated on the relative proportions of IL-1 to IL-IRa 
with evidence that in those with IBD there is a bias favouring inflammation 
(increased IL-l:IL-lRa ratio) (Cassini-Raggi et al., 1995; Mahida et al., 1996). 
However, despite the use of IL-IRa in rheumatoid arthritis with clinical success 
(Jiang et al., 2000), there has not been a concomitant breakthrough using such an 
agent in IBD (Cominelli et al., 1990). There is also no clear information concerning 
the role of IL-1 in colorectal carcinoma.
1.3.3 Interferon y
Interferon y (IFNy) is a Thl immunomodulatory cytokine belonging to a family of 
interferons initially characterised by their antiviral actions. It is termed a type II 
interferon to distinguish it from the structurally distinct Type I interferons (IFNa and 
p). Human IFNy is a non-covalent homodimer consisting of two 17kDa chains 
which can be variably glycosylated. It has a variety of anti-proliferative effects as 
well as upregulating MHC class I and inducing MHC class II as has been shown in 
IECs (Hoang et al., 1992). IFNy is induced by immune and inflammatory stimuli 
and is synthesised solely by T cells and natural killer cells.
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There is only one known IFNy receptor which is expressed on the majority of cell 
types and it is comprised of two subunits (Figure 1.11). The IFNGR1 (a  chain or 
CD119w) is a 90kDa polypeptide with a Janus kinase (JAK)-1 binding site on its 
cytoplasmic tail, whereas the IFNGR2 (p chain or accessory factor-1) is smaller 
(62kDa) and has a JAK2 binding site. Both are required for signal transduction 
although IFNGR2 plays only a minor role in ligand binding. The receptor subunits 
do not associate in the absence of stimulation but do associate with JAK1 and JAK2. 
Ligand binding by IFNGR1 generates binding sites for IFNGR2 allowing association 
to form an active receptor complex. The inactive JAK1 and JAK2 molecules are 
brought into close association and activate each other by auto- and trans­
phosphorylation (JAK2 —» JAK1). Once activated, the receptor associated JAKs 
phosphorylate a functionally critical, tyrosine containing sequence (440YDKPH444) 
near the carboxy terminus of IFNGR1. This creates paired, ligand induced, docking 
sites for signal transducer and activator of transcription (STAT)-l. Two inactive 
ST ATI molecules bind via their SH2 motifs and are then phosphorylated by the 
receptor associated JAKs. Once phosphorylated, the STATs dissociate and form a 
homodimer which translocates to the nucleus and bind to gamma activated sequence 
(GAS) elements in IFNy responsive genes stimulating transcription (see Figure
1.11).
Among the IFNy primary response genes are members of the Interferon Regulatory 
Factor family of transcription factors (IRFs) (Mamane et al., 1999). Members of this 
family, such as IRF1, can be induced by IFNy and subsequently bind to IFN 












T A T I STAT1
A ctive STAT1
Figure 1.11: Signalling via the IFNy receptor 
Schematic representation showing the sequential, ligand induced, 
activation of JAK2 and JAK1 resulting in activation and dimerisation 
of ST ATI. This STAT1 homodimer translocates to the nucleus where 
it acts as a transcription factor. See text for further explanation and 
abbreviations.
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further effects (Mamane et al., 1999; Blanco et al., 2000). Members of the IRF 
family can also be antagonistic or constitutively expressed and provide a complex 
level of regulation of IFNy responses.
Work with chimeric receptors has demonstrated that the specificity of JAK1 and 
JAK2 to these events is due to their binding to the IFNGRs rather than substrate 
specificity (Kotenko et al., 1996). There is evidence that this specific receptor 
association is crucial as cells lacking JAK1 or JAK2 are unable to activate STAT1 in 
response to IFNy (Watling et al., 1993; Muller et al., 1993). STAT1 can be activated 
by other cytokines via other member of the JAK family. However, it does appear to 
be central to IFNy responses with STAT1-/- knockout mice having a global deficit in 
IFNy responses (Meraz et al., 1996), although there is new evidence indicating that 
there may be some heterogeneity in different systems (Dupuis et al., 2001).
1.3.3.1 IFNy and Inflammatory Bowel Disease
IFNy is spontaneously secreted by normal intraepithelial lymphocytes and lamina 
propria mononuclear cells and this is increased in IBD (Breese et al., 1993; Carol et 
al., 1998). Furthermore it has been shown to play an essential role in the CD45RBhl 
CD4+ T cell restored SCID mice model of IBD (Powrie et al., 1994). These 
findings would fit with it driving a classical Thl response, especially in Crohn’s 
disease. However, a more complex role for IFNy is hinted at by its accepted use as a 
treatment for chronic granulomatous disease, which shares features with Crohn’s 
disease (The international chronic granulomatous disease cooperative study group., 
1991). Also IFNy has been used in a small trial for the treatment of Crohn’s disease
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(Debinski et al., 1997). Despite this, it is generally regarded as playing a 
contributory role, particularly in Crohn’s disease, although this has not been 
exploited as a therapeutic target.
Similarly to IL-1, there is little information concerning IFNy and colorectal 
carcinogenesis.
1.3.4 Th2 anti-inflammatory cytokines
The T cell derived cytokines IL-4, IL-10 and IL-13 are classically regarded as anti­
inflammatory cytokines which promote a Th2 immune response and are all believed 
to be involved in gastrointestinal tract physiology.
1.3.4.1 Interleukin-4 and Interleukin-13
IL-4 and IL-13 share many similarities in functional response due to common 
receptor components and downstream signalling pathways. Indeed it has been 
proposed that IL-4 can mimic every IL-13 induced response (Callard et al., 1996). 
The functional outcome of these cytokines is typified by the findings for IL-13 
whose many anti-inflammatory actions include the down regulation of a variety of 
chemokines (IL-8 , M IP-la), pro-inflammatory cytokines (TNFa, IL-6 , IFNy), and 
other inflammatory mediators (nitric oxide) in systems such as LPS stimulated 
monocytes, intestinal epithelial cells, activated monocytes/macrophages or 
endothelial cells (Minty et al., 1993; de Waal Malefyt et al., 1993; Kolios et al., 
1996; Wright et al., 1997). Furthermore, both cytokines have been shown to activate
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PI 3-Kinase in macrophages (Montaner et al., 1999). IL-13 has also been shown to 
activate PI 3-Kinase in intestinal epithelial cells and this mechanistic pathway 
appears to mediate the anti-inflammatory actions of this cytokine in this system 
(Wright et al., 1997).
Both IL-4 and IL-13 are produced by T cells and monocytes/macrophages and are 
present in the normal colon (Carol et al., 1998; Vainer et al., 2000). Both have also 
been demonstrated as being decreased in IBD with IL-13 decreased in ulcerative 
colitis, especially when active (Vainer et al., 2000), and IL-4 decreased in both 
ulcerative colitis and Crohn’s disease (West et al., 1996). These findings suggest an 
immunological deficit, congenital or acquired, which may predispose to IBD.
1.3.4.2 Interleukin-10
IL-10 is a pleiotropic cytokine which has attracted much interest in the context of 
IBD. The best evidence of its involvement comes from IL-10-/- mice which develop 
an enteritis with many features of IBD (Kuhn et al., 1993). This is supported by in 
vitro studies showing that IL-10 is a potent suppressor of pro-inflammatory cytokine 
and chemokine generation by activated monocytes/macrophages (Moore et al., 
1993). It is therefore disappointing that targeting IL-10 in the treatment of IBD, as 
with IL-4 and IL-13, has not yielded more impressive clinical benefit (Van Deventer 
etaL, 1997).
40











































Proline rich domain 








Figure 1.12: The PI 3-Kinase Family




1.4.1.1 PI 3-Kinases and their downstream effector targets
The term PI 3-Kinase is applied to a family of proteins that are able to phosphorylate 
the D-3 position of the inositol head groups of phosphoinositide lipids, namely 
phosphatidylinositol (PI), phosphatidylinositol(4)phosphate (PI(4)P) and 
phosphatidylinositol(4,5)bisphosphate (PI(4 ,5 )P2). This results in the formation of 
PI(3)P, PI(3 ,4 )P2 and PI(3 ,4 ,5 )P3 respectively (Fruman et al., 1998; Wymann and 
Pirola, 1998; Vanhaesebroeck and Waterfield, 1999;). PI(3)P is constitutively 
present in eukaryotic cells and its levels are largely unaltered upon cellular 
stimulation. In contrast, PI(3 ,4 )P2 and PI(3 ,4 ,5 )P3 are generally absent from resting 
cells, but their intracellular concentration rises markedly upon stimulation via a 
variety of receptors suggesting a second messenger function. PI 3-Kinases can be 
divided into three main classes on the basis of the in vitro lipid substrate specificity, 
structure and likely mode of regulation (Figure 1.12). Hence, the class I PI 3- 
Kinases phosphorylate PI, PI(4)P and PI(4 ,5 )P2, resulting in the formation of PI(3)P, 
PI(3 ,4 )P2 and PI(3 ,4 ,5 )P3 . They also interact with Ras and form heterodimeric 
complexes with adaptor proteins that link them to different upstream signalling 
events. The prototypical class Ia PI 3-kinase is a heterodimer consisting of the 
85kDa regulatory subunit (responsible for protein-protein interactions either via 
protein tyrosine phosphate-binding SH2 domains or SH3 domains and/or proline- 
rich regions) and a catalytic 1 lOkDa subunit. The existence of multiple isoforms of
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both components, which do not appear to preferentially associate, means that there is 
considerable scope for specific variation between tissues and with association to 
different receptor tyrosine kinases. The class Ib PI 3-Kinases are stimulated by G 
protein Py subunits and do not interact with the SH2-containing adaptors that bind 
class Ia PI 3-Kinases. Instead, the first identified member of this family, pllOy, 
associates with a unique p i01 adaptor molecule. The class II PI 3-Kinases (e.g. PI 3- 
Kinase-C2a) are characterised by the presence of a C-2 domain at the carboxyl 
terminus and utilise predominantly PI and PI(4)P as substrates, whereas the class III 
PI 3-Kinases utilise only PI as a substrate (e.g. mammalian PI 3-kinase and 
Saccharomyces cerevisiae Vps34p). The Mammalian homologue is likely to be the 
main source of PtdIns(3)P and has been shown to be expressed, along with class Ia 
PI 3-Kinases, in a colonic carcinoma derived intestinal epithelial cell line (Petiot et 
al., 2 0 0 0 ).
A number of proteins have been identified that directly bind PI(3 ,4 ,5 )P3 and/or 
PI(3 ,4 )P2 via PH domains including protein kinase B (PKB/Akt), PI(3 ,4 ,5 )P3- 
dependent protein kinase-1 (PDK-1), Bruton’s tyrosine kinase, various PLC isoforms 
and exchange factors for the ADP-ribosylation factor family of GTP-binding 
proteins (Figure 1.13). Moreover, the D-3 phosphoinositide lipids have been linked 
to the triggering of a diverse array of cellular responses including cell survival, 
mitogenesis, membrane trafficking, glucose transport, neurite outgrowth, membrane 
ruffling, superoxide production as well as actin polymerisation and chemotaxis.
Of these downstream effectors of PI 3-Kinases, PKB is of particular interest. It is a 













Figure 1.13: Downstream effectors o f  the PI 3-Kinase Family
Schematic representation showing the activation of PI 3-Kinase by G 
protein coupled receptors and Tyrosine Kinase linked receptors. Binding to 
these receptors will also have other effects. Once activated PI 3-Kinase 
activates a number of downstream effectors which may in turn have a 
number of differing functional effects. PTEN Phosphatase and Tensin 
Homologue Deleted from Chromosome 10; PDK PI 3-Kinase dependent 
kinase; PLCy phospholipase Cy; BTK bruton’s tyrosine kinase; PKB 
protein kinase B; PKC protein kinase C; FKHLR forkhead related ligand; 
IKK IkB kinase
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and which probably both involve the upstream kinase PH domain-containing kinase 
PDK-1. PKB has now been demonstrated to phosphorylate a number of proteins, 
particularly those involved in regulating glucose metabolism and cell survival, 
reviewed in Datta et al (Datta et al., 1999). In particular, PDK-1 and PKB as well as 
the PI 3-Kinase homologue, mammalian target of rapamycin (mTOR), contribute to 
the activation of p70S6 kmase, an enzyme thought to initiate protein synthesis.
1.4.1.2 PI 3-Kinases and Colorectal Carcinoma
There is now a growing body of evidence to support the notion that activation of PI 
3-Kinases is associated with colorectal carcinoma and that this increased activity is 
playing an aetiological role. This evidence is considered below:
1, Development o f colon cancers in the absence o f 3'-phosphoinositide lipid 
phosphatases. One line of evidence comes from work on the tumour suppressor 
gene PTEN (phosphatase and tensin homologue deleted from chromosome 10). The 
PTEN gene product is a 3' phosphatase which specifically degrades the major 
primary product of PI 3-Kinase activity, namely PI(3 ,4 ,5 )P3 (Maehama and Dixon, 
1998; Cantley and Neel, 1999;). Germ-line mutations of PTEN occur in related, 
inherited, neoplastic disorders such as Cowden’s syndrome, Lhermitte-Duclos 
disease and Bannayan-Zonana syndrome. These disorders share similar pathological 
traits including the formation of multiple benign tumours and an increased incidence 
of malignant cancers throughout the body, including the colon (Lynch et al., 1997; 
Chi et al., 1998). This is supported by work using PTEN+/- heterozygous mice 
which develop intestinal polyps which interestingly often cluster to a small part of 
the gastrointestinal tract (DiCristofano et al., 1998; Podsypanina et al., 1999).
43
Introduction
2. Expression o f P I 3-Kinases in colon cancers. The best characterised effector of 
the PI 3-Kinases and its 3'-phosphoinositide lipid products is PKB, which has a well- 
defined role in promoting cell survival and cumulative evidence indicates that the PI 
3-Kinase/PKB pathway is oncogenic and involved in neoplastic transformation of 
mammalian cells. Thus, PKBp is amplified and over-expressed in some ovarian 
cancers whilst PKBy is overproduced in some breast cancers. However, to date there 
is no information as to whether PKB is up-regulated in colon cancers. Nevertheless, 
the suggestion of a causative role for PI 3-Kinases in colorectal cancer is supported 
by the fact that there is increased PI 3-Kinase activity in colorectal carcinoma 
specimens. Immunoprecipitation of whole colonic cancer tissue with specific 
antibodies to subunits of the p85/pll0 heterodimer demonstrates significantly 
greater activity in in vitro lipid kinase assays compared to adjacent normal colonic 
mucosa (Phillips et al., 1998; Benistant et al., 2000). Similar increases in PI 3- 
Kinase expression and activity were detected in several adenocarcinoma cell lines 
compared to non-transformed fibroblasts (Benistant et al., 2000). Moreover, micro­
injection of neutralising antibodies to p i 1 0  catalytic isoforms into adenocarcinoma 
cell lines, revealed that both p i 1 0 a  and p play important roles in human colon 
cancer growth with a specific role for pllOp in de novo DNA synthesis and an 
involvement of p i 10a in cell survival. It is of note that in this system pllOy 
inhibition had no effect on DNA synthesis or induction of apoptosis (Benistant et al., 
2000). However, the micro-injection studies are at odds with interesting data derived 
from knockout mice deficient in the class Ib PI 3-Kinase, PI 3-Kinasey. The PI 3- 
Kinasey-/- mice have been shown to spontaneously develop colorectal carcinomas 
(Sasaki et al., 2000). This raises the possibility of conflicting roles of different
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classes of PI 3-Kinases in the development of colorectal carcinoma, although it is 
worth noting that similar genetic constructs from other laboratories do not appear to 
demonstrate this phenotype (Hirsch et al., 2000). However, the findings relating to 
development of carcinomas in PI 3-Kinasey-/- mice are also supported by work on 
human tumours and transformed cell lines. Accordingly, there is a decrease in pilOy 
expression in whole human tumour tissue compared to adjacent normal mucosa as 
assayed by western blotting. These workers also showed that transfection of three 
transformed adenocarcinoma cell lines with PI 3-Kinasey resulted in a decrease in 
their growth in both culture, and as tumours resulting from their subcutaneous 
injection into mice. However, confounding this was the finding that the same 
growth inhibition was seen with a kinase-dead mutant of PI 3-Kinasey. Hence, the 
inhibitory effects of PI 3-Kinasey on cancer growth may not be dependent on the 
catalytic activity of this isoform of PI 3-Kinase.
3. Effect o f PI 3-Kinase inhibitors on tumour growth and intestinal epithelial cell 
apoptosis. Given the clear indication for a pivotal role of PI 3-Kinases in 
determining colorectal cancer, it begs the question as to what is the effect of PI 3- 
Kinase inhibitors on cancer cell growth? Indeed, pharmacological inhibition of PI 3- 
Kinases has also been demonstrated to inhibit the growth of several colon and 
ovarian carcinoma cells in vitro and also display anti-tumour activity in some human 
tumour xenograft models (Schultz et al., 1995). Meanwhile, IL-13 was shown to 
abrogate cytokine-stimulated (e.g.TNFoc/IL-la/IFNy) apoptosis of a colonic 
epithelial cell line via a PI 3-kinase dependent pathway (Wright et al., 1999). 
Similarly, the Ras-induced down-regulation of the pro-apoptotic protein Bak has 
been shown to be sensitive to pharmacological inhibition of PI 3-Kinases (Rosen et
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al., 1998). Together these data indicate that PI 3-Kinases are key signals responsible 
for the inhibition of apoptosis in intestinal epithelial cells (Wright et al., 1999). 
However, these pharmacological experiments are limited by concerns about the 
specificity of available PI 3-Kinase inhibitors and the inability of such experiments 
to dissect the differing contributions of the classes of PI 3-Kinases to the biological 
read-outs employed.
4. PI 3-kinase and regulation o f cell cycle progression. PI 3-Kinase activation is 
sufficient for cell cycle entry concomitant with cellular changes characteristic of 
oncogenic transformation (Klippel et al., 1998). Indeed, upon activation of PI 3- 
Kinase, cells can enter S-phase as illustrated by activation of cyclin-dependent 
kinase (Cdk4) and Cdk2 and by the induction of DNA synthesis (Klippel et al., 
1998). Inhibition of PI 3-Kinase activity induces a senescence-like cell cycle arrest 
mediated by up-regulation of p27Klpl (Collado et al., 2000), a cyclin-dependent 
kinase inhibitor, that is regulated by AFX, a member of the Forkhead family of 
transcription factors. These transcription factors, which also include FKHR and 
FKHRL, are directly phosphorylated by PKB, resulting in their export from the 
nucleus to the cytoplasm, where they form a complex with 14-3-3 proteins that 
effectively retains them in the cytoplasm away from their nuclear targets 
(Vanhaesebroeck, 2001). Hence, the induction of p27Klpl in response to inhibition of 
PI 3-Kinase activity appeared in conjunction with inactivation of PKB and 
consequent activation of the PKB substrate AFX (Collado et al., 2000). 
Interestingly, an increase in PI 3-Kinase and PKB activity contributes to prostate 
cancer progression as demonstrated by an accelerated tumour growth and diminished 
AFX-forkhead-mediated transcription of p27K,pl (Graff et al., 2000). It is tempting
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to speculate therefore, that the observed increase in PI 3-Kinase activity observed in 
colorectal tumours (Phillips et ah, 1998; Benistant et ah, 2000) might also correlate 
with diminished p27Kipl transcription. To date however, there is no information 
available concerning the PI 3-Kinase-dependent regulation of p27Klpl in colonic 
carcinomas.
5. Transcriptional Regulation by P I 3-Kinases/PKB. So far, the role of PI 3- 
Kinases/PKB in colon cancer has been considered from the point of view of its well- 
defined role in promoting cell growth and survival. However, using fibroblasts and 
HEK293 cells, it is now emerging that PKB phosphorylates IKK-a, in response to 
TNF and PDGF. Although the precise mechanistic pathways mediating this effect 
remain contentious, this event in turn regulates IkB and ultimately leads to activation 
of the transcription factor NFkB which is involved in regulating transcription of a 
variety of genes important for a functional immune response (Ozes et al., 1999; 
Romashkova and Makarov, 1999). This has been demonstrated to be relevant only 
in some cell types (Gustin et ah, 2001), but among the proteins whose expression is 
determined by NFkB is COX-2.
1.4.1.3 PI 3-Kinases and Inflammatory Bowel Disease
The role of PI 3-Kinases in IBD has received far less research interest than their role 
in tumourigenesis. Current theories are based on studies of non-gastrointestinal 




Evidence for PI 3-Kinases Promoting Inflammation.
1. The f-Met-Leu-Phe (fMLP) induced oxidative burst in neutrophils is a PI 3- 
Kinase dependent effect. The response to this pro-inflammatory peptide is 
believed to be involved in the pathogenesis of IBD where neutrophils from 
patients with Crohn’s Disease have significantly increased receptors for fMLP 
(Anton et al., 1989). More recently, two studies using knockout mouse models 
showed that it is the class Ib PI 3-Kinasey which are involved in this response to 
fMLP (Li et al., 2000; Hirsch et al., 2000). Indeed, in a septic peritonitis model 
using PI 3-Kinasey-/- mice, there was severely defective macrophage 
accumulation indicating a crucial role for class Ib PI 3-Kinasey in chemotaxis 
and in successful inflammatory responses. Finally, it has recently been 
demonstrated that PI 3-Kinase products can bind the PX domain of phagocyte 
NADPH oxidase promoting reactive oxygen metabolite formation (Ellson et al., 
2001; Kanai et al., 2001;).
2. The activation of PI 3-Kinases by the pro-inflammatory Thl cytokine TNFa has 
been shown in a number of cell systems, including epithelial cells (Hanna et al., 
1999; Kim et al., 1999; Pastorino et al., 1999). However this has not been 
previously investigated in a gastrointestinal system.
3. It has been previously mentioned that the repertoire of responses of IECs 
includes chemokine secretion. Furthermore there is ample evidence that 
chemokines play a role in IBD and in trafficking and homing of intestinal 
lymphocytes. There is now a body of evidence derived from biochemical,
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molecular and genetic studies that strongly supports the activation of PI 3- 
Kinases by chemokine receptors. PI 3-Kinasey is the primary lipid kinase 
activated by chemokines and is thought to be required for cell migration. 
However, there is substantial evidence for the activation of the p85/pl 10 
heterodimer as well the class II PI 3-Kinase-C2a depending on the chemokine in 
question (Sotsios and Ward, 2000). There is thus, the potential that individual 
chemokine receptors can couple to one or more PI 3-Kinases and as such to 
different upstream activators and/or downstream effectors which one might 
expect to operate with different spatial and temporal characteristics.
Evidence fo r  PI 3-Kinases Inhibiting Inflammation
I . In apparent conflict with the pro-inflammatory role of PI 3-Kinases in intestinal
inflammation outlined previously, is the activation of PI 3-Kinases in intestinal 
epithelial cells by the Th2 cytokine IL-13 which is widely regarded as being anti­
inflammatory (Wright et al., 1997). This is supported by work in other systems 
demonstrating the activation of PI 3-Kinase by IL-13 and other Th2 cytokines 
including IL-4 and IL-10 (Mirmonsef et al., 1999; Ceponis et al., 2000). In the 
intestinal epithelium the activation of PI 3-Kinase by IL-13 was shown to be the 
mechanism mediating the inhibition of iNOS by this cytokine (Wright et al.,
1997). Although classically regarded as pro-inflammatory the functional role of 
iNOS in the context of IBD is contentious. This makes it difficult to comment 
on pro- or anti- inflammatory actions of PI 3-Kinase with respect to iNOS; 




2. A second likely anti-inflammatory action of PI 3-Kinase is its involvement in 
restitution -  the migration of viable intestinal epithelial cells over an area of 
damage to restore epithelial continuity. This process is ongoing at times of 
damage such as in IBD. Using an in vitro wound model with intestinal epithelial 
cells, Insulin, Insulin-like growth factor-I (IGF-I) and a truncated analogue of 
IGF-I induced cell migration without altering proliferation. This process was 
inhibited by pharmacological inhibition of PI 3-Kinase, although there was no 
effect on restitution stimulated by phorbol 12-myristate 13-acetate (PMA) 
(Andre et al., 1999). Human Intestinal Trefoil Factor (ITF) also promotes 
restitution and prevents the apoptosis that would occur with epithelial 
detachment in other circumstances. Elegant studies have dissected the molecular 
mechanisms involved in these processes (Kinoshita et al., 2000; Taupin et al., 
2000). These showed that although, in this context, restitution is independent of 
PI 3-Kinases, the prevention of apoptosis occurring at this time is wholly 
dependent on activation of PI 3-Kinases and the downstream effector PKB or 
Akt. This in turn is dependent on the conformation and dimerisation of ITF. 
Despite their distinction between restitution per se and the prevention of 
apoptosis needed for restitution to occur, the pharmacological methods used do 
not shed any light on the classes or sub-classes of PI 3-Kinases involved.
1.4.2 Mitogen Activated Protein Kinases
The mitogen activated protein kinases (MAP kinases) are a major group of pathways 
which transduce extracellular signals to intracellular responses. The members of the 
MAP kinase pathways share core features concerning their consitutent kinases:
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1. All MAP kinases are activated via phosphorylation of both Thr and Tyr 
in a Thr-Xxx-Tyr motif.
2. This activation is catalysed by a dual specificity serine-threonine MAP 
kinase Kinase (MAPKK) which, in turn, is phosphorylated and activated 
by an upstream MAP kinase kinase kinase (MAPKKK)
3. Once activated all MAP kinases can phosphorylate and activate other 
kinases or transcription factors, in the presence of ATP, to exert their 
biological effect
There are three main categories of MAP kinases -  extracellular-regulated protein 
kinase (ERK or p42/44), p38 MAP kinase and c-Jun NH2-terminal kinase (JNK or 










Extracellular-regulated protein kinase (ERK) was the initial classical MAP kinase 
and is involved in transducing signals from mitogens and growth factors involved in 
cellular proliferation and differentiation. Receptor ligand interaction promotes the 
recruitment of the small guanosine triphosphatase (GTPase) Ras, which then 
activates the serine-threonine kinase raf, which can activate members of the MAP 
kinase/ERK kinase (MEK) family. ERK1 (p44) and ERK2 (p42) are activated by 
MEK1 and MEK2 which are acting as MAPKKs. In this context raf is acting as a 
MAPKKK.
Downstream of ERK activation are its effectors, which include the transcription 
factors ATF2 and Elk, and the MAP kinase activated protein kinases (MAPKAPKs) 
1 and 5. Study of the cellular effects of ERKs has been made possible by the use of 
small specific MEK1/2 inhibitors such as PD90859.
1.4.2.2 p38
The p38 MAP kinase is often grouped with c-Jun NH2-terminal kinase (JNK) as the 
stress activated protein kinases. They are both involved in regulating the cells 
responses to stress, inflammation and also apoptosis pathways. The p38 MAP 
kinase isoforms (a, p, p2, y and 8 ) share a Thr-Gly-Tyr motif and are preferentially 
activated by pro-inflammatory cytokines (TNFa and IL-1), UV light, as well as heat 
and osmotic shock. There is some confusion over the precise details of the 
activating pathways for p38 MAP kinase which stems from the convergence of many 
upstream kinase dependent pathways (Herlaar and Brown, 1999; Ichijo, 1999;).
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However p38 is activated by the MAPKKs MKK3 and MKK6  which act as points of 
convergence for MAPKKK pathways.
The effects of p38 activation are mediated by activation of transcription factors such 
as ATF2 and Elkl as well as activating MAPKAPKs 2, 3 and 5. p38 activation 
plays a role in regulating development, inflammation and apoptosis, although this 
latter role is cell stimulus specific. The study of the functional consequences of its 
activation is assisted by the use of specific inhibitors of the pyridinyl imidazole 
family, such as SB203580 (Young et al., 1997; Davies et al., 2000).
1.4.2.3 JNK
There are many similarities between p38 MAP kinase and JNK. They are both 
activated by similar cellular stresses and have similar functional consequences. 
JNKs are phosphorylated on their common Thr-Pro-Tyr motif by MKK4 and MKK7 
which, as with p38, integrate a wide variety of triggering stimuli (Davis, 1997).
Downstream of JNK activation and mediating its effects is activation of the 
transcription factors API, ATF2 and Elkl. The functional consequences of this are 
believed to be similar to p38 activation but research in this area is hindered by the 
lack of a specific inhibitor for JNK.
1.4.2.4 MAP kinases and the intestine
Despite the conceptual hypotheses that ERK may be involved in tumourigenesis, and 
that the stress activated protein kinases could play an important part in inflammation,
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the data on clinical outcomes of MAP kinase activation has been confusing. ERK 
has been found to be raised (Licato and Brenner, 1998), unaltered (Miki et al., 1999) 
and down-regulated in colorectal adenocarcinoma or adenomatous polyps (Attar et 
al., 1996). p38 MAP kinase and, most consistently, JNK activity is seen to be 
increased in colorectal carcinoma (Licato and Brenner, 1998; Hardwick et al., 
2001;).
From the point of view of IBD there is no clear evidence of altered MAP kinase 
activation in either Crohn’s disease or ulcerative colitis. However there is evidence, 
in in vitro models of intestinal disease, that MAP kinases do mediate pro- 
inflammatory mechanisms (Goke et al., 1998).
1.5 Transcription Factors
1.5.1 Nuclear Factor k  B
Nuclear Factor kB (NFkB) is an inducible transcription factor first described as a B 
cell-specific factor that binds to a lObp motif in the Ig k  light chain intronic enhancer 
(Sen and Baltimore, 1986a; Sen and Baltimore, 1986b). NFkB is a dimer of 
members of the Rel family of proteins with the prototype being a heterodimer 
composed of the RelA (p65) and NFkBI (p50) subunits. This combination is the 
most potent gene activator among the NFkB family and is the major NFkB protein 
found in the nucleus of cytokine stimulated IECs (Jobin et al., 1997).
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1.5.1.1 Activation and regulation of NFkB
NFkB can be activated by a wide variety of stimuli which include:
• Cytokines and growth factors -  such as TNFa, IL-lp and PDGF
• Bacteria and bacterial products -  such as LPS, H.pylori and EPEC
• Mitogens -  such as PHA and ConA
• Miscellaneous -  such as oxidative stress and viruses including EBV and 
HBV
This activation is mediated by an elegant mechanism involving endogenous NFkB 
inhibitors belonging to the IkB family of proteins, which are characterised by an 
ankyrin repeat domain involved in protein/protein interaction. The prototypical 
member of this group is IkBcc that binds to the p65 subunit of NFkB in the 
cytoplasm of unstimulated cells keeping it in an inactive state. On appropriate 
stimulation, there is activation of a complex of IkB kinases (IKK) which 
phosphorylate the Serine and Serine residues of IkBoc. This step initiates the 
degradation, by ubiquitination, of IkBoc which allows the release of free NFkB. This 
reveals its nuclear translocation signal resulting in transportation to the nucleus and 
NFkB dependent gene transcription. Among the many genes with a NFkB response 
element is the gene for IkBa which is subsequently resynthesised approximately 60- 
90 minutes after activation. This binds to the cytoplasmic NFkB resulting in its 
inhibition as shown in Figure 1.15.
However, all members of the IkB family do not follow this paradigm. IkBP is not 
regulated by NFkB and does not have this intrinsic negative feedback resulting in
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C0X2; iNOS; TNFa; 
IL-1; IL-8; IL-6
Figure 1.15: Activation o f N F kB
Schematic representation of the activation of transcription factor 
NFkB and its regulation, in a negative feedback loop, by IkB.
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persisting activation. Furthermore there is evidence of post-translational 
modification of RelA phosphorylation state providing an alternative mechanism of 
regulating NFkB (Egan et al., 1999).
Activated NFkB transcriptionally regulates a large number of genes including many 
immediate early (IE) genes. These include iNOS, IL-8 , RANTES, TNFa, IL-ip, IL- 
6 , ICAM-1 and COX-2. With regard to COX-2, its induction has been shown to be 
NFkB dependent in FIT-29 intestinal epithelial cells using adenoviral transfection of 
a non-degradable form of iKBa to act as a specific NFkB inhibitor (Jobin et al.,
1998). Such NFkB inhibition had no effect on constitutive COX-1 levels. The 
genes which are transcriptionally activated by NFkB are generally pro-inflammatory 
and include cytokines that activate NFkB allowing potential amplification of the 
inflammatory response that needs to be tightly regulated.
1.5.1.2 NFkB and Inflammatory Bowel Disease
The general pro-inflammatory response to NFkB activation suggests an involvement 
in inflammatory diseases and also presents a potential target for anti-inflammatory 
therapies and this is particularly true for IBD. NFkB activation has been 
demonstrated in biopsy specimens, as well as lamina propria mononuclear cells 
(LPMCs) and primary IECs in both Crohn’s disease and ulcerative colitis (Ardite et 
al., 1998; Rogler et al., 1998; Neurath et al., 1996; Schreiber et al., 1998).
It has also been demonstrated that many of the traditional treatments for IBD inhibit 
NFkB activation. In particular, the NFkB activation seen in biopsy samples from
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people with IBD decreases with systemic steroid therapy (Ardite et al., 1998). This 
does not rule out a bystander effect of NFkB activity decreasing with clinical 
improvement. Evidence against this is found in cases of Crohn’s Disease of matched 
severity with those patients on steroids having decreased NFkB activation (Thiele et 
al., 1999). There is also support from in vitro models where glucocorticoid 
treatment has been shown to decrease RelA binding activity, compared to those not 
receiving steroid, due to a physical interaction with the glucocorticoid receptor 
(McKay and Cidlowski, 1998; Adcock et al., 1995). However this mechanism of 
glucocorticoid action is not universally seen with others reporting glucocorticoid 
induced impairment of IkB oc degradation with no alteration of DNA binding 
(Hofmann et al., 1998).
A similar picture is seen with the aminosalicylates. Sulphasalazine, a combination of 
sulphapyridine and 5-ASA, has been shown to be a specific inhibitor of NFkB 
activity by inhibiting phosphorylation of IkBoc in colonic epithelial cells (Wahl et 
al., 1998). It has also been shown to inhibit NFkB activation in T cells (Liptay et al.,
1999) and in both of these studies 5-ASA alone had no effect. In contrast, 5-ASA 
was seen to decrease NFkB mediated transcription in Caco-2 intestinal epithelial 
cells albeit at high concentrations (40mM) (Egan et al., 1999) as well as inhibiting 
induced IkBoc degradation in mouse IECs (Kaiser et al., 1999). Although the 
general theme is of current therapeutic agents mediating their effects via NFkB, the 
multiple mechanisms of NFkB regulation, allied with the various differing assays to 




Attempts have been made to exploit NFkB as a therapeutic target for IBD. The best 
example of this was the use of a specific antisense oligonucleotide to RelA which, 
when locally administered to IL-10-/- knockout mice which spontaneously develop 
colitis, resulted in an abrogation of inflammation (Neurath et al., 1996). An in vitro 
model of NFkB inhibition using a non-degradable IkBoc has been delivered into 
IECs by adenovirus with marked inhibition of IL-8 , iNOS and COX-2 (Jobin et al.,
1998). There has been much excitement about NFkB inhibition and this method of 
adenoviral delivery which unfortunately has yet to yield therapeutic benefits in 
humans.
1.5.1.3 NFkB and colorectal carcinoma
The role of NFkB in colorectal carcinogenesis has received far less interest than its 
more apparent inflammatory associations. Generally NFkB is regarded as having a 
protective action against apoptosis with RelA-/- knockout mice dying in utero of 
massive liver apoptosis (Beg et al., 1995). This information has not been confirmed 
in IECs and, indeed there is conflicting evidence of a pro-apoptotic function 
(Giardina et al., 1999). Finally there is evidence of NFkB having a negative 
influence on the cyclin dependent kinases thus inhibiting cell cycle progression 
(Hinz et al., 1999). Thus it can be seen that NFkB may have a role in carcinogenesis 
but what that is in the colon is, as yet, far from clear.
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1.5.2 Peroxisome Proliferator Activated Receptors (PPARsl
The first PPAR family member was discovered in 1990 and initially attracted only 
moderate interest because peroxisome proliferation, from which they get their name, 
is only of physiological importance in rodents and there were no identified human 
ligands (Issemann and Green, 1990). However, they are now recognised as 
important ligand dependent transcription factors, involved in differentiation, 
adipogenesis and the inflammatory response (Vamecq and Latruffe, 1999).
PPARs are members of the nuclear hormone receptor superfamily and have three 
currently identified isoforms -  a , 5, and y. PPARs are activated by a combination of 
ligand binding, interaction with the heat shock protein hsp72, and cellular signalling 
which alters the phosphorylation state of receptor. Once activated the receptor forms 
a heterodimer with a 9 c/s-retinoic acid receptor, RXRa, and then can interact with 
the peroxisome proliferator response element (PPRE) in the target gene to promote 
transcriptional activation.
1.5.2.1 PPARa
PPARa is an important regulator of lipid metabolism although an important function 
in intestinal physiology is unrecognised. As with all PPARs a number of fatty acid 
derivatives bind and activate PPARa and these include the lipoxygenase products 
LTB4 and 8 -S-HETE (Yu et al., 1995; Devchand et al., 1996). The NSAIDs 
indomethacin, fenoprofen, ibuprofen and flufenamic acid also act as ligands as well 
as the fibrate class of hypolipidaemic drugs which exert their therapeutic effect via
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this mechanism (Lehmann et al., 1997). Once activated PPARa has been shown to 
inhibit COX-2 via a NFkB dependent pathway and has been hypothesised as having 
an anti-inflammatory action (Staels et al., 1998). In contrast the potent PPARa 
ligand, WY-14,643, induced COX-2 protein in a breast epithelial cell line 
demonstrating the lack of concensus in this area (Meade et al., 1999).
1.5.2.2 PPARS
Little is known of the physiological role of PPAR8 , also known as PPARp, although 
it has been shown to act as a receptor for the COX product PGL in a model of 
blastocyst implantation (Lim et al., 1999). It is also emerging as having a potential 
role in colorectal carcinogenesis (DuBois, 2001) where its mRNA is seen to co- 
localise with that for COX-2 although the full implications of this finding are yet to 
become clear.
1.5.2.3 PPARy
PPARy has been found to be an important member of this family of receptors. It is 
an established regulator of adipocyte differentiation and has been targeted for novel 
diabetic therapies. It is known to bind to COX products PGA2 and PGD2 (Yu et al., 
1995), with the cyclopentenone derivatives of PGD2 such as 15-deoxy-A12’14- 
prostaglandin J2 (PGJ2) being potent activators (Forman et al., 1995; Kliewer et al., 
1995). It also binds the NSAIDs indomethacin, fenoprofen, ibuprofen and 




The details of this interaction with aspects of the COX pathway need further 
elucidation. PGJ2 has been demonstrated to inhibit LPS induced COX-2 expression 
at the mRNA level in macrophage like cells (Inoue et al., 2000) whereas PPARy 
agonists as well as NSAIDs were shown to induce COX-2 mRNA and protein in 
epithelial carcinoma cell lines (Meade et al., 1999). Whether this is due to 
differences in sole induction or regulating another agent is unknown and needs 
further investigation.
PPARy and IBD: Soon after PPARy ligands were identified, an anti-inflammatory 
response to their binding was identified. They were shown to suppress pro- 
inflammatory cytokine production by monocytes (Jiang et al., 1998), as well as 
inhibiting macrophage activation, the latter being due to antagonising the activities 
of the transcription factors AP-1, STAT1 and NFkB (Ricote et al., 1998). When this 
was pursued in a colonic model, PPARy activation inhibited the production of MCP- 
1 and IL- 8  in Caco-2 and HT-29 intestinal epithelial cells and the mechanism for this 
was prevention of IkBcx degradation and hence inhibition of NFkB binding (Su et 
al., 1999). Others have subsequently shown that PGJ2 can inhibit NFkB in a PPARy 
dependent and independent fashion (Straus et al., 2000). In an animal model of 
colitis PPARy agonists cause a marked abrogation of inflammation in mice receiving 
oral dextran sodium sulphate (DSS) (Su et al., 1999). This approach is now being 
studied in patients with ulcerative colitis (Lewis et al., 2000) and may be the 
mechanism for the known beneficial effects of fish oil in IBD.
PPARy and colorectal carcinoma: As PPARy is prominently expressed in the 
colonic epithelium, is regulated by eicosanoids and by exogenous dietary fatty acids,
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and has an important role in cellular differentiation, the functions of PPARy in 
colorectal carcinoma have been studied. PPARy is expressed in the epithelial cells 
of human colorectal carcinomas although there is some debate about its role (DuBois 
et al., 1998; DuBois, 2001). In the Min mouse model mimicking human FAP, oral 
thiazolidinedione drug caused an increase in the number of colonic polyps which 
developed (Lefebvre et al., 1998; Saez et al., 1998). However work in this model 
stands alone in suggesting a pro-neoplastic action of PPARy activation. Work using 
human colonic carcinoma derived cell lines, both in vitro and injected into nude 
mice, show that PPARy agonists decrease tumour growth and increase differentiation 
(Sarraf et al., 1998). Furthermore, the same group in a different study identified a 
subset of human colorectal carcinomas that contain somatic mutations in PPARy and 
proposed a causal role (Sarraf et al., 1999). With the licensed clinical availability of 
pharmacological PPARy agonists, the effect of PPARy activation in human 





p-Glycerophosphate Sigma, Poole (UK)
[32P]-Orthophosphate (8500-9120 
Ci/mmol)
DuPont NEN (Stevenage, UK)
2,3-Diaminonaphthalene (DAN) Lancaster Synthesis Ltd.




5-Aminosalicylic Acid (5-ASA) Sigma Chemical, UK. It was diluted in 
48mM Hydrochloric acid to give a 
concentration of 20mM and stored in 
aliquots at 4°C.
5'Digoxygenin labelled iNOS probe R&D Systems (Abingdon,UK)
Absolute Ethanol Hayman Ltd., Witham, UK
Acrylamide/bis acrylamide Bio-Rad, UK
Adenosine triphosphate Sigma, Poole (UK)
Agarose Sigma, Poole (UK)
Ammonium persulphate BDH, Poole (UK)
Blocking reagent (for Northern analysis) Boehringer Mannheim (UK)
Bovine serum albumin (BSA) Sigma, Poole (UK)
Bromophenol blue BDH, Poole (UK)
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cDNA for COX-1 Oxford Biomedical, USA
cDNA for COX-2 Oxford Biomedical, USA
Cell culture plastics Nunc, UK
Chloroform Fisons, Loughborough (UK)
Control Digoxigenin Labelled DNA Roche, Lewes, UK
COX-1 antibodies Santa Cruz, USA
COX-2 antibodies Santa Cruz, USA
Diethyl pyrocarbonate (DEPC) Sigma, Poole (UK)
DIG High Prime Digoxigenin Labelling kit Roche, Lewes, UK
Digoxigenin chemiluminescent detection 
kit for Northern blotting
Boehringer Mannheim (UK)
Dimethyl sulphoxide (DMSO) Sigma, Poole (UK)
Dithiothretol (DTT) Sigma, Poole (UK)
Enhanced chemiluminescence detection kit 
for Western blotting (ECL)
Amersham International, UK
Ethidium bromide Sigma, Poole (UK)
Ethylenediaminetetraacetic acid (EDTA) Sigma, Poole (UK)
Flo-scint IV scintillation fluid Canberra Packard (UK)
Foetal bovine serum (FBS) Gibco BRL, Paisley, UK
Folch lipids Sigma, Poole (UK)
Formaldehyde BDH, Poole (UK)
Formamide BDH, Poole (UK)
Glacial acetic acid Fisons, Loughborough (UK)
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Glycerol Sigma, Poole (UK)
Glycine Sigma, Poole (UK)
Goat anti-rabbit peroxidase conjugate DAKO, Denmark
Hank’s balanced salt solution Gibco BRL, Paisley, UK
Hepes (1M liquid) Gibco BRL, Paisley, UK
Hydrochloric acid BDH, Poole (UK)
IFN-y: human recombinant; specific 
activity > 2xl0 7 U/mg
Boehringer Mannheim, UK; stored in 
aliquots at -70°C
IL-1 a: human recombinant; specific
n
activity 5x10 U/mg
Gift from Glaxo (Greenford, UK); diluted 
in sterile PBS + 0.25% (w/v) BSA and 
stored in aliquots at -70°C)
IL-13: purified from culture supernatants of 
stable transfected CHO cells (Minty et al., 
1993)
Gift from Dr. A. Minty (Sanofi Recherche, 
Labege, France); diluted in sterile PBS + 
0.25% (w/v) BSA and stored in aliquots at - 
70°C
IL-4: human recombinant; specific activity 
> lxlO 7 U/mg
Genzyme and Pepratech, UK
Leupeptin Sigma, Poole (UK)
Lithium chloride (LiCl) Sigma, Poole (UK)







Maleic acid Sigma, Poole (UK)
McCoy’s 5A medium Gibco BRL, Paisley, UK
Methanol Fisons, Loughborough (UK)
Methylamine Fisons, Loughborough (UK)
Molecular weight markers Bio-Rad
N-(2-(Cyclohexyloxy)-4-nitrophenyl) 
methanesulfonamide (NS-398)
Research Biochemicals International (RBI), 
USA. It was diluted to 20mM in absolute 
ethanol and stored in aliquots at -20°C.
N-(3-(Aminomethyl)benzyl)acetamidine
(1400W)
Alexis Corporation, UK. It was diluted to 
20mM in MilliQ water and was stored in 
aliquots at -20°C
Neutral buffered formalin Sigma, Poole (UK)
Nitrocellulose Schleicher and Schuell
NP40 Sigma, Poole (UK)
Ovalbumin Donated by Dr. M. Welham
Phosphate buffered saline Gibco BRL, Paisley, UK
Phosphatidylinositol Sigma, Poole (UK)
Phosphatidylserine Sigma, Poole (UK)
PKB-a 473 Ser, polyclonal Ab New England Biolabs, USA
PKB-a, polyclonal Ab Santa Cruz, USA
PKB-a, polyclonal Ab New England Biolabs, USA
PMSF Sigma, Poole (UK)
Polaroid film (type 55) Sigma, Poole (UK)
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Ponceau S Sigma, Poole (UK)
Propan-l-ol Fisons, Loughborough (UK)
Propan-2-ol Fisons, Loughborough (UK)
Propidium iodide Sigma, Poole (UK)
Protein G beads Sigma, Poole (UK)
RNase A Sigma, Poole (UK)
RNAzolB Tel Test, Texas, USA
Sarcosyl BDH, Poole (UK)
Sodium azide Sigma, Poole (UK)
Sodium chloride Sigma, Poole (UK)
Sodium dodecyl sulfate (SDS) Sigma, Poole (UK)
Sodium fluoride Sigma, Poole (UK)
Sodium hydroxide Sigma, Poole (UK)
Sodium molybdate Sigma, Poole (UK)
Sodium nitrite Sigma, Poole (UK)
Sodium orthovanadate Sigma, Poole (UK)
TEMED Sigma, Poole (UK)
Tetrabutylammoniumhydrogen sulphate Fluka, Germany
Tissue culture reagents Gibco BRL, Paisley, UK
TNF-a: human recombinant; specific 
activity 6xl0 7 U/mg
Gift from Bayer (Slough, UK); diluted in 
sterile PBS + 0.1% (w/v) BSA and stored 
in aliquots at-70°C)
Trisodium citrate dihydrate Sigma, Poole (UK)
Triton X-100 Sigma, Poole (UK)
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Trizma base Sigma, Poole (UK)
Tween-20 Sigma, Poole (UK)
Versene Gibco BRL, Paisley, UK
Wortmannin Sigma, Poole (UK)




3.1 Cell Culture Conditions
3.1.1.1 HT-29 cells
The human colonic epithelial cell line HT-29 was obtained from the European 
Collection of Animal Cell Cultures (ECACC). HT-29 cells are human colon 
adenocarcinoma grade II cells isolated from a primary tumour in a 44 year old 
Caucasian female (ECACC). They are a well characterised epithelial cell line and have 
characteristics of normal intestinal epithelium such as epithelial polarity, presence of 
the actin-biding protein villin and the occurrence of an enterocytic differentiation 
(Chantret et ol., 1988).
•  •  9 •HT-29 colonic epithelial cells were routinely cultured in 80cm tissue culture flasks 
in McCoy’s medium supplemented with penicillin (lOu/ml), streptomycin 
(lOpg/ml), fungizone (0.5pg/ml), and 10% (v/v) FBS (referred to as complete 
medium). Cultures were maintained at 37°C in an atmosphere of 5% CO2 . The 
medium was changed every 3 days. To subculture confluent monolayers, the
^  1
medium was removed and the cells were washed 3 times with PBS (w/o Ca and
'y.
Mg ). Cells were then washed with a 3ml Trypsin-EDTA mixture of 0.05% (w/v) 
Trypsin and 0.02% (w/v) EDTA. The excess solution was removed and the cells 
were incubated for approximately 5mins at 37°C until the cells had detached from 
the flask. The action of trypsin/EDTA was inhibited by adding 10ml of complete
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McCoy’s medium and the cell suspension was centrifuged at 200g for 5min. The 
cell pellet was resuspended in complete medium and cell counting and viability were 
checked in a Neubauer haematocytometer after mixing with Trypan Blue (Sigma). 
Dead cells stained blue, due to the uptake of Trypan Blue. Cell viability was always 
greater than 95%. Cells were counted and then seeded at 2-3 x 104/ml of McCoy’s 
complete medium, into 80cm tissue culture flasks for further culture, into 6 -well 
plates for northern experimental protocols, into 97mm petri dishes for western and 
ELISA experimental protocols and into 170cm flasks for radioactive lipid labelling. 
Flasks and plates reached confluency after approximately 6  days. For storage, cells 
were resuspended at 4 x 106 cells/ml of freeze medium. The freeze medium 
contained 10% of dimethylsulphoxide (DMSO) (Sigma), 40% FBS, and 50% 
McCoy’s medium. The cell suspension was transferred to cryotubes (Nunc) at 1 
ml/tube, gradually cooled in vapour phase of liquid nitrogen overnight and then 
stored in liquid nitrogen tanks. For resuscitation of cells from liquid nitrogen, cells 
were rapidly defrosted at 37°C in a water bath, washed in McCoy’s medium, 
resuspended in complete medium and cells from 1 cryotube were seeded into 80cm 
tissue culture flasks in McCoy’s medium, continuing as above.
3.1.1.2 Caco-2 cells
The human colonic epithelial cell line Caco-2 was obtained from the European 
Collection of Animal Cell Cultures (ECACC). It was established in 1974 from a 
colorectal adenocarcinoma in a 72 year old Caucasian male (Rousset, 1986).
Caco-2 colonic epithelial cells were maintained in a similar fashion with a few 
distinctions. The medium used was Eagles Minimum Essential Medium (EMEM)
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with Earles Balanced Salt Solution (EBSS). This was supplemented with 1% Non- 
Essential Amino Acids (NEAA) and 2mM Glutamine as well as penicillin (lOu/ml), 
streptomycin (lOpg/ml), fungizone (0.5pg/ml), and 10% (v/v) FBS. Cultured cells 
were maintained in similar conditions to HT-29 cells and were passaged in the same 
way. Caco-2 cells had a visibly different phenotype to HT-29 cells, were easier to 
detach with Trypsin-EDTA and grew slightly more slowly.
3.1.1.3 Primary Colonic Epithelial Cell Isolation
Colonic epithelial cells were isolated from biopsy specimens obtained at 
colonoscopy, and from colonic resection specimens, both obtained with ethical 
approval from the Royal United Hospital, Bath. The specimens came from patients 
with a normal colonoscopy, or from resection specimens for colorectal carcinoma 
when tissue away from the tumour was used. The specimens were collected in ice 
cold HBSS (pH 7.3) and transported to cell culture facilities. They were then 
washed three times for five minutes each in fresh HBSS to remove any visible 
debris. Once cleaned the mucosal layer was carefully dissected from the underlying 
submucosa and then cut into 2-3mm pieces. These mucosal pieces were then washed
^  r ^  I
in Ca / Mg free HBSS three times for five minutes each. The cleaned mucosal 
pieces were then transferred to Ca2+ / Mg2+ free HBSS containing ImM DTT and 
incubated for 15 minutes at room temperature with rocking. The mucosal pieces 
were then washed again in Ca / Mg free HBSS three times for five minutes each 
and then transferred to Ca2+ / Mg2+ free HBSS containing ImM EDTA and 
incubated for 30 minutes at 37°C with rocking. The supernatant, containing 
intestinal epithelial cells, was collected and spun down at 2 0 0 g for five minutes and 
the cell pellet resuspended in 3ml RPMI. These cells were then placed on a Percoll
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centrifugation gradient (Percoll at 0%; 30%; 40%; 60%; and 100%) and spun at 250g 
for 30 minutes without a brake. The epithelial cells were removed from the 0%-30% 
interface and resuspended IEC culture medium. At this point they were counted and 
viability was assessed using trypan blue staining. They were then aliquoted into 
experimental points of 107 cells per point.
3.2 E x p e rim en ta l P ro toco l
HT-29 or Caco-2 colonic epithelial cells were cultured in the container appropriate to 
the planned experiment:




Northern analysis 6 well plates 3.5 xlO6 cells 2 xlO6 cells
Western analysis 92mm petri dishes 10? cells 6 xlO6 cells
ELISAs 92mm petri dishes 10' cells 6x10* cells
J2P Lipid labelling 170cm2 flasks
Twenty-four hours prior to the experiment the confluent monolayers were washed 
and cultured in FBS-free medium. Growth arrested cultures were then treated with 
fresh FBS-free medium and stimulated with the appropriate doses of either drugs, or 
cytokines, or vehicle controls for the times described in the results section. 
Supernatants were collected, centrifuged to remove cellular debris and stored at
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-80°C until assayed. Total RNA and cellular proteins were extracted as described 
below. Cell counting and viability were routinely checked at the beginning and the 
end of the experiment, by phase microscopy and by trypan blue exclusion, using 
representative wells. Cell viability was always greater than 95%.
3.3 Northern Analysis
3.3.1 Overview
Northern analysis is a technique for directly assaying the total amount of a specific 
mRNA in a population of cells. Once cells have been incubated in the appropriate 
conditions, the cells are lysed and the RNA isolated, purified and quantified. This 
RNA is then separated according to its mass by migration, in an electric current, 
through an agarose gel. The RNA is then transferred from the gel to a nylon 
membrane which can be stored. At a later date the membrane can be incubated with 
a labelled piece of cDNA complementary to the RNA to be assayed. Once bound, 
the membrane can be washed and the amount of label (either Digoxigenin or [32P]) 
can be assessed and is directly proportional to the total amount of RNA under 
investigation present. This method of assaying RNA levels was chosen as it 
represents a direct measure of RNA present in the cell.
The alternative method of assessing RNA in cells is based on the polymerase chain 
reaction and involves both the initial reverse transcription of RNA to cDNA 
followed by the amplification of the specific cDNA in question. These extra steps
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make this a less direct assay of RNA based on certain assumptions and therefore 
northern analysis was chosen for this work.
3.3.2 Generation of Membranes
3.3.2.1 RNA isolation
RNA was isolated from colonic epithelial cells using RNAzol B (Biotecx). This is a 
refinement of previous methods and promotes the formation of complexes of RNA 
with guanidium and water molecules. It also abolishes the hydrophilic interactions 
of DNA and proteins allowing them to be efficiently removed from the aqueous 
phase. The RNA remains in the aqueous phase allowing its extraction. After the 
removal of cell cuture supernatant, 1ml of RNAzol B was added to the cells resulting 
in cell lysis. The sample was solubilised by passing the lysate through a pipette 
several times. The samples were then placed in a 1.5ml eppendorf and frozen for a 
minimum of 12 hours at -80°C. When thawed lOOpl of chloroform was added to each 
eppendorf and the samples were shaken vigorously for 15 seconds. They were then 
kept at 4°C for 5 mins before being centrifuged at 12000g for 15mins at 4°C. When 
removed the homogenate had formed two phases -  a lower blue phenol/chloroform 
organic phase and a colourless upper aqueous phase. The DNA and proteins were in 
the interphase and organic phase while the aqueous phase contained the RNA which 
was carefully pipetted off into a new eppendorf. 500ml of Isopropanol was then added 
to the aqueous phase and the samples stored at 4°C for 15mins. They were then 
centrifuged at 12000g for 15mins at 4°C and an RNA pellet was subsequently visible at
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the bottom of the tube. The supernatant was removed and replaced with 1ml cold 75% 
ethanol and the samples were then stored at -80°C.
3.3.2.2 Sample preparation
Eppendorfs containing the RNA samples were defrosted and centrifuged at 12,000 g 
for 15 mins at 4°C. The supernatant was removed and again replaced with 1ml cold 
75% ethanol and this wash step was repeated. The supernatant was removed and the 
pellets air dried in a fume cupboard for 1 hour. RNA pellets were resuspended in 
50pl MilliQ water and kept on ice. RNA was quantified by measuring absorbance of 
2pi RNA in 98pi MilliQ water at 260nm. The amount of RNA present in the 
samples (in pg) was calculated by:
A260 x dilution factor (50) x 40 x volume of remaining RNA solution in ml 
(0.048)
ODs were also read at 280nm and 230nm to assess the purity of RNA. A value of 
less than 2 for the OD26o:OD28o ratio indicated protein contamination. A low 
OD260• OD230 ratio indicated guanidine contamination. 30pl of RNA sample buffer 
was added to lOpg RNA and the samples were vortex mixed and heated for 15-30 
minutes at 80°C. The samples were cooled on ice and 2.5pl of bromophenol blue 
solution was added. Samples were mixed and briefly centrifuged (5 secs) prior to 
loading on agarose gels.
3.3.2.3 Gel preparation and transblotting
1% agarose gel was prepared by dissolving 3.6g agarose (Roche) in 280ml MilliQ 
water and then heating in a microwave oven until the agarose dissolved. 18ml 20X
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MOPS buffer and 65ml formaldehyde were added and the gel solution allowed to 
cool to ~ 60°C before pouring. The gel was set with three 15 lane combs using tanks 
purchased from Bio-Rad Scientific Instruments (Bio-Rad Laboratories, Hercules, 
CA, USA). After 40 mins, the gel was transferred to a submarine tank (Bio-Rad), 
which was surrounded with ice, and covered with cold IX MOPS running buffer. 
lOpg RNA per lane was loaded and the gel run at constant current of 100mA, until 
the bromophenol blue band had migrated 5cm (~ 2.5 hours). The gel was placed 
under a UV light and the ethidium-bromide stained 18S and 28S ribosomal RNA 
bands observed to assess equal loading. The gel was photographed using a polaroid 
CU5 88-46 land camera (Genetic research instrumentation Ltd) and type 55 polaroid 
film (Sigma). The gel was cut at the bottom right hand comer to allow orientation, 
and then agitated gently in MilliQ water for 30-60 mins to remove formaldehyde, 
prior to transblotting. The blotting tank consisted of a glass plate suspended in a 
sandwich box, which was half filled with 20X SSC buffer. A wide strip of 3MM 
filter paper (Whatman, Maidstone, UK), placed over the glass plate and reaching 
down into the buffer solution at each end, acted as a wick. The gel was placed 
upside down on the filter paper and covered with a piece of positively charged nylon 
membrane (Roche), which had been briefly soaked in 20X SSC. All air bubbles 
were removed by rolling with a sterile glass pipette, before covering the membrane 
with three pieces of similar size 3MM filter paper and a stack of paper towels. A 
500g weight was placed on top and left overnight to allow the RNA to transfer by 
capillary action. The RNA was fixed onto the nylon membrane by baking in a 
vacuum oven (Jouan) at 120°C for 20 mins. The membrane was sealed in a plastic 
bag and stored at room temperature prior to hybridisation.
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3.3.3 Digoxigenin (DIG) labelled COX cDNA probes
3.3.3.1 Generation of Digoxigenin (DIG) labelled COX cDNA probes
The COX-1 and COX-2 cDNA (Oxford Biomedical, USA) were used as templates 
for the synthesis of smaller probes (c200bp) labelled with Digoxigenin using the 
DIG-High Prime method from Roche. This method was originally developed by 
Feinberg and Vogelstein (Feinberg and Vogelstein, 1983; Feinberg and Vogelstein, 
1984) and is based on the hybridisation of oligonucleotides of all possible sequences 
to the denatured cDNA to be labelled. The complementary DNA strand is 
synthesised by Klenow enzyme using the 3’-OH termini of the random 
oligonucleotides as primers. Modified deoxyribonucleoside-triphosphates labelled 
with Digoxigenin present in the reaction are incorporated into the newly synthesised 
complementary DNA strand. The DIG High Prime kit consists of a reaction mixture 
containing the Klenow enzyme and substrates such that DIG-ll-dUTP is 
incorporated every 20th to 25th nucleotide in the newly synthesised DNA probes. To 
generate labelled probes either lOng or lOOng of template cDNA for COX-1 or 
COX-2 was taken and added to MilliQ water to a final volume of 16pl. The cDNA 
was denatured in a boiling water bath for lOmins and then snap chilled at -80°C for 1 
min. 4pl of the DIG High Prime reaction mixture was added, then mixed and 
centrifuged briefly before being incubated at 37°C for 20 hours. The reaction was then 
stopped by adding 2ml of 0.2M EDTA and by heating to 65°C for 10 min. By this 
method lOng of template should yield 600ng of DIG labelled DNA probe and lOOng 
should yield 1500ng. Comparing the newly labelled probe to control DIG-labelled 
DNA using a dot blot method checked the efficiency of this labelling process. Serial
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dilutions of the control DNA and the newly DIG-labelled probes were spotted onto a 
piece of nylon membrane used for northern blotting. This was then baked at 120°C for 
2 0  mins and the membrane was developed using the hybridisation process described 
below.
3.3.3.2 Hybridisation with DIG-labelled cDNA COX probes
Hybridisation of membranes and detection of bound probes was performed 
essentially as described in the Digoxigenin (DIG) chemiluminescent detection kit for 
Northern blotting by Boehringer Mannheim. The DIG detection system is based on 
the labelling of nucleic acid probes with the steroid hapten, Digoxigenin. The DIG- 
labelled probes are then hybridised to membrane-bound RNA. Specific 
hybridisation is immuno-detected with an alkaline phosphatase conjugated anti- 
Digoxigenin antibody and visualised with the chemiluminescent substrate, CSPD, 
using X-ray film.
Sequential experiments were performed to optimise all the hybridisation conditions 
for each probe. These included performing “mock blots” on membranes without 
bound RNA to assess background levels of probe at differing concentrations and 
temperatures. After initial experiments COX-2 probes were hybridised at 42°C, 
while COX-1 probes were used at 50°C. Both probes were used at a final 
concentration of 25ng/ml.
The volumes specified are for a 100cm membrane and pre-hybridisation,
hybridisation and wash steps were all performed at the appropriate hybridisation
temperature. The membrane was prehybridized by incubating with 20ml high SDS
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hybridisation solution for 1 hour in a sealed bag. The hybridisation solution was 
discarded and 2.5ml of probe, diluted to 25ng/ml in high SDS hybridisation solution, 
was added. The total cDNA probe needed (62.5ng/2.5ml) had already been boiled 
for 10 mins in lOOpl of the high SDS hybridisation solution before being snap 
chilled for 1 min at -80°C and made up to the final concentration of 25ng/ml. This 
denatured the cDNA allowing it to bind to the target RNA on the membrane. All air 
bubbles were removed and the bag resealed and incubated overnight. The membrane 
was transferred to a small sandwich box and washed:
• twice for 15 min in 2X SSC / 0.1% SDS solution at the hybridisation 
temperature
• twice for 15 mins in 0.1X SSC / 0.1% SDS solution at the hybridisation 
temperature.
The probed membranes were then developed.
3.3.3.3 Hybridisation with DIG-labelled oligonucleotide probes
The methods for hybridisation using oligonucleotide probes were closely related to 
those for cDNA probes with the following alterations. Hybridisation temperature 
was optimised for P-actin probes and they were hybridised at 42°C at a final 
concentration of lOng/ml. The standard hybridisation buffer used throughout did not 
need to have a high SDS content. Similarly, the oligonucleotide probes did not 
require boiling and then snap chilling prior to use. Otherwise the hybridisation steps 
were the same as those described above.
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3.3.3.4 Visualisation of DIG-labelled probes
The following steps were then performed at room temperature on a shaking water 
bath. Membranes were washed for 10 mins in washing buffer, prior to blocking for 
30 mins with 100ml buffer 2. Membranes were incubated for 30 min with 20ml 
alkaline phosphatase conjugated anti-DIG antibody diluted 1:10,000 in buffer 2. 
Membranes were then washed twice for 15 mins each in washing buffer and 
equilibrated for 5 mins in buffer 3. The membrane was drained and incubated for 5 
mins between two plastic sheets with 1ml of lumigen PPD substrate diluted in 1:100 
in buffer 3. The membrane was drained again, sealed in a plastic bag and incubated 
for 15 mins at 37°C in the dark. The membrane was then exposed to Kodak X-omat 
AR5 X-ray film (Sigma) for an appropriate time (1-4 hours) at room temperature.
After some time developing this technique, it eventually gave clear, interpretable 
results. However these subsequently became unpredictable despite repeated 
manipulation of experimental conditions, cDNA templates, solutions used and 
equipment and containers used for probing. This necessitated the development of an 
alternative method for specifically probing COX-2 cDNA.
3.3.4 [32PldCTP labelled COX-2 cDNA probes
3.3.4.1 Generation of [32P]dCTP labelled COX-2 cDNA probes
This way of developing labelled COX-2 cDNA probes shares many similarities to 
the above described technique and involves the incorporation, using a random
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priming method, of [ P]dCTP into newly synthesised cDNA probes. After 
hybridisation these can be visualised directly using auto-radiography.
The same COX-2 cDNA was used as for the Digoxigenin method with 50ng being 
dissolved in 11 pi MilliQ water in a screw-topped 1.5ml eppendorf. This was 
denatured by boiling for 10 mins and then spun down briefly. 4pi of High Prime
”39enzyme (Roche) was added to this, followed by 5pi of [ P]dCTP (Amersham, UK). 
The reaction mixture was briefly mixed, spun down and incubated at 37°C for 20 
mins. Meanwhile an Elutip (Schleicher and Schuell, London, UK) was flushed very 
slowly with 2ml of High Salt solution followed by 5ml of Low Salt solution. After 
incubation, 1ml of Low Salt solution was added to the reaction mixture, aspirated 
and flushed and discarded slowly through Elutip. This process was then repeated to
^9ensure all newly synthesised [ P] dCTP labelled probe was bound to Elutip. Then, 
lml of High Salt solution was flushed through Elutip, eluting the labelled probe 
which was collected in the first 500pl passed. The second 500pl was appropriately 
discarded.
The efficiency of the labelling was assessed by counting the radioactivity emitted by 
the newly labelled probe, lp l of the probe was placed in a scintillation vial and to 
this was added 5ml of scintillant (Flo-Scint IV, Packard, USA). This was then 
counted using a liquid scintillant counter (1209 Rackbeta, LKB Wallace, USA). The 
technique required 3x106 counts per ml of hybridisation solution (ie: 21 xlO6 for a 
standard hybridisation tube with 7ml of hybridisation solution).
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3.3.4.2 Hybridisation with |32P]dCTP labelled eDNA COX-2 probes
Membranes for hybridisation were rinsed in 2X SSPE, then layered with Nylon 
sheets and placed in a hybridisation tube with a maximum of five membranes per 
tube. 7ml hybridisation solution was added to each tube and these were then pre- 
hybridised using a rotator in an oven at 63°C for 1-3 hours. Once the [ P]dCTP 
labelled cDNA COX-2 probe was ready, an appropriate volume containing 21xl06 
counts was added to each tube. The tubes were then placed in the oven overnight for 
hybridisation. The next day the membranes were washed in their tubes:
• twice for 5 mins with 6 X SSPE / 0.1% SDS at 37°C
• twice for 15 mins with IX SSPE / 0.1% SDS at 37°C
• twice for 15 mins with 2X SSPE / 0.1% SDS at 63°C 
The probed membranes were then visualised.
3.3.4.3 Visualisation of [32P]dCTP labelled cDNA COX-2 probes
The probed membranes were removed from their hybridisation tubes and placed in 
plastic envelopes. All air bubbles were removed and the envelopes were then sealed. 
These envelopes were placed in clean phosphorimager cassettes which had been 
wiped by exposure to a light box for 10 minutes. Their co-ordinates within the
cassette were noted and they were left for 3 days at room temperature. After this
time the cassettes were opened in a dimmed room and placed in a phosphorimager 
plate reader (Phosphorimager SF, Molecular Dynamics, USA) which produced an 
electronic image of the membrane. This could be analysed using ImageQuant 
software (version 3), allowing measurement of band intensity, and the image could 
be converted to a .tif file for presentation. Alternatively the membranes could be
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exposed to Kodak X-omat AR5 X-ray film (Sigma) for an appropriate time (3 days) 
at room temperature.
3.3.5 Stripping of Membranes
Membranes were stripped by washing twice in 0.1% SDS at 100°C while cooling to 
room temperature
3.4 Western Blot Analysis
3.4.1 Overview
Western analysis is a technique of assaying the relative amounts of specific proteins 
within cells. Once the cells have been incubated in the appropriate conditions the 
cells are lysed and the whole cell proteins are extracted and quantified. The whole 
cell extracts can then be run in a current through a polyacrylamide gel to separate the 
proteins according to their molecular weight. The proteins can then be transferred to 
a membrane which can be incubated with a primary antibody specific for the protein 
to be assessed. A second incubation with a labelled secondary antibody against the 
primary antibody is then carried out. The membrane is then washed and the relative 
amount of the labelled secondary antibody is then assessed, usually by using a horse 




From the point of view of the primary antibodies that are used, they can be specific 
for certain conformations of the protein to be assayed. In particular they can be 
directed to a phosphorylated form of the protein where phosphorylation indicates a 
change in function such as activation. Such an antibody can then be used to assess 
relative changes in the amount of this phosphorylated form of the protein, and by 
inference is a surrogate marker of any associated change in function. To ensure that 
the total amount of the specific protein is unchanged the results from these 
phosphorylated antibodies are compared to results using an antibody against all 
forms of the specified protein, referred to as a pan antibody.
Finally, running whole cell extracts on a gel involves separating all the cell proteins 
and transferring them to a membrane. To allow only the protein of interest to be run 
on the gel, the whole cell extract can first be immunoprecipitated with an antibody to 
select only this protein. In this work, this was done for assaying protein kinase B 
(see 3.4.1.4)
3.4.1.1 Collecting samples
Attached monolayers of colonic epithelial cells were stimulated and incubated at 
37°C as described. Stimulations were terminated at the appropriate times with 
aspiration of the supernatant, one gentle rinse with 5ml of ice cold PBS without Ca2+ 
or Mg2+, and then the addition of 1ml ice cold lysis buffer. Cells were solubilised 
using a cell scraper and the resulting lysates were transferred to 1.5ml eppendorf 
tubes and incubated at 4°C for 15 mins. The samples were then centrifuged at
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12000g for 5 mins at 4°C and the protein containing supernatant was transferred to a 
fresh eppendorf tube. Samples could be frozen at -80°C at this point.
3.4.1.2 Protein assay
Total protein per lysate was estimated using the Bio-Rad DC Protein Assay. This 
assay is based on the Bradford dye-binding procedure. Known concentrations of 
bovine serum albumin (BSA) diluted in lysis buffer were used as a standard curve. 
5pi of sample or standard were placed in a 96 well plate with 25pi of working 
reagent A’ (20pl reagent S into 1ml reagent A) and 200pl of reagent B. After 
15min, the plate was read at 595nm on a Dynatech MR5000 platereader. The protein 
concentrations were calculated by linear regression from the standard curve and, if 
significantly variable, the lysate volumes were adjusted using the lysis buffer, thus 
ensuring equal concentrations of protein in each sample.
3.4.1.3 Whole cell extracts
An aliquot, usually 80 pi, was transferred to a new eppendorf containing an 
appropriate volume (eg 20pl) of 5X SDS sample buffer. This was vortexed briefly, 
boiled for 5 mins and spun down before loading onto a gel. Samples could be frozen 
at -80°C at this point.
3.4.1.4 Immunoprecipitation for protein kinase B
For western analysis for protein kinase B (or Akt), immunoprecipitation was used 
rather than running whole cell lysates. lOpl of goat polyclonal Akt antibody (Santa
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Cruz Biotechnology) was added to the remaining whole cell lysate, briefly vortexed 
and incubated for 1 hour at 4°C. 30pl of a 50% (v/v) suspension of protein G in PBS 
was then added and the mixture was incubated on a rotator for 2 hours at 4°C. At the 
end of this time the beads were captured by centrifugation at 12000g for 1 min at 
4°C. The supernatant was aspirated and the pellet washed three times in lysis buffer 
with the immunocomplexes spun down between washes. After the last wash all the 
supernatant was aspirated and the pellet was resuspended in 24pl of IX SDS sample 
buffer. This was vortexed briefly, boiled for 5 mins and spun down before loading 
onto a gel. Samples could be frozen at -80°C at this point.
3.4.1.5 Separation of cellular proteins by electrophoresis
Proteins were analysed by one dimensional gel electrophoresis, which under 
reducing conditions separates proteins based on molecule size. Sodium Dodecyl 
Sulphate - Polyacrylamide Gel Electrophoresis (SDS-PAGE) was carried out 
essentially as described by Laemmli (Laemmli, 1970). Proteins were separated by 
SDS-PAGE using the Bio-Rad Mini Protean II.
Minigels of the appropriate percentage were prepared as described in buffers and 
solutions section. The resolving gel was poured into the gel equipment and overlaid 
with MilliQ water. After the 20 mins for the resolving gel to set, the water was 
removed. The stacking gel was poured on the top of the running gel and set with a 
10 or a 15 lane comb inserted. When the stacking gel was set the comb was 
removed, the wells were washed thoroughly with MilliQ water followed by running 
buffer. Then ~50pg of sample was loaded per lane (~10-20pl) alongside a molecular
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weight marker. Gels were run at room temperature at 80V, until the bromophenol 
blue tracking dye entered the running gel. The voltage was then increased to 150 
volts. Gels were run until the bromophenol blue band had reached the bottom of the 
resolving gel. Gels were then placed into transfer buffer.
3.4.1.6 Semi-dry transfer of proteins to nitrocellulose
The graphite electrodes of the semi-dry transfer apparatus (Pharmacia-Biotech 
Multiphor II) were dampened with semi-dry transfer buffer. This was followed by 
placing a sandwich of four pieces of 3MM Whatman paper cut to the size of the gel, 
one piece of nitrocellulose membrane, the gel and another four pieces of 3MM 
Whatman paper, all soaked in transfer buffer. Each layer was rolled gently to expel 
air bubbles. The transfer was run for one hour at 0.8mA/cm of membrane (~40mA 
per gel). The membrane was then stained with Ponceau S to check for transfer and 
equal loading of the samples and also to confirm the location of the molecular weight 
markers. The stain was removed by washing the membrane in distilled water for 2 
mins, followed by a 10 mins wash in Tris buffered saline (TBS).
3.4.1.7 Immimoblotting of nitrocellulose bound protein
Non-specific binding sites on the nitrocellulose were blocked by overnight incubation 
of the membrane with the appropriate blocking buffer at room temperature on a rocking 
platform. The nitrocellulose membrane was washed for 10 mins in TBS and then 
incubated with the primary antibody, made up in a 1:5 dilution of fresh blocking buffer 
in TBS, for 2 hours -  overnight. The membrane was then washed on a rocking 
platform at room temperature:
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• one 10 min wash in TBS
• three times for 10 mins in TBSN
• one 10 mins wash in TBS
The membrane was then incubated for 1 hour with the appropriate secondary antibody 
diluted in TBSN (0.1pg/ml usually equivalent to 1:10000). After this incubation 
washings were repeated as previously before a final wash for 10 mins in TBSN. lOmls 
of Enhanced Chemiluminescent Lumigen (ECL) reagent was added for 1 min and the 
membrane was then exposed to X-ray film for 0.5 -  30 mins. The film was developed 
using an RGII Fuji X-ray film developer.
3.4.1.8 Membrane stripping
Where appropriate, blots were stripped of bound antibody and reprobed with a 
different primary antibody. After the ECL procedure described above, the 
membrane was washed once in TBS for 10 mins and then placed in 50ml of stripping 
buffer in a sealed sandwich box and incubated at 55°C for one hour. After extensive
washing in at least three changes of TBSN followed by a TBS wash, the membrane




3.5 p38 MAP kinase assay
3.5.1 Overview
This assay to measure p38 MAP kinase activity uses a kit from Cell Signaling 
Technology. A monoclonal phosphoThrl80/Tyrl82-specific antibody to p38 MAP 
kinase is used to selectively immunoprecipitate active p38 MAP kinase from cell 
lysates. The resulting immunoprecipitate is then incubated with ATF-2 fusion 
protein in the presence of ATP and kinase buffer, which allows immunoprecipitated 
active p38 MAP kinase to phosphorylate ATF-2. Phosphorylation of ATF-2 at Thr 
71 is measured by western blotting using a phospho71’171-specific antibody and acts as 
a marker of p38 MAP kinase activity.
3.5.1.1 Collecting Samples
Attached monolayers of HT-29 cells were stimulated and incubated at 37°C as 
described. Stimulations were terminated at the appropriate times with aspiration of
^  I ^  j
the supernatant, one gentle rinse with 5ml of ice cold PBS without Ca or Mg , and 
then the addition of 0.5ml IX ice cold cell lysis buffer plus ImM PMSF. The dish 
was then incubated on ice for 5 mins before cells were scraped off, transferred to 
microcentrifuge tubes and centrifuged at 4°C for 10 mins at 12000g. The protein 
containing supernatant was transferred to a fresh eppendorf tube. Samples could be 
frozen at -80°C at this point.
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3.5.1.2 Immunoprecipitation using immobilised phospho1807182 p38 antibodies
To 200 j l l 1 of cell lyate was added 20pl of resuspended immobilised 
phosphoThrl807Tyrl82-specific p38 MAP kinase monoclonal antibody. This was 
incubated in a rotator at 4°C overnight. The next day the mixture was centrifuged at 
12000g for 1 min at 4°C. The pellet was washed twice with 500pl of IX cell lysis 
buffer and kept on ice. This was followed by two washes with IX kinase buffer also 
keeping the pellets on ice.
3.5.1.3 Kinase assay
The washed pellet was suspended in 50pl of IX kinase buffer supplemented with 
200mM ATP and 2pg ATF-2 fusion protein and incubated for 30 mins at 37°C. The 
reaction was terminated with the addition of 12.5pi of 5X SDS sample buffer. The 
sample was boiled for 5 mins, vortexed briefly and then centrifuged at 12000g for 2 
mins.
3.5.1.4 Western analysis
The sample was loaded onto a 10% SDS-PAGE gel and run as described above. The 
resulting gel was routinely transblotted and the subsequent membrane blocked 




3.6 Accumulation of D-3 Phosphoinositide lipids in intact cells
3.6.1 Overview
In order to assay PI 3-Kinase activity the accumulation of its D-3 phosphoinositide 
lipid products was assayed. Cells are initially washed with phosphate free media and 
then incubated with a radiolabelled phosphate donor. Aliquots of cells are then 
stimulated as appropriate and subsequently the lipids are extracted. This lipid 
fraction is then deacylated to render the glycerophosphorylinositol derivatives water 
soluble, and run on an HPLC column to separate the lipids and quantify them by 
their relative radioactive emissions.
3.6.1.1 Sample preparation
HT-29 cells were dissociated from the 170cm flask using 4ml of Trypsin-EDTA 
mixture (0.05% (w/v) Trypsin and 0.02% (w/v) EDTA). They were then washed 
three times in phosphate-free Dulbecco’s Modified Eagles Medium (DMEM) with 
10 mins incubations at 37°C before each spin at 400g for 5 mins. The cells were 
subsequently resuspended in 10ml phosphate-free DMEM containing 10% dialysed 
foetal bovine serum and 20mM HEPES at 107 cells/ml and incubated at 37°C for 4 
hours with lmCi of [32P]-orthophosporic acid (NEN).
After incubation, the cells were washed three times in phosphate-free DMEM and 
resuspended in McCoy’s 5A (with 20mM HEPES, but without FBS) at 107 [32P]- 
labelled cells per 120pl. Each aliquot of 120pl was placed in a 1.5ml screw topped
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1.5ml eppendorf tube and equilibrated at 37°C for 10 mins. Each point was 
stimulated with 12 pi of agonist or vehicle for the appropriate times and the reaction 
quenched by the addition of 700pl of ice cold chloroform/methanol/water 
(32.6%/65.3%/2.1%). The samples were then immediately placed on ice. 200pl of 
chloroform containing lOpg of Folch lipids as a carrier protein were then added 
along with 200pl of 2.4M HC1 / 5mM tetrabutylammoniumhydrogen sulphate 
(TBAS). The extraction mixtures were vortexed and centrifuged at 3000g for 5 
mins. The lower phase was removed and added to 400pl of 1M HC1 / 5mM EDTA. 
The mixtures were vortexed again and centrifuged at 3000g for 5 mins. The lower 
phase was removed to screw topped 1.5ml eppendorfs with pierced lids and dried in 
vacuo using a Savant SpeediVac. When dried down, 1ml of 25% (v/v) 
methylamine/methanol/N-butanol (4/4/1) was added to the residue and, after 
vortexing, the samples were incubated in a 53 °C water bath for 40 mins. This 
deacylation procedure renders the glycerophosphorylinositol derivatives of PI (3) P 
(GroPI (3) P), PI (3,4) P2 (GroPI (3,4) P2), PI (3,4,5) P3 (GroPI (3,4,5) P3) water 
soluble. The samples were then cooled for 1 min on ice and then dried in vacuo as 
before. Finally 500pl of water and 600pl of N-butanol/40-60% petroleum 
ether/ethyl formate (20/4/1) were added. The samples were vortexed and centrifuged 
at 75Og for 30 secs. The upper phase was removed and discarded and the lower 
phase was dried in vacuo. The samples were then stored at -20°C until analysis.
3.6.1.2 HPLC analysis of samples
Anion exchange high performance liquid chromatography (HPLC) was used to 
analyse the lipid content of the samples using a water and phosphate buffer gradient
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(Stephens et al., 1989). The samples were resuspended in water and injected onto a 
Partisphere SAX column. The eluant was detected using a Canberra Packard A-500 
Flo-One on line beta radiodetector where it was mixed in a ratio of 1:3 with Flo- 
Scint IV scintillation cocktail, according to the manufacturer’s specifications. The 
results were analysed on a Flo-one data program. The retention times were 
compared to standards of [3H] PI (4) P  and of [3H] PI (4,5) P2 . The identity of the 
various peaks obtained using this separation technique has been defined previously 
(Ward, 2000). The PI (3) P elution time was compared to that determined by Dr 
S.G. Ward by immunoprecipitating PI 3-Kinase using an anti-p85 antibody and 
performing an in vitro lipid kinase assay. The PI (3) P was isolated by thin layer 
chromatography (TLC) and then extracted from the TLC plate and its elution time on 
the HPLC monitored (personal communication). The elution times of the other 3- 
phosphorylated lipids were compared to those quoted in the literature (Stephens et 
al., 1989; Ward, 2000). The levels of PI were used as an internal standard to confirm 
that each sample contained a similar amount of radioactivity, as the PI pool should 
not vary upon agonist stimulation.
3.7 Prostaglandin E? ELISA
3.7.1.1 Overview
This assay to measure PGE2 concentration uses a kit from R&D Systems (Abingdon, 
UK). It is based on the competitive binding technique in which PGE2 present in the 
sample competes with a fixed amount of alkaline phosphatase-labelled PGE2 for 
sites on a mouse monoclonal antibody. During the incubation, the mouse
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monoclonal antibody becomes bound to the goat anti-mouse antibody coated onto 
the microplate. Following a wash to remove excess conjugate and unbound sample, 
a substrate solution is added to the wells to determine the bound enzyme activity. 
The intensity of the colour generated is inversely proportional to the concentration of 
PGE2 in the sample (Figure 2.1).
3.7.1.2 Assay procedure
Known concentrations of a PGE2 standard were diluted in cell culture medium and 
used for a standard curve (5000pg/ml to 39pg/ml) which gave a quoted assay 
sensitivity as less than 36.2pg/ml. lOOpl of standard or cell culture supernatant 
sample were placed in microplates coated with goat anti-mouse antibody. To each 
was added 50 pi of PGE2 conjugate (conjugated to alkaline phosphatase) and 50pl of 
PGE2 antibody solution (mouse monoclonal). The plates were covered and 
incubated on a shaking platform for two hours at room temperature. After this 
incubation the wells were aspirated and washed with 200pl wash buffer using a 
multi-channel pipette. This was repeated to give a total of three washes and after the 
last wash the microplates were inverted and blotted against clean paper towelling. 
200pl of pNPP substrate was then added to all wells and incubated at room 
temperature without agitation. The optical density at 405nm was determined 
immediately using a Dynatech MR5000 plate reader. The PGE2 concentrations were 
calculated by comparison to the sigmoid standard curve using BioLinx software.
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3.8 Prostaglandin D? ELISA
3.8.1.1 Overview
This assay to measure PGD2 concentration uses a kit from Cayman Chemicals (Ann 
Arbor, MI, USA). It begins by converting the relatively unstable PGD2 to stable 
PGD2-methoxime (PGD2-MOX) by methoximation (Figure 2.2). It is then based on 
the competitive binding technique in which the PGD2-MOX now present in the 
sample competes with a fixed amount of acetylcholinesterase-labelled PGD2-MOX 
for sites on a specific rabbit antibody (Figure 2.1). During the incubation, the rabbit 
anti PGD2-MOX antibody becomes bound to the mouse anti-rabbit monoclonal 
antibody coated onto the microplate. Following a wash to remove excess conjugate 
and unbound sample, a substrate solution (Ellman’s reagent) is added to the wells to 
determine the bound enzyme activity. The intensity of the colour generated is 
inversely proportional to the concentration of PGD2 in the sample.
3.8.1.2 Assay procedure
Firstly the methyl oximating reagent was prepared by diluting supplied 
methoxylamine HC1 in 10ml of a 10% (v/v) solution of ethanol in water. To this was 
added the supplied sodium acetate to give the final reagent. The PGD2 standard was 
then diluted in 900pl of MilliQ water and a 1:1 solution was prepared with the 
methyl oximating reagent. This was heated to 60°C for 30 mins resulting in a 
methoximated standard solution with a concentration of 20ng/ml. This was used to 
generate of standard curve by dilution in ELA buffer (7.8pg/ml to lOOOpg/ml). Next, 
the cell culture supernatant samples were thawed slowly on ice and 100ml was added
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to the same volume of methyl oximating reagent. This solution was heated to 60°C 
for 30 mins, then centrifuged at 12000g for 5 mins and the supernatant diluted 1:5 in 
EIA buffer. The required number of microplates were washed in wash buffer prior 
to use in the assay. 50pl of standard or sample were placed in microplates coated 
with mouse anti-rabbit monoclonal antibody. To each was added 50pl of PGD2 
conjugate (conjugated to acetylcholinesterase) and 50ptl of PGD2 antibody solution 
(rabbit antiserum). The plates were covered and incubated overnight at room 
temperature. After this incubation the wells were aspirated and washed with 200pl 
wash buffer using a multi-channel pipette. This was repeated to give a total of five 
washes and after the last wash the microplates were inverted and blotted against 
clean paper towelling. 200pl of Ellman’s reagent was then added to all wells and 
incubated at room temperature in the dark on a rocking platform for 60 mins. The 
optical density at 405nm was determined immediately using a Dynatech MR5000 
platereader (range required 405-420nm -  optimum 412nm). The PGD2 
concentrations were calculated by comparison to the standard curve (linear when 
plotted on log/lin scale) using BioLinx software.
3.9 Statistics
Statistical analysis was used in two contexts in this work. Firstly, when comparing 
quantities such as PGE2 production, statistical significance was assessed by two- 
way analysis of variance followed by Dunnett’s correction for multiple comparisons 
with a control. Data on bar charts are expressed as means +/- SEM from three 
independent experiments unless otherwise stated. p<0.05 was taken as the criterion
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for a significant difference. Secondly, for comparing half life decay curves for 
mRNA, statictical significance was assessed by comparing a modelled regression 
curve to the observed regression curve. By using the sum of the squared deviations 
about the line an F value can be obtained and tested for significance with the 
appropriate number of degrees of ffeeedom. Again, p<0.05 was taken as the 
criterion for a significant difference.
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3.10 BUFFERS AND SOLUTIONS
3.10.1 Solutions and reagents for cell culture
Tissue culture reagents were used for cell cultures and all solutions were prepared 
using sterile MilliQ water.






Stored at -20°C in 50ml aliquots (heat- 
inactivated).
HBSS (pH 7.3)






65% TrowelTs T8 
25% RPMI-1640 
lOmM HEPES buffer 
2mM glutamine 
10% FBS
Supplemented with penicillin (10 units/ml), 
streptomycin (10 pg/ml) and fungizone 
(0.5pg/ml) before use.
Trypsin -  EDTA Solution




HT-29 medium: McCoy’s medium 5A
Supplemented with penicillin (10 units/ml), 
streptomycin (10 pg/ml) and fungizone 
(0.5pg/ml) before use.
Caco-2 medium: EMEM (EBSS)
Supplemented with 2mM Glutamine, 1% 
Non Essential Amino Acids, penicillin (10 
units/ml), streptomycin (10 pg/ml) and 
fungizone (0.5pg/ml) before use.
Freeze medium -  HT-29 cells
10% (v/v) DMSO
40% (v/v) FBS
50% (v/v) HT-29 medium
Freeze medium -  Caco-2 cells
10% (v/v) DMSO
40% (v/v) FBS
50% (v/v) Caco-2 medium
3.10.2 Solutions and buffers for Nitrite assay
HC1 solution NaOH solution
0.62M HC1 in MilliQ water. 2.8M NaOH in MilliQ water.
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3.10.3 Solutions and buffers for Northern Analysis
3.10.3.1 Required for membrane generation
DEPC- Treated Water or Buffer
MilliQ Water or Buffer was treated With 
1ml of Diethyl Pyrocarbonate per litre of 
water and incubated overnight at 37°C. 
Autoclave (for 20 minutes at 121 °C).
20% (w/v) SDS Solution
20g SDS diluted in 100ml sterile MilliQ 
water
75% (v/v) ethanol solution
75 ml absolute ethanol in 25 ml MilliQ 
water.
0.5M EDTA stock solution, pH 8
0.5M EDTA in MilliQ water, adjust pH. 
Autoclave
3M Sodium acetate, pH 5.2
3M sodium acetate dissolved in 250ml 
MilliQ water. Adjust pH with 3M glacial 
acetic acid. DEPC treat and autoclave.
1 mg/ml Ethidium bromide solution
lOmg ethidium bromide in 10ml DEPC- 
treated water.
20X MOPS running buffer
0.4M 3-[N-morpholino]-propane-sulfonic 
acid (MOPS)
0.02M EDTA (4 ml of 0.5M stock/100 ml) 
0.2M sodium acetate (6.64 ml of 3M 
stock/100ml)
Adjust volume to 100ml with MilliQ water 
and pH with solid NaOH.
RNA sample buffer (per sample)
30pl of:
7 pi 36% (w/v) formaldehyde
4pi 20X MOPS running buffer
2pl 1 mg/ml ethidium bromide solution
20pl formamide
Made up fresh before use.
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IX MOPS running buffer
50ml 20X MOPS in 950ml DEPC-treated 
water.
20X SSC, pH 7
3M NaCl
0.3M trisodium citrate dihydrate 
Milli-Q water, DEPC treat and autoclave
Bromophenol solution
0.025g bromophenol blue 
3 ml glycerol
Adjust volume to 10ml with DEPC-treated 
water
3.10.3.2 Required for Digoxigenin labelled probes
Buffer 1 Blocking stock solution
0.1M maleic acid lOg blocking reagent in 100 ml buffer 1.
0.15MNaCl Microwave to dissolve (do not boil).





For oligonucleotide probes 
0.02% SDS (0.1ml of 20% stock/lOOml) 
5X SSC (25ml of 20X stock/100ml) 
0.1% sarcosyl (0.33ml of 30% stock/lOOml) 
1 % blocking buffer (10ml of 10% 
stock/lOOml) in MilliQ water.
High SDS Hybridisation solution
For cDNA probes
7% SDS (35g of stock/500ml) 
5X.SSC (83ml of 30X stock/500ml) 
0.1% sarcosyl (5ml of 10% stock/500ml) 
2% blocking buffer (100ml of 10% 
stock/500ml)
50% Formamide (250ml of 
stock/500ml)
50mM sodium phosphate, pH 7.0 (25ml 
of 1M stock/500ml)
made up to 500ml with MilliQ water and 
then autoclaved.
IX SSC, 0.1% SDS solution
2.5ml of 20X SSC
2.5ml of 20% SDS stock
Adjust volume to 500ml with DEPC-treated
water.
2X SSC, 0.1% SDS solution
50ml of 20X SSC
2.5ml of 20% SDS stock
Adjust volume to 500ml with DEPC-treated
water.
Buffer 2
10% (v/v) blocking stock solution in buffer 
1.
Buffer 3, pH 9.5
0.1M Tris-HCl 
O.lMNaCl
in sterile Milli-Q water.
Washing buffer
0.3% (v/v) Tween-20 in buffer 1.
Stripping solution
0.1% SDS 2.5ml of 20% stock 
in 500ml MilliQ water
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3.10.3.3 Required for [32P] labelled probes




pH with NaOH and make up to 1000ml with 
Milli-Q water and autoclave
0.5M Na2H P04 (pH 7.2)
0.5M Na2HP04 in MilliQ water , adjust pH 
to 7.2 with phosphoric acid
Hybridisation solution
0.001M EDTA 0.2ml of 0.5M stock 
0.25M Na2HP04 (pH 7.2) 50ml of 0.5M 
stock
7% SDS 35ml of 20% stock 
Make up to 100ml with MilliQ water
6X SSPE, 0.1% SDS solution
60ml of 20X SSPE
1ml of 20% SDS stock
Adjust volume to 200ml with MilliQ water.
2X SSPE, 0.1% SDS solution
20ml of 20X SSPE
1ml of 20% SDS stock
Adjust volume to 200ml with MilliQ water.
IX SSPE, 0.1% SDS solution
10ml of 20X SSPE
1ml of 20% SDS stock
Adjust volume to 200ml with MilliQ water.
Low Salt solution
0.2M NaCl 4ml of 5M stock
20mM Tris-HCl(pH 7.4) 2ml of 1M
stock
ImM EDTA 0.2ml of 0.5M stock 
Adjust volume to 100ml with MilliQ water
High Salt solution
1M NaCl 20ml of 5M stock
20mM Tris-HCl(pH 7.4) 2ml of 1M
stock
ImM EDTA 0.2ml of 0.5M stock 
Adjust volume to 100ml with MilliQ water
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3.10.4 Solutions and buffers for SDS-PAGE and Western blotting
Lysis buffer
50mM Tris-HCl pH 7.5 (stock 1M)
150mM NaCl (stock 5M)
1% (v/v) Nonidet P40 (stock 10% (v/v)) 
10% glycerol
5mM EDTA (stock 0.5M, pH 8.0)





1 pg/ml pepstatin A (stock in methanol) 
lOpg/ml aprotinin 
10pg/ml leupeptin 
10pg/ml soyabean trypsin inhibitor 
MilliQ water
Stock solutions
1M Tris-HCl pH 8.8 (60.6gtrizma 
base/500 ml MilliQ water)
1M Tris-HCl pH 6.8 (60.6gtrizma 
base/500 ml MilliQ water)
Acrylamide/bis acrylamide (30:0.8) (store 
at 4°C)
10% (w/v) SDS (100 ml, 10 g SDS + 
91ml MilliQ water)
10% (w/v) ammonium persulphate (1 ml 




SDS-PAGE running buffer 5X SDS-sample buffer
25mM Trizma base 5% SDS
192mM glycine 50% glycerol
0.1% (w/v) SDS 200mM Tris-HCl pH 6.8
MilliQ water, no need to pH, should be MilliQ water
above pH 8.3 Bromophenol blue
5% 2-mercaptoethanol (50pl/ml) or 10% 
1M DTT (for reducing buffer)
Semi-dry transfer buffer Tris-buffered saline (TBS)
39mM glycine 20mM Tris-HCl pH 7.5
48mM Trizma base 150mM NaCl
0.0375% SDS MilliQ water, pH 7.5
20% (v/v) methanol
Tris-buffered saline (TBSN) Ponceau S
TBS + 0.05% (v/v) NP40 0.1% (w/v) Ponceau S 
5% (v/v) acetic acid
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Blocking buffer Coomassie blue stain
For COX antibodies: 0.25% (w/v) Coomassie blue
5% (w/v) non-fat powdered milk (Marvel) 45.4% (v/v) methanol
in TBS 9.2% (v/v) glacial acetic acid





Stripping buffer Destain solution
62.5 mM Tris-HCl, pH 6.8 45.4% (v/v) methanol
2% (w/v) SDS 9.2% (v/v) glacial acetic acid




3.10.4.1 Recipes for various percentage gels
Resolving gel -  5 ml is sufficient for 1 mini gel 
Stacking gel* -  1.5 ml is sufficient for 1 mini gel
Final % gel 5%* 7.5% 10%
Range (kDa) 70-200 20-100
Acrylamide 1.67 3.75 5
MilliQ H20 6 5.6 4.35
1M Tris pH 8.8 5.6 5.6
1M Tris pH 6.8 1.25
10% SDS 0.15 0.25 0.25
Total (ml) 9.07 15.2
Plus 50pl 10% APS and 20pl TEMED
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3.10.4.2 Antibodies used for immunoblotting




Cyclo-oxygenase 1 68-74 Anti-goat HRP
Cyclo-oxygenase 2 68-74 Anti-goat HRP
Pan PKB 60 Anti-rabbit HRP
Phosphobcr4,J PKB 60 Anti-rabbit HRP
Panp38 43 Anti-rabbit HRP
Phospholhrl 8U/1 yrl 82 p3 8 43 Anti-rabbit HRP
Pan ERK1/2 42/44 Anti-rabbit HRP
Phosphonua'm y'm  ERK1/2 42/44 Anti-rabbit HRP
Pan JNK 46/54 Anti-rabbit HRP
Phospho ™1“ lyrl8:’JNK 46/54 Anti-rabbit HRP




Phospho™'1 ATF-2 70 Anti-rabbit HRP
(ATF-2 GST fusion Protein) 39
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pH adjusted to 3.8 using orthophosphoric 
acid
Phosphate free medium
Add powdered DMEM with L-Glutamine 
and 4500mg glucose to 900ml MilliQ water. 
Add 49.3ml (7.5% (w/v)) sodium 
bicarbonate, 20ml of IM HEPES (20mM). 
Adjust pH to 7.2 and adjust volume to 11. 


























Alkaline Phosphatase-labelled PGE2 as assay reagent 
Fixed Goat anti-mouse antibody
Mouse anti-PGE2 monoclonal antibody as assay reagent
Figure 2.1: Schematic representation o f prostaglandin ELISAs 
This demonstrates the competitive binding technique used in the ELISAs for 













Figure 2.2: Schematic representation o f PGD2 derivatives
This demonstrates the metabolism of PGD2 to both the J series of 
cyclopentenone prostaglandins, as well as the conversion to the stable 
methoximated derivative
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4 Results - Induction of COX-2
4.1 Introduction
COX-2 is known to be an inducible enzyme which has been shown to be induced by 
a variety of agents in a number of systems. With respect to the intestinal epithelium, 
this work concentrated on whether COX-2 was induced by pro-inflammatory 
mediators known to play a role in intestinal pathophysiology. In order to investigate 
this hypothesis, techniques needed to be developed to assess COX-2 induction at the 
mRNA, protein and product level. Furthermore, the cellular models for the intestinal 
epithelium needed to be chosen and the results interpreted in the context of the 
model used.
Having established the basic properties of COX-2 induction in the model used, these 
results could be used as a foundation for further work. In particular, although COX- 
2 is known to be highly regulated, it is one link in a long path from arachidonic acid 
liberation to prostanoid generation and metabolism. It has been demonstrated in 
other systems that COX-2 products can feed back and regulate COX-2 expression 
and activity. The existence of any such feedback loops is important in the 
interpretation of all experiments on COX-2 regulation.
Finally 5-ASA, which is known to have therapeutic value in IBD and have a 
multiplicity of differing actions, was used to see whether it altered COX-2 
expression and activity.
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4.2 Results
4.2.1 Development of COX-2 Probe
4.2.1.1 Digoxigenin labelled COX probe
In order to investigate COX expression at the mRNA level an assay for COX mRNA 
had to be developed. Northern blot analysis was chosen over PCR based methods 
because it allows a direct measurement of the total amount of a specific mRNA and 
avoids the assumptions of reverse transcription seen with PCR. A probe, suitable for 
northern analysis was therefore required, and initial attempts used the Digoxigenin 
labelling of COX-1 and COX-2 cDNA as described in Methods. COX-2 cDNA 
could be labelled reliably with Digoxigenin and this was shown using a dot blot to 
compare the Digoxigenin dependent signal to control labelled DNA (Figure 4.1 A). 
However, the probe proved very sensitive to conditions in a manner which was not 
always predictable. Figure 4.IB and 4.1C show the effect of probe concentration 
and temperature of hybridisation on mock blot development ie: membranes without 
any mRNA present. As probe concentration increased, or temperature decreased, the 
intensity of the background signal rose to unacceptable levels. Some successful 
probing was carried out allowing interpretation of COX-2 mRNA expression but, in 
view of the high and unpredictable background, a new method of labelling COX-2 
cDNA was sought.
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4.2.1.2 [32P] labelled COX-2 probe
T9The technique of labelling COX-2 cDNA with [ P] shares many methodological 
similarities as that for Digoxigenin labelling. However the predictability of the 
results, the low levels of background and the resulting increased sensitivity meant 
that this proved to be a superior method. Figure 4.ID shows a comparison between 
duplicate membranes probed with either Digoxigenin or [ P] labelled COX-2 probes 
with the latter much clearer. As a result all COX-2 northern blots shown are probed 
with [32P] labelled COX-2 cDNA. Figure 4.ID also compares the methods of 
demonstrating equal loading: either stripping and reprobing for the housekeeping 
gene (3-Actin, or showing the photograph of the ethidium stained blot where the 18S 
and 28S ribosomal RNA bands can be visualised. There was no difference seen 
between these two methods during this work and they are both used throughout.
4.2.2 Induction of COX-2
It is commonly reported that COX-2 is commonly inducible in other cell lines by 
stimulation with a variety of pro-inflammatory cytokines, bacterial products, tumour 
promoters and other mitogens. Therefore the pro-inflammatory Thl cytokines IL-1 
and TNFa were initially chosen in an attempt to induce COX-2 in intestinal 
epithelial cells.
4.2.2.1 COX-2 mRNA and protein induction in HT-29 Cells
HT-29 intestinal epithelial cells were stimulated over a twenty four hour time course 
with TNFa or IL-1 a  and mRNA was isolated for northern blot analysis for COX-2
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(Figure 4.2A). Both cytokines caused COX-2 induction although that by TNFa was 
both more intense, appeared quicker and was more prolonged. Whereas the response 
to IL-1 a  was a peak of COX-2 mRNA at two hours, the response to TNFa was more 
complex. TNFa also caused an initial peak in COX-2 mRNA at two hours but, after 
a decline in intensity at four hours, there was a second peak in COX-2 expression at 
twelve hours.
In view of both IL-1 a  and TNFa both inducing COX-2 mRNA with an early peak at 
two hours, this time point was chosen to perform a dose response. HT-29 cells were 
stimulated with increasing concentrations of either TNFa (0-100ng/ml) or IL-1 a  (0- 
30ng/ml) for two hours and mRNA was isolated and analysed by northern blot. Both 
cytokines showed a concentration dependent response with visible induction even at 
low concentrations (Figure 4.2B). Subsequent experiments therefore used TNFa at 
lOOng/ml and IL-1 a  at lOng/ml as proven potent inducers of COX-2 in HT-29 cells.
As there are two isoforms of IL-1, IL -la  and IL-lp, the response of HT-29 cells to 
IL-1 p stimulation (0-10ng/ml) for two hours was also assessed with regard to COX-2 
induction (Figure 4.2C). IL-lp proved to induce COX-2 mRNA and was more 
potent than IL -la  but not TNFa. It also demonstrated a plateau effect with no 
increase in induced signal above lng/ml.
Finally, regarding COX-2 mRNA induction in HT-29 cells, LPS (lOpg/ml) and 
Interferon-y (IFNy) (300u/ml) failed to induce COX-2 mRNA over a twenty four 
hour period (Figure 4.2D). This figure also demonstrates the very low levels of basal
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COX-2 mRNA seen, representing the small amount of constitutive expression in this 
colorectal carcinoma derived cell line.
In light of TNFa and IL -la  inducing COX-2 mRNA in HT-29 cells, western blot 
analysis was used to assess whether the same stimulation also caused induction of 
COX-2 protein. HT-29 cells were stimulated over a six hour time course with TNFa 
(lOOng/ml) and protein was isolated, analysed by western blotting and probed for 
COX-2 using a specific anti-COX-2 antibody (Figure 4.3A). A time dependent 
induction of COX-2 protein is seen from three hours and a continuing rise at six 
hours. This lags behind the induction of COX-2 mRNA as would be expected in 
order to allow for protein translation. It can also be seen that stimulation with TNFa 
over the same time period has no effect on COX-1 protein expression, which is 
constitutively expressed at low levels throughout the time course (Figure 4.3A). 
Using six hours as an early point giving clear increases in COX-2 protein, TNFa was 
compared to IL -la  (lOng/ml) in the same cells (Figure 4.3B). IL -la  is seen to 
induce COX-2 protein but this induction is weaker in comparison to that seen with 
TNFa.
4.2.2.2 COX-2 mRNA and protein induction in Caco-2 Cells
The Caco-2 cell line was chosen as a second model of intestinal epithelial cells. To 
investigate the induction of COX-2 expression in this cell line, cells were stimulated 
with TNFa (lOOng/ml), LPS (lOpg/ml), IFNy (300u/ml) or IL -la  (lOng/ml) over a 
twenty four hour time course. mRNA was isolated and probed for COX-2 using 
northern blot analysis (Figure 4.4A). As can be seen, IL -la  was the only agent
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capable of inducing COX-2 mRNA expression in Caco-2 cells. As with HT-29 cells 
this induction peaks at two hours.
Subsequent to the finding of induction of COX-2 mRNA in Caco-2 cells, IL -la  was 
used to stimulate cells over a six hour time course with protein being isolated for 
western blot analysis (Figure 4.4B). This showed that IL -la  caused a concomitant 
time dependent induction of COX-2 protein in Caco-2 cells although this was not of 
great magnitude.
4.2.2.3 Induction of Prostaglandin production as a marker of COX-2 activity
Downstream of COX activity, specific isomerases determine production of the 
individual prostaglandins. PGE2 is the most abundant prostaglandin product in the 
colon (Boughton-Smith et al., 1983) and appeared to be a good product to assay as a 
potential downstream marker of COX-2 functional activity. HT-29 cells were 
stimulated in triplicate with TNFa over a 72 hour time course with supernatants 
being assayed for PGE2 using a specific ELISA (Figure 4.5A). This showed that 
TNFa induced a time dependent increase in PGE2 production which was still 
increasing at 72 hours. There is some evidence that serum deprivation may cause 
physiological changes in cellular responses in its own right (Battu et al., 1998). In 
light of this, and although the appropriate controls did not support this with respect 
to PGE2 production, PGE2 assays tended to be carried out over 24-48 hours.
Next it was investigated whether TNFa induced PGE2 production was concentration 
dependent, as has already been demonstrated with COX-2 mRNA production. Also,
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if it is assumed that inducible PGE2 production in this system is indeed COX-2 
dependent, it should be inhibited by a specific COX-2 inhibitor. HT-29 cells were 
stimulated in triplicate for twenty four hours with increasing concentrations of TNFa 
(10 and lOOng/ml) with the higher concentration also being used to stimulate cells 
which had been pre-treated with the specific COX-2 inhibitor NS-398 for one hour at 
lpM  (Figure 4.5B). The results showed that TNFa induction of PGE2 production 
was indeed both concentration dependent and COX-2 dependent.
Finally the possibility of PGE2 induction by IL -la  both in HT-29 cell and in the 
Caco-2 cell line was explored. Caco-2 and HT-29 cells were stimulated in triplicate 
with IL -la  (lOng/ml) for 72 hours whilst HT-29 cells were incubated with TNFa as 
a positive control. The prolonged time period was chosen in the hope of enhancing 
the sensitivity of the assay. IL -la  did not stimulate PGE2 production in either cell 
line despite its proven ability to induce COX-2 expression (Figure 4.5C).
It is known that downstream of COX-2 there are a variety of differing COX-2 
dependent products and it has been proposed that these may have opposing actions 
and therefore be regulated differently (Gilroy et al., 1999). The cyclopentenone 
prostaglandins are believed to have differing actions to PGE2 and, although these are 
unstable, a stable derivative of the PGD2 can be assayed using an ELISA technique. 
HT-29 cells were stimulated over twenty four or forty eight hours with a variety of 
possible inducing agents: TNFa (lOOng/ml), IL -la  (lOng/ml), IFNy (300u/ml) both 
alone and in combination with TNFa or IL -la, and the Th2 cytokines IL-4 and IL- 
13 (both 30ng/ml). Supernatants were collected and assayed for the stable 
methoximated derivative of PGD2 as a marker of PGD2 production (Figure 4.6). The
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assay, which worked well with a standard curve acting as a positive internal control, 
revealed that none of these stimuli induced methoximated PGD2, and by implication 
PGD2 production, in HT-29 cells at a level to be assayed using this ELISA method.
4.2.2.4 Expression of COX-2 in isolated primary intestinal epithelial cells
In the hope of supporting the above findings in colonic epithelial cell lines, attempts 
were made to investigate COX-2 expression in freshly isolated human colonic 
epithelial cells. It is known that these cells do express COX-2 when involved in 
colonic tumours or in colonic inflammation (Eberhart et al., 1994; Singer et al., 
1998). It is also reported in the literature that they have receptors to IL-1 although 
not TNFa (Panja et al., 1998), and a functional response to IL-1 p has been 
demonstrated (Jobin et al., 1998).
Primary intestinal epithelial cells (IECs) were isolated from fresh colonic resection 
specimens and aliquots of 10 cells were either stimulated for two hours with IL-1 p 
(lOng/ml) or left unstimulated as a control. mRNA was then isolated and analysed 
by northern blot using HT-29 cells stimulated by TNFa as a positive control (Figure 
4.7A). There was no visible induction of COX-2 mRNA in these fresh IECs as 
compared to that seen in HT-29 cells. To investigate this further, IECs were 
similarly stimulated for sixteen hours with IL-1 p (lOng/ml) and protein was isolated 
for western analysis and probing for COX-2 (Figure 4.7B). Again there was no 
visible induction of COX-2 protein by IL-1 p although there appeared to be a small 
amount present constitutively.
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4.2.3 Regulation of COX-2 by its Products
4.2.3.1 PGE2
It has been demonstrated above that TNFa induction of COX-2 results in a 
downstream induction of COX-2 dependent PGE2 production. PGE2 is the greatest 
prostaglandin product produced in the colon and the question was raised as to 
whether there was any positive or negative feedback on COX-2 mRNA or protein 
expression. HT-29 cells were stimulated in the presence or absence of TNFa 
(lOOng/ml) and in turn in the presence or absence of pre-treatment with increasing 
concentrations of PGE2 (0-5000pg/ml) for either two hours for mRNA isolation or 
six hours for isolation of protein. COX-2 mRNA, as well as COX-2 and COX-1 
protein levels, were analysed by northern and western blotting respectively. The 
concentrations of PGE2 chosen were based on the amounts produced in this system 
as quantified by ELISA. The presence of PGE2 caused a concentration dependent 
inhibition of COX-2 mRNA and protein production in these HT-29 cells and this 
was best seen at the highest concentrations of 2500-5000pg/ml (Figure 4.8A and 
4.8B). PGE2 on its own had no effect on COX-2 expression even at high 
concentrations. Also, the protein expression of the constitutive isoform of COX, 
COX-1, was unaltered either by TNFa or by PGE2 (Figure 4.8B lower panel).
4.2.3.2 PPARy agonists
As mentioned earlier with respect to prostaglandin induction, differing COX-2 
dependent products have been shown to have differing and indeed opposing actions. 
The cyclopentenone prostaglandins are known to mediate their actions by binding to
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the nuclear hormone receptor PPARy. As well as cyclopentenone prostaglandins 
such 15-deoxy A12,14 prostaglandin J2 (PGJ2), drugs are now available, such as 
ciglitazone - a member of the thiazolidinedione family, which can act as PPARy 
agonists. PGJ2 and ciglitazone were used to investigate the actions of PPARy 
agonists on cytokine induced COX-2 expression in HT-29 intestinal epithelial cells.
Cells were stimulated with TNFa in the presence or absence of pre-treatment with 
PGJ2 or ciglitazone (one hour at lOpM) and mRNA was isolated at two hours for 
northern blot analysis and COX-2 probing (Figure 4.9A). Neither PPARy agonist 
was seen to have a significant effect on COX-2 expression at the mRNA level. To 
see whether the same could be said for COX-2 protein expression, HT-29 cells were 
stimulated for six hours as above and protein isolated for western blot analysis and 
COX-2 probing (Figure 4.9B). This revealed that both PPARy agonists caused an 
added up-regulation in TNFa induced COX-2 protein expression.
Finally, experiments were carried out to assess whether this up-regulation of induced 
COX-2 protein by PPARy agonists was reflected in downstream PGE2 production. 
HT-29 cells were stimulated with TNFa (lOOng/ml) and IFNy (300u/ml) to provide a 
potent induction of PGE2 production as further discussed in Chapter 5. This was 
carried out in the presence or absence of either PGJ2 or ciglitazone for twenty four 
hours and supernatants were collected and analysed for PGE2 by ELISA (Figure 
4.9C). The marked induction of PGE2 by TNFa and IFNy was inhibited by the 
PPARy agonists and this effect was significant and far more marked for PGJ2 (~90% 
inhibition - p<0.01) than for ciglitazone («25% inhibition). For PGE2 production, as
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well as COX-2 mRNA and protein expression, neither PPARy agonist had any effect 
in isolation.
4.2.4 Regulation of COX-2 by 5-ASA
5-ASA is a widely used therapeutic agent in IBD that has been shown to have a 
variety of actions (Greenfield et al., 1993). Although it has been shown to alter 
prostaglandin production in the gastrointestinal tract (Hawkey and Truelove, 1983), 
this work was carried out prior to the description of an inducible isoform of COX. 
The action of 5-ASA on COX-2 expression and activity in HT-29 cells was therefore 
specifically investigated. Cells were stimulated with TNFa (lOOng/ml) in the 
presence or absence of pre-treatment with increasing, therapeutically relevant, 
concentrations of 5-ASA (10-lOOOpM for one hour), or equivalent amounts of its 
dilute HC1 vehicle. At two hours mRNA was isolated and subsequently analysed by 
northern blot and probed for COX-2. This showed a minimal inhibitory effect of 5- 
ASA, only at the highest concentration of lOOOpM compared to its vehicle, on COX- 
2 mRNA expression (Figure 4.10A).
To see whether this relative lack of regulation of COX-2 by 5-ASA extended beyond 
the mRNA level, TNFa induced PGE2 production was assessed in the presence of 5- 
ASA. HT-29 cells were stimulated for 72 hours with TNFa as above in the presence 
or absence of 5-ASA or its HC1 vehicle. Supernatants were collected and the PGE2 
content was quantified with ELISA (Figure 4.1 OB). This showed that 5-ASA, whilst 
having no effect in isolation, caused a significant concentration dependent inhibition
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of TNFa induced PGE2 production. This inhibition was complete at lOOOpM and 
significantly greater than the inhibition caused by the vehicle alone («50% at 
equivalent HC1 to lOOOpM 5-ASA). These results gave an IC50 for 5-ASA on TNFa 
induced PGE2 production of 119pM.
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Figure 4.1: Development o f  COX2 probe fo r  northern analysis.
A. Dot blot of Digoxigenin labelled COX2 cDNA at a variety of predicted concentrations 
(100-0.0lpg/ml) compared to a control Digoxigenin labelled standard DNA. B. Five mock 
blots each carried out using different concentrations of Digoxigenin labelled COX2 probe (0- 
20ng/ml) and developed at the same time in the same way. C. Two mock blots carried at two 
different hybridisation temperatures (42°C and 62°C) with the same concentration of 
Digoxigenin labelled COX2 probe (25ng/ml). D. Comparison of Digoxigenin labelled versus 
[32P] labelled COX2 cDNA probes on duplicate membranes (upper panels). HT-29 cells were 
stimulated with TNFa (lOOng/ml) over a 12 hour time course. The lower panels demonstrate 
equal loading with a photo of the ethidium stained 18S and 28S ribosomal RNA bands on the 
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Figure 4.2: Induction o f COX2 mRNA in HT-29 cells.
A to D. Northern analyses of mRNA isolated from HT-29 cells and probed for COX2.
A. Cells were stimulated with TNFa (lOOng/ml - left) or IL -la (lOng/ml - right) over a 24 
hour time course. The membranes were stripped and reprobed for P-actin to demonstrate 
loading. B. Cells were stimulated for two hours with increasing concentrations of TNFa (0- 
lOOng/ml - left) or IL -la (0-30ng/ml - right). The membranes were stripped and reprobed for 
p-actin to demonstrate loading. C. Cells were stimulated for two hours with increasing 
concentrations of IL -la (0-10ng/ml - left) or IL-1 p (0-10ng/ml - right) and compared to 
unstimulated control and TNFa (lOOng/ml). The 28S band is shown to demonstrate loading. 
D. Cells were stimulated over a 24 hour time course with LPS (lOpg/ml) or IFNy (300u/ml) 
and compared to unstimulated control and TNFa (lOOng/ml). The 28S band is shown to 





Figure 4.3: Induction o f COX2 protein in HT-29 cells.
A. Western analysis of protein isolated from HT-29 cells stimulated with TNFa 
(lOOng/ml) over a six hour time course and probed with a specific anti-COX2 
antibody (upper panel) or a specific COX1 antibody (lower panel). B. Western 
analysis of protein isolated from HT-29 cells comparing stimulation for six 
hours with either TNFa (lOOng/ml) or IL -la (lOng/ml) and probed with a 
specific anti-COX2 antibody . Blots were from single experiments but are 
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Figure 4.4: Induction o f COX2 mRNA and protein in Caco-2 cells.
A. Northern analysis of mRNA isolated from Caco-2 cells and probed for 
C0X2. Cells were stimulated with TNFa (lOOng/ml), LPS (lOpg/ml), IFNy 
(300u/ml) or IL-la (lOng/ml) over a 24 hour time course and compared to 
unstimulated cells. The 28S band is shown to demonstrate loading. B. Western 
analysis of protein isolated from cells stimulated with IL -la (lOng/ml) over a six 




















Figure 4.5: Stimulation o f PGE2 production in intestinal epithelial cells.
A. Bar chart showing PGE2 production by HT-29 cells stimulated with TNFa (lOOng/ml) 
over a 72 hour time course, prior to removal of the cell culture supernatant for PGE2 assay 
by ELISA. B. Bar chart showing PGE2 production by HT-29 cells stimulated with 
increasing concentrations of TNFa (0-100ng/ml) for 24 hours. This is compared to 
stimulation with TNFa (lOOng/ml) in the presence of pre-treatment with the specific COX2 
inhibitor NS-398 (lpM  for one hour). C. Bar chart representing PGE2 production in both 
HT-29 cells and Caco-2 cells. Cells were stimulated for 72 hours with TNFa (lOOng/ml - 
HT-29 cells only) or IL -la (lOng/ml - both Caco-2 and HT-29 cells) and compared with 
unstimulated cells. Cells were stimulated in triplicate and the results represent at least two 
independent experiments.
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Figure 4.6: Methoximated PGD2production in HT-29 cells.
Bar chart showing production of the stable PGD2 derivative (PGD2-MOX) by HT- 
29 cells stimulated for 24 or 48 hours with a variety of stimuli: TNFa (lOOng/ml), 
IL -la (lOng/ml), IFNy (300u/ml), IFNy combined with TNFa or IL-la, IL-4 and 
IL-13 (both 30ng/ml). The standard curve for the assay is shown beneath to 
demonstrate the internal positive control.
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Figure 4.7: COX2 expression in primary intestinal epithelial cells.
A. Northern analysis of mRNA comparing HT-29 cells, both stimulated for two 
hours with TNFa (lOOng/ml) or left unstimulated, with 107 primary intestinal 
epithelial cells stimulated with IL-1 p (lOng/ml) or left unstimulated, and probed for 
COX2. Both the 18S and 28S bands are shown to demonstrate loading. B. Western 
analysis of protein isolated from primary intestinal epithelial cells stimulated for 16 
hours with IL-lp (lOng/ml) compared to unstimulated control, and probed for 
COX2. Blots are from single experiments but are representative of at least one other.
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Figure 4,8: Regulation o f induced COX2 expression by PGE2.
A. Northern analysis of mRNA isolated from HT-29 cells pre-treated with increasing 
concentrations of PGE2 (0-5000pg/ml for one hour prior) in the presence or absence of 
TNFa (lOOng/ml for two hours) as the stimulating cytokine and probed for COX2. 
The 28S band is shown to demonstrate loading. B. Western analysis of protein 
isolated from HT-29 cells pre-treated with increasing concentrations of PGE2 (0- 
2500pg/ml for one hour) in the presence or absence of TNFa (lOOng/ml for six hours) 
as the stimulating cytokine and probed for COX2. The membrane was stripped and 
reprobed with a specific antibody against COX1 showing equal loading. Some of 
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Figure 4.9: Regulation o f COX2 expression by PPARy agonists.
A. Northern analysis of mRNA isolated from HT-29 cells stimulated with TNFa 
(lOOng/ml) for two hours in the presence or absence of pre-treatment with the PPARy 
agonists PGJ2 or ciglitazone (both at lOpM for one hour) and probed for COX2. The 28S 
band is shown to demonstrate loading. B. Western analysis of protein isolated from HT- 
29 cells stimulated with TNFa (lOOng/ml) for six hours in the presence or absence of 
pre-treatment with PGJ2 or ciglitazone (both lOpM for one hour) and probed with a 
specific antibody against COX2. C. Bar chart representing PGE2 production by HT-29 
cells stimulated by TNFa (lOOng/ml) and IFNy (300u/ml) for 24 hours in the presence or 
absence of pre-treatment with PGJ2 or ciglitazone (both 10pM for one hour). ** 
represents a significant inhibition at p<0.01. Blots were from single experiments but are 
representative of one other. Some of these results were obtained supervising Mr D.G. 
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Figure 4.10: Regulation o f COX2 expression by 5-ASA.
A. Northern analysis of mRNA isolated from HT-29 cells stimulated with TNFa 
(lOOng/ml) for two hours in the presence or absence of pre-treatment with 
increasing concentrations of 5-ASA (O-lOOOpM) or its HC1 vehicle equivalent, 
and probed for COX2. The 28S band is shown to demonstrate loading. B. Bar 
chart representing PGE2 production by HT-29 cells stimulated in triplicate by 
TNFa (lOOng/ml) for 72 hours in the presence or absence of pre-treatment with 
increasing concentrations of 5-ASA (O-lOOOpM) or its HC1 vehicle equivalent. 
Blots were from single experiments but are representative of one other.
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4.3 R esu lts  S u m m ary
• The agents shown to induce COX-2 are as outlined in the Table below. LPS and 
IFNy failed to induce COX-2 in either HT-29 or Caco-2 cells.
Induced  COX- 
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Protein S V
PGE2 product V X
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• PGE2 caused a concentration dependent decrease in TNFa induced COX-2 
expression at the mRNA and protein level.
• PPARy agonists had conflicting effects on TNFa induced COX-2 expression. 
They had no effect on COX-2 mRNA, caused an up-regulation of COX-2 protein 
and an inhibition of PGE2 production.
• 5-ASA caused minimal inhibition of TNFa induced COX-2 mRNA but caused a 
more marked inhibition of TNFa induced PGE2 production (IC5o=l 19pM).
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4.4 Discussion
The investigation of intestinal epithelial cell biology is limited by the inability to 
culture and passage freshly isolated primary intestinal epithelial cells (IECs) (Evans 
et al., 1994). This inability to easily manipulate the cells one wishes to draw 
conclusions about is despite much work in this area and sporadic reports of limited 
success in supporting fresh human IECs in vitro (Brandsch et al., 1998; Rogler et al., 
1998). However, freshly isolated primary human IECs cannot reliably be supported 
in culture and, after a four hour isolation process which includes mechanical and 
enzymatic disruption, only remain viable for at most 24 hours. This does allow 
some simple experiments to be performed as shown here but there is the concern 
that, although the cell type is fresh and human, the results may be artefactual due to 
the isolation process.
As a result of this, researchers have come to depend on a number of transformed cell 
lines which are usually derived from human adenocarcinomas. They are readily 
available and easily grown and passaged, have a characteristic genotype and 
phenotype (albeit with marked differences from normal human cells) and their use is 
widely reported in the relevant scientific literature. Ideally reports of findings in cell 
lines can then be corroborated by work in primary IECs.
Three cellular models were used to explore COX-2 expression in intestinal epithelial 
cells; two transformed intestinal epithelial cell lines -  HT-29 and Caco-2 -  along 
with freshly isolated primary human intestinal epithelial cells. The HT-29 cell line 
was established from a colonic adenocarcinoma in a 44 year old Caucasian female in
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1964 while the Caco-2 cell line was established in 1974 from a similar 
adenocarcinoma in a 72 year old Caucasian male (Rousset, 1986). Although both 
cell lines are established models of intestinal epithelial cells, the main difference 
between them is that HT-29 are generally less differentiated than Caco-2 cells.
This work looks at COX-2 expression at the mRNA, protein and product level. To 
investigate COX-2 mRNA expression northern analysis was used as opposed to RT- 
PCR as a more direct technique with less assumptions and allowing better 
comparison between samples. Initial development of a COX-2 cDNA probe for 
northern analysis was carried out using Digoxigenin labelling, but lack of 
reproducibility forced the change to radioactive labelling of commercially available 
COX-2 cDNA with [32P] (Soriani et al., 1999). This gave reproducible and clear 
results for COX-2 and was the technique adopted throughout the work shown here.
'X'JThe switch to [ P] labelling did not help improve the quality of COX-1 northern 
blots as conditions could not be found, using this technique, to allow consistent 
reproducible COX-1 mRNA analysis. Although COX-1 has occasionally been 
shown to be inducible in some systems, and inducible in the gastrointestinal tract by 
irradiation (Cohn et al., 1997), there was no evidence in this work or in the work of 
others that COX-1 is inducible by cytokines in any intestinal model of epithelial cell 
function.
Both the colorectal carcinoma derived cell lines used display a small amount of 
constitutive COX-2 expression at both the mRNA and protein level which is faintly 
seen in blots with good sensitivity (Figures 4.10 and 4.9 for mRNA and protein
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respectively in HT-29 cells; Figure 4.3 for Caco-2 cells). This is in keeping with 
results from other groups (Tsujii and DuBois, 1996; Tsujii et al., 1997; Battu et al., 
1998; Hsi et al., 2000), and that the origin of these transformed cell lines is from 
colorectal cancers. However the small amount of constitutive expression seen is not 
reflected in detectable amounts of PGE2 production.
It has been demonstrated here that the pro-inflammatory cytokines TNFa, IL -la  and 
IL-1 (3 can induce COX-2 in intestinal epithelial cell lines. This is not especially 
surprising as these cytokines have been shown to induce COX-2 in a number of 
systems and have been shown to induce other responses in intestinal epithelial cells 
(Eckmann et al., 1997; Jobin et al., 1998; Kolios et al., 1999). However there are a 
few features of these results which are surprising.
Firstly, regarding HT-29 cells, these cells are known to have TNFa and IL-1 
receptors and ligand binding has been shown to activate NFkB which is essential to 
COX-2 transcription (Jobin et al., 1998; Jobin et al., 1999). HT-29 cells have also 
been shown to have mRNA and protein for the LPS receptor CD 14 (Cario et al., 
2000) and can respond to LPS activation by activating NFkB as well as inducing IL- 
8 generation (Toshina et al., 2000; Schuerermaly et al., 1994), a chemokine known 
to be NFkB dependent in these cells (Jobin et al., 1998). Surprisingly, LPS did not 
activate COX-2 in this system, a result which is not contradicted in the literature. 
When considered with published results for COX-2 induction (Jobin et al., 1998), 
this implies that activation of NFkB is necessary but not sufficient for COX-2 
induction in HT-29 cells.
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Inducing Agent Cell type Reference
TNFa HT-29 (Eckmann et al., 1997)
Caco-2 (Stenson et al., 1993)
Bacterial Invasion HT-29 (Eckmann et al., 1997)
IGF-II Caco-2 (Di Popolo et al., 2000)
Dihydroxy Bile Acids SK-GT-4 (Zhang et al., 1998)
HCT 116 (Glinghammar and Rafter,
2 0 0 1 )
Table 4.1: Agents proven to induce COX-2 in intestinal epithelial cell lines
A second point of interest concerning COX-2 induction in HT-29 cells is the 
observed lack of effect of IFNy (Results Figure 4.2). IFNy has been shown to induce 
COX-2 in other systems (Matsuura et al., 1999). It has also been shown to be 
necessary in the induction of iNOS in HT-29 cells, an enzyme that shares many 
features with COX-2, although in that context it has to work in synergy with IL-la 
(Kolios et al., 1995). Although regarded as part of the Thl response, IFNy is an 
immunomodulatory cytokine, as opposed to a classic pro-inflammatory cytokine 
such as TNFa, and its regulatory properties on TNFa induction of COX-2 are 
further explored in chapter 5.
The COX-2 dependent induction of PGE2 by TNFa in HT-29 is a logical sequelae of 
its marked induction at the level of mRNA and protein. However this is at odds with 
Hsi et al who report that the COX-2 found in HT-29 cells is catalytically inactive
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and unable to result in PGE2 synthesis despite no mutation in the COX-2 gene (Hsi 
et al., 2000). This is further confounded by the fact that they cloned HT-29 derived 
COX-2 into HCT-116 IECs and the cloned COX-2 was active. Such results are 
confusing and an explanation may be in the fact that these workers did not use 
cytokine stimulation, and perhaps the TNFa is having an additional post- 
translational effect. The work presented here, which is supported by the literature 
(Jobin et al., 1998), would seem to prove the HT-29 COX-2 can synthesise PGE2 
when in the presence of TNFa. Indeed, it may be that there needs to be a critical 
amount of COX-2 protein to allow PGE2 production. IL -la  caused a less marked 
induction of COX-2 mRNA and protein with no resulting PGE2 synthesis. Similarly, 
no PGE2 production was seen in Caco-2 cells where the equivalent induction of 
COX-2 was smaller. Against this is the fact that Hsi et al report PGE2 synthesis by 
unstimulated Caco-2 cells, something that was not seen during this work (Hsi et al., 
2000).
Finally, concerning HT-29 cells and COX-2 induction, is the lack of induction of 
PGD2 production as assessed by measuring its stable methoximated derivative by 
ELISA. As a contrasting prostaglandin to PGE2, it is not known whether the 
intestinal epithelium can synthesis PGD2, or whether the conditions for its synthesis 
have not been met, and there is no supporting evidence in the literature.
With respect to Caco-2 cells, the response to IL -la  is again not unexpected. 
However the lack of clear response to TNFa is surprising as it is known that these 
cells can respond in a number of ways to TNFa including generation of IL-8 
(Toshina et al., 2000), IL-ip (Chowers et al., 2001) and MMP-9 (Gan et al., 2001).
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One would expect the IL-8 response to be NFkB dependent although activation of 
NFkB in Caco-2 cells by TNFa has not been demonstrated. Secondly, as with HT- 
29 cells, no induction of COX-2 was seen in response to LPS in Caco-2 cells. 
However, there is evidence that these cells may not be able to respond to LPS 
(Toshina et al., 2000). In contrast, the lack of observed response to IFNy in Caco-2 
cells may mirror the situation in HT-29 cells as Caco-2 cells do have the ability to 
respond to IFNy (Cavicchi and Whittle, 1999).
Having established the characteristics of COX-2 induction in two in vitro cell lines 
supportive evidence was sought in primary intestinal epithelial cells (IECs). As 
previously mentioned, intestinal epithelial research is limited by the difficulties in 
isolating and then subsequently culturing primary celis. IECs have been shown to 
have receptors for IL-1, and also respond to IL-ip (Jobin et al., 1998), and this was 
therefore chosen as an inducing agent. However, there was no evidence of induction 
of COX-2 mRNA or protein with this cytokine. One possible explanation concerns 
the cell population stimulated. The technique used to isolate IECs was one widely 
used in the literature. However, the final cell population was not assessed by FACS 
(Fluorescent Activated Cell Sorting) analysis to confirm a uniform epithelial cell 
population. A second option is that this is a true result and that there are significant 
differences between IECs and the in vitro models used to investigate their biology. 
This would be supported by the absence of TNFa receptors on IECs compared to 
their presence on many intestinal epithelial cell lines (Panja et al., 1998). A third 
possible explanation is that this isolation process, which results in cell death by 24 
hours, causes changes in cell physiology rendering them either unresponsive, or with 
markedly altered responses from those of their normal physiology. On the basis of
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the accepted difficulties of working with IECs in this area of research, it was felt that 
drawing reliable conclusions from such work was not possible and the use of IECs 
was not pursued.
The regulation of COX-2 by downstream products, such as PPARy agonists (PGJ2) 
and PGE2, raises many issues particularly concerning PGE2 which is a known 
product of COX-2 in this system. PGE2 is shown to negatively regulate induced 
COX-2 mRNA and protein at concentrations chosen because they reflect the amount 
of PGE2 induced by cytokine stimulation. They also represent concentrations which 
are similar to those reported in patients with UC (Sharon et al., 1978). This supports 
the fact that these results are likely to be physiologically relevant with the induced 
PGE2 production providing negative feedback for COX-2. This would effectively 
help limit the COX-2 dependent response. Evidence for a possible mechanism of 
action for this effect comes from recent work on the signalling pathways activated by 
PGE2 (Sheng et al., 2001). The binding of PGE2 to its EP4 receptor has been shown 
to activate the PI 3-Kinase signalling cascade and its downstream effector PKB. 
Evidence presented in chapter 6 points to a negative regulatory role for PI 3-Kinase 
on COX-2 expression (Weaver et al., 2001), thus providing a possible mechanistic 
pathway of action (Figure 4A). However this has not been rigorously proven and 
there is conflicting evidence from PGE2 binding causing an increase in cAMP and a 
resulting positive effect on COX-2 expression (Fournier et al., 1997; Inoue et al., 
2000). Such a hypothesis does not fit with the results presented here but may be 
playing a contributory role albeit with the net effect one of COX-2 inhibition.
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TNFa >  COX- 2  ------► PGE2 -------► PGE2
©T
PI 3-Kinase <
Figure 4A: Schematic representation o f possible mechanism fo r PGE2 negatively 
regulating COX-2 via a PI 3-Kinase dependent pathway.
Although the synthesis of PGD2, a precursor of cyclopentenone prostaglandins, 
could not be demonstrated in this system, there is evidence that such potential COX- 
2 products can regulate COX-2 expression and activity. The use of two differing 
PPARy agonists reveals consistent results with contrasting interpretations. Both 
ciglitazone, a thiazolidinedione class drug, and PGJ2 , reported as being a 
physiological agonist, both increase COX-2 protein when used alone or in 
conjunction with TNFa stimulation. However they both inhibit TNFa induced 
PGE2 production with PGJ2 being more effective than ciglitazone. Both aspects of 
these results receive support from the literature and it is obviously possible to have 
conflicting regulation at different points of the RNA to protein to product pathway, a 
theme which is explored in chapter 5. In this context it is probably most valid to 
consider the functional readout of COX-2, that is its enzymatic activity to synthesise 
PGE2, as the best marker of PPARy agonist stimulation. Inhibition of PGE2 
production is supported by work in a macrophage cell line (Inoue et al., 2000). Also, 
with the hypothesis that COX-2 expression and PGE2 production in this acute model 
is generally pro-inflammatory, would be supported by the generally reported anti­
inflammatory actions of PPARy on chemokine generation, iNOS activation and 
macrophage activation (Jiang et al., 1998; Ricote et a l., 1998; Momoi et al., 1999
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Petrova et al., 1999). It is believed that PPARy agonists exert their effects at least in 
part by inhibiting the NFkB pathway by direct inhibition of IkB Kinase (Rossi et al., 
2000). This would correlate with a general anti-inflammatory profile and inhibiton 
of COX-2. However, in this context one would expect to see inhibition of COX-2 
transcription with decreased mRNA levels. Also, NFkB inhibition is at odds with 
the increase in COX-2 protein and the post-translational effect of decreased PGE2 
production. Therefore there must be additional mechanisms for PPARy activation to 
mediate its effects in this system.
Finally it should be pointed out that regulation of COX-2 by its products may 
involve altering the prostaglandin profile produced rather than altering COX-2 
mRNA or protein levels per se. This system lacks the sophistication to assess this, 
due to lack of a second prostaglandin as a functional readout of COX-2 activity. 
Regulation of differing prostaglandin synthases may explain some of the contrasting 
evidence as is particularly seen with the PPARy agonist results.
The regulation of prostaglandin production by 5-ASA in models of IBD is an 
important clinical question as this is a common therapeutic agent in IBD in general 
and colitis in particular. 5-ASA is related to aminosalicylates, but is not a non­
steroidal anti-inflammatory drug (NSAID), and has been documented as having 
many potentially beneficial actions in IBD (Greenfield et al., 1993). It has been 
shown to inhibit prostaglandin production when used in the mM concentration range 
(Sharon et al., 1978; Hawkey and Truelove, 1983; Greenfield et al., 1993;). In 
contrast, it promotes prostaglandin production in the pM concentration range 
(Hawkey et al., 1985; Greenfield et al., 1993;), which raises the important question
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of which concentration of 5-ASA is relevant to its use in the treatment of IBD (De 
Vos et al.; 1992Riley, 1998). The measurement of 5-ASA in the colon is 
challenging and there is debate about which site is the most appropriate to measure; 
the lumen, mucosa or serum? Taking a consensus view that the pM range was most 
physiologically appropriate, 5-ASA was used to assess regulation of COX-2, rather 
than the previous work looking solely at prostaglandin synthesis often done prior to 
the discovery of inducible cyclo-oxygenase. This reveals that 5-ASA only inhibits 
COX-2 mRNA once in the mM range, and even then only slightly, and that the IC50 
for inhibition of PGE2 production was 119pM. At lOpM 5-ASA there was no 
apparent regulatory action on COX-2 mRNA or PGE2 production.
The optimal therapeutic concentration for 5-ASA is crucial to interpreting these 
results. If it is in the low pM range then 5-ASA is unlikely to be exerting any effects 
via COX-2 inhibition. However, if it is higher then this may be a relevant action of 
5-ASA in IBD although it may not be beneficial to chronic intestinal inflammation 
as inhibition of COX exacerbates IBD, and inhibition of COX-2 exacerbates animal 
models of this disease (Reuter et al., 1996). Furthermore, there is evidence that 5- 
ASA may decrease the risk of malignant transformation (Brown et al., 2000). Such 
an action could be related to chronic COX-2 inhibition as is seen with decreased 
rates of colorectal carcinoma in long term users of NSAIDs (Giovannucci et al., 
1994; Giovannucci et al., 1995). In summary, because of the many actions of 5- 
ASA, and the uncertainties about the relevant therapeutic concentration, theories 
concerning its detailed action can only be speculative.
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5 Results -  Regulation of Induced COX-2 by Cytokines
5,1 Introduction
Having established that the pro-inflammatory cytokines TNFa and IL-1 a  or p can 
induce COX-2 mRNA in intestinal epithelial cells, the next aim was to assess any 
possible regulatory role for other cytokines relevant to gastrointestinal biology and 
disease. In particular, although Interferon-y (IFNy) had no effect on COX-2 
induction in isolation (chapter 4), the possibility of an interaction with TNFa or IL- 
l a  was addressed. IFNy has been shown to be raised in IBD and has been shown to 
induce COX-2 in human keratinocytes (Matsuura et al., 1999). Furthermore it has 
been demonstrated to interact synergistically with TNFa to induce chemokines in 
HT-29 intestinal epithelial cells (Warhurst et al., 1998). In contrast, it has been 
shown to inhibit IL-1 p induced COX-2 transcription in human macrophages 
(Barrios-Rodiles and Chadee, 1998).
The second aim was to explore the possible immunoregulatory role of Th2 cytokines 
such as IL-4, IL-10 and IL-13. Although HT-29 cells appear to lack the machinery 
to respond to IL-10 (Bourreille et al., 1999), IL-4 and IL-13 have been shown to 
inhibit pro-inflammatory cytokine activation of iNOS, as well as chemokine 
production, in HT-29 cells (Wright et al., 1997; Kolios et al., 1999). With respect to 
the regulation of COX-2, there are reports of an inhibitory role of Th2 cytokines in 
other non-gastrointestinal systems.
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5.2 Results
5.2.1 Regulation of cytokine induced COX-2 by Interferon-y
5.2.1.1 Interferon-y and COX-2 mRNA
To investigate the effect of IFNy on the cytokine induction of COX-2 mRNA, HT-29 
cells were simultaneously stimulated with TNFa or IL-1 a  in the presence of 
increasing concentrations of IFNy (0-300u/ml) for two hours before isolation of 
mRNA for northern blot analysis and probing for COX-2 (Figure 5.1 A and 5.IB). 
IFNy inhibited the induction of both TNFa and IL-1 a  induced COX-2 mRNA, and 
this inhibition was concentration dependent.
Having established an inhibitory action of IFNy on induced COX-2 mRNA 
generation, a possible mechanism of action of IFNy was explored using the selective 
JAK2 inhibitor AG490. IFNy is believed to signal through a receptor complex 
requiring the activation of JAK2. Once activated it can activate the other receptor 
associated JAK, JAK1, and then together they phosphorylate the tyrosine containing 
440YDKPH444 sequence near the C-terminus of the IFNGR1. This allows the 
formation of ST ATI docking sites, their subsequent activation and downstream 
effects (Stark et al., 1998). It would therefore be expected that JAK2 inhibition 
would inhibit any effects of IFNy mediated through its receptor. HT-29 cells were 
stimulated in the presence or absence of simultaneously added IFNy, with or without 
pre-treatment with the JAK2 inhibitor AG490 at lOOpM for 15 minutes (Figure
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5.1C). TNFa was seen to induce COX-2 mRNA which was partially inhibited by 
300u/ml IFNy. Interestingly, pre-treatment with AG490 had no effect on this 
inhibitory action of IFNy as well as having no effect when used in isolation (Figure 
5.1C).
The next question to address was whether the action of IFNy on inhibiting total 
quantities of induced COX-2 mRNA was due to reducing the mRNA stability. 
COX-2 is known to be regulated in this way via the adenylate and uridylate rich 
elements or AREs in the 3' untranslated region. Indeed, it has been shown that the 
majority of the increase seen in COX-2 mRNA post induction is due to increased 
stability rather than increased transcription (Huang et al., 2000). To assay COX-2 
mRNA stability, Actinomycin D chase experiments were performed. Actinomycin 
D (AcD) prevents RNA synthesis and this is demonstrated in Figure 5.2A. HT-29 
cells were pre-treated for one hour with increasing concentrations of AcD (5- 
20pg/ml) and then stimulated with TNFa at lOOng/ml. When compared to a positive 
control without AcD pre-treatment, it can be seen that AcD prevents TNFa induced 
COX-2 mRNA generation at all concentrations (Figure 5.2A). To perform a chase 
experiment, HT-29 cells were stimulated with a cytokine for two hours (initially 
TNFa at lOOng/ml), and then AcD was added preventing any new mRNA synthesis. 
The mRNA synthesised in the first two hours then decays at a rate depending on its 
stability. Figure 5.2B demonstrates that this occurs similarly for AcD at 
concentrations of 5-20pg/ml and therefore 5pg/ml was subsequently used 
throughout. AcD on its own had no effect on COX-2 induction (Figure 5.2D) and 
the vehicle for AcD, DMSO, did not alter the cytokine induction of COX-2 mRNA 
in any way (Figures 5.2C and D).
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HT-29 cells, in the presence or absence of IFNy, were stimulated for two hours with 
TNFa. At two hours AcD was added to give a concentration of 5pg/ml and mRNA 
was then isolated at this point and at one to six hours thereafter and analysed for 
COX-2 mRNA by Northern blot analysis. The decay of signal seen on Northern blot 
analysis allows the calculation of a half life for COX-2 mRNA. For this series of 
experiments the half life of TNFa induced COX-2 mRNA was shown to be about 3 
hours and this was not significantly altered by the presence of IFNy (Figure 5.3)
5.2.1.2 Interferon-y and TNFa induced COX-2 protein and PGE2 product
Having established an inhibitory effect of IFNy on TNFa or IL-1 a  induced COX-2 
mRNA in HT-29 cells, the work progressed to assess the effects of IFNy on TNFa 
induced COX-2 protein. HT-29 cells were stimulated for six hours with increasing 
concentrations of TNFa alone (30 and lOOng/ml) and in combination with 
IFNy (300u/ml). Subsequent western blot analysis for COX-2 shows that the 
induction of COX-2 protein by TNFa is concentration dependent (Figure 5.4A). 
The additional presence of IFNy caused a further significant increase in COX-2 
protein compared to TNFa alone. This synergistic action between TNFa and IFNy 
on COX-2 protein induction is surprising considering the opposite action of IFNy at 
the level of COX-2 mRNA.
It was then explored, as with the work on IFNy inhibition of induced COX-2 mRNA, 
whether the mechanism of action of IFNy on further inducing COX-2 protein was 
mediated via a JAK2 dependent pathway. HT-29 cells were stimulated with TNFa
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and IFNy for six hours in the presence or absence of increasing concentrations of the 
specific JAK2 inhibitor AG490 (10 and lOOpM). Subsequent western analysis of 
isolated protein showed that the marked induction of COX-2 protein by TNFa and 
IFNy was partially inhibited by AG490 at the higher concentration of lOOpM (Figure 
5.4B). Because AG490 is dissolved in DMSO, a reciprocal experiment using this 
DMSO vehicle at appropriate dilutions to represent differing concentrations of 
AG490, was carried out and the membrane probed for COX-2 protein. This showed 
no effect of DMSO vehicle on TNFa and IFNy induced COX-2 protein (Figure 
5.4C).
Finally, regarding COX-2 protein, it was important to ensure that the AG490 was 
specifically inhibiting only the super-induction effect of IFNy and not the basic 
induction by TNFa alone. HT-29 cells were stimulated with TNFa and IFNy both 
alone and in combination, along with TNFa in combination with AG490 pre­
treatment (lOOpM for one hour), and protein analysed for COX-2 by western blot 
analysis (Figure 5.4D). This demonstrated that AG490 did not effect the induction 
of COX-2 by TNFa alone and confirmed that IFNy alone had no inductive effect on 
COX-2 protein.
Considering the conflicting regulatory action of IFNy on induced COX-2 at the 
mRNA and protein level, the regulatory action of IFNy on the PGE2 generation, as a 
functional activity of COX-2, was assessed. HT-29 cells were stimulated with 
TNFa and increasing concentrations of IFNy for 24 hours and supernatants collected 
for measurement of PGE2 (Figure 5.5). Increasing concentrations of IFNy caused a
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significant, concentration dependent, synergistic increase to TNFa induced PGE2 
production. This super-induction of PGE2 production by the combination of TNFa 
and IFNy was COX-2 dependent as demonstrated by the total inhibition by NS-398, 
a specific COX-2 inhibitor.
Finally it was investigated whether JAK2 inhibition abrogated the synergistic action 
of IFNy with TNFa at this level of COX-2 functional activity as well as at COX-2 
protein production. HT-29 cells were stimulated with TNFa and IFNy for 24 hours 
in the presence or absence of AG490 and the supernatants were assayed for PGE2 . 
JAK2 inhibition with AG490 significantly decreased PGE2 production in a 
concentration dependent manner with lOOpM causing 70% inhibition 
(p<0.01)(Figure 5.6). This inhibitory action was compounded by an effect of the 
DMSO vehicle not seen at the level of protein and mRNA. However, the inhibitory 
action of AG490 is greater than that of its vehicle at comparable amounts, and this 
difference is significant at lOOpM (p<0.05).
5.2.2 Regulation by Th2 Cytokines
5.2.2.1 Th2 cytokines and HT-29 cells
In view of the proven role of Th2 cytokines in regulating iNOS and C-C chemokines 
in HT-29 cells (Wright et al., 1997; Kolios et al., 1999), as well their regulation of 
COX-2 in other non-gastrointestinal systems, there was good evidence to suggest a 
regulatory role on COX-2 in HT-29 cells. HT-29 cells pre-treated with IL-4, IL-10 
or IL-13 (all at 30ng/ml for 1 hour), prior to stimulation with TNFa for two hours,
138
Results and Discussion: Regulation o f  Induced COX-2 by Cytokines
showed that IL-4 and IL-13, but not IL-10, caused significant inhibition of TNFa 
induced COX-2 mRNA (Figure 5.7A).
In view of the demonstration that IL-4 and IL-13 have a marked inhibitory action on 
TNFa induced COX-2 mRNA it was evaluated whether similar effects were 
observed at the level of protein expression. Indeed, western blot analysis, using a 
specific anti-COX-2 antibody, revealed that IL-4 and IL-13 again caused a marked 
inhibition of TNFa induced COX-2 protein, with IL-10 having no effect (Figure 
5.7B).
Finally, the action these cytokines had on COX-2 enzyme functional activity, as 
measured by PGE2 production was assessed. Again IL-4 and IL-13 were shown to 
significantly inhibit TNFa induced PGE2 production (p<0.01). The effect of IL-10 
was not significant (Figure 5.7C).
§.2.2.2 Th2 cytokines and Caco-2 cells
To explore whether the actions of Th2 cytokines in inhibiting COX-2 induction in 
HT-29 cells were representative of other intestinal epithelial cells, their action on 
induced COX-2 mRNA was investigated in Caco-2 cells. Using a similar protocol to 
that used in HT-29 cells, Caco-2 cells were pre-treated with IL-4, IL-10 or IL-13 (all 
at 30ng/ml for 1 hour), prior to stimulation with IL-1 a  for two hours. mRNA was 
then isolated and probed for COX-2 using northern blot analysis. In contrast to work 
with HT-29 cells, this showed no alteration of IL-1 a  induced COX-2 mRNA by IL- 
4, IL-10 or IL-13 (Figure 5.8).
139
Results and Discussion: Regulation o f  Induced COX-2 by Cytokines
5.2.2.3 IL-4 and IL-13 activate PKB in HT-29 cells
Finally, with regard to cytokine regulation of COX-2, previous work carried out at 
the University of Bath has shown that IL-13 activates the signalling pathway PI 3- 
Kinase and that is how it mediates its inhibition of iNOS (Wright et al., 1997). 
Although it is known that IL-4 and IL-13 share similar receptor mediated signalling 
pathways, and that they can both activate PI 3-Kinase in other systems, it has not 
been shown that IL-4 and IL-13 have the same action in the HT-29 cell line. In 
particular, it has not been shown that IL-4, like IL-13, can activate PI 3-Kinase 
dependent signalling cascades. Hence, the effect of IL-4, IL-10 and IL-13 on the 
activation by phosphorylation of PKB, a downstream effector of PI 3-Kinase which 
is commonly used as a marker of PI 3-Kinase activation, was assessed. This was 
done by western blot analysis using a phospho-specific antibody against the 
phospho-Ser473 within the PKB activation loop. HT-29 cells were treated in the 
presence of the three Th2 cytokines, IL-4, IL-10 or IL-13, over a short time course 
(0-30 minutes). Cells were lysed, immunoprecipitated with an antibody targeted 
against PKB using an epitope common to both phosphorylated (active) and 
unphosphorylated (inactive) forms of the protein, and associated proteins were 
separated by SDS-PAGE. After transfer to nitrocellulose the separated proteins were 
probed with an anti-phospho-Ser473 PKB antibody, with the same blot being stripped 
and reprobed for pan PKB to demonstrate equal loading (Figure 5.9). There was 
some constitutive PKB activation, which was to be expected in this cell line which 
has been shown to have constitutive PI 3-Kinase activity and is derived from a 
human colorectal carcinoma (Wright et al., 1997). However, above and beyond this, 
there was activation of PKB by both IL-4 and IL-13, supporting the prior assumption
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Figure 5.1: Inhibition o f cytokine induced COX2 mRNA by Interferon-y.
A and B. Northern analyses of mRNA isolated from HT-29 cells, which have been 
stimulated with TNFa (lOOng/ml) (A) or IL-1 a  (lOng/ml) (B) for two hours having 
been pre-treated with increasing concentrations of IFNy (0-300u/ml) and probed for 
COX2 (upper panels). The membranes were stripped and reprobed for p-Actin to 
demonstrate loading (lower panels). C. Northern analysis of mRNA from HT-29 
cells, which have been stimulated as described for two hours (TNFa at lOOng/ml; 
IFNy at 300u/ml; AG490 at 100pM one hour prior) and probed for COX2 (upper 
panel). The 28S band from the membrane prior to probing is shown to demonstrate 







o 1 TNFa 1
doU
1
5pg/ml , , lOpg/ml 11
1
2 0 pg/ml ,
2
II II
2 6 12 24 2 6 12 24
1
2 6 12 24
m
* * * * * * * *  mm *■
oH 1 TNFaCou 1 i 5ug/ml i i lOug/ml i I 2 0 |ig/m|
2
I I 1 1
6 12 24 6 12 24
1 1
6 12 24
m Up ilfrf' - w flHp SB ^  * mm f§
m mm m m m  mm mm mm
TNFa 
IL-1 a  
DMSO +
+ + -  -
+ + 






2 6 12 24 2 6 12 24 3 4 6 8 12 24





Figure 5.2: Inhibition o f mRNA synthesis by ActinomycinD, and DMSO control blots
A to D. Four Northern analyses of mRNA isolated from HT-29 cells and probed for 
COX2 (upper panels). A and B. Cells were stimulated with TNFa (lOOng/ml) over a 24 
hour time course, having been either pre-treated for one hour with increasing 
concentrations of Actinomycin D (AcD) (5-20pg/ml) (A), or with AcD added two hours 
after TNFa (B). The 28S band demonstrates equal loading. C. Cells were stimulated for 
two hours with TNFa (lOOng/ml) or IL-1 a  (30ng/ml) in the presence or absence of the 
vehicle for both AcD and AG490, DMSO (10pl (0.005%v/v) - equivalent to 5pg/ml AcD 
or 200pM AG490). The membrane was stripped and reprobed for p-Actin to demonstrate 
loading. D. mRNA was isolated from cells over a 24 hour time course, having been 
stimulated by TNFa (lOOng/ml) in the presence or absence of DMSO (lOpl), or treatment 
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Figure 5.3: Decay o f COX2 mRNA in the presence or absence o f  interferony
Logarithmic line plot of [Intensity] of COX2 mRNA as measured by Northern analyses 
(arbitrary units where maximum intensity is 1) vs time in hours. HT-29 cells were 
stimulated with TNFa (A) for 2 hours in the presence or absence of IFNy (300u/ml). At 
2 hours Actinomycin D (5pg/ml) was added to prevent new RNA synthesis. The 
subsequent decay in the mRNA signal was plotted to allow calculation of the half life - 
time at which Intensity is 0.5. The blots shown are representative of three experiments. 
The membranes were photographed to show the 18S and 28S bands to ensure equal 






















Figure 5.4: Synergy between TNFa and IFNy  
A to D. Western analyses of protein isolated from HT-29 cells and probed for COX2. A. 
Cells were treated for six hours with increasing concentrations of TNFa (0-100ng/ml) and 
then in combination with IFNy (300u/ml) added simultaneously. B. Cells were treated for 
six hours with combined TNFa (lOOng/ml) and IFNy (300u/ml) in the presence or absence 
of pre-treatment with the JAK2 inhibitor AG490 (at 10 and lOOpM for one hour). C. Cells 
were treated for six hours in the presence or absence of the AG490 vehicle, DMSO, at 
concentrations equivalent to AG490 (10-100pM - 0.00025% to 0.0025% v/v). D. Cells 
were treated with TNFa (lOOng/ml) and IFNy (300u/ml), either alone or in combination for 
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Figure 5.5: Synergy between TNFa and IFNy  
Bar chart of PGE2 production (pg/ml) stimulated by TNFa (lOOng/ml) for 24 
hours in the presence of increasing concentrations of IFNy (0-300u/ml). The 
combination of TNFa and IFNy (300u/ml) was pre-treated with the specific 
COX2 inhibitor, NS-398 at lpM for one hour to demonstrate COX2 
dependence of induced PGE2 production.
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Figure 5.6: JAK2 inhibition o f IFNy super-induction o f TNFa induced PGE2
Bar chart of PGE2 production (pg/ml) stimulated for 24 hours with TNFa 
(lOOng/ml) and IFNy (0-300u/ml) in the presence of increasing concentrations of 
the specific JAK2 inhibitor AG490 (KMOOpM) or equivalent concentrations of its 
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Figure 5.7: Regulation o f TNFa induced COX2 expression by Th2 cytokines.
A. Northern analyses of mRNA isolated from HT-29 cells, which have been pre­
treated with the Th2 cytokines IL-4, IL-10 or IL-13 (30ng/ml for one hour) and 
stimulated with TNFa (lOOng/ml) for two hours (A) and probed for COX2 (upper 
panels). The membrane was stripped and reprobed for p-Actin to demonstrate loading 
(lower panels). B. Western analysis of protein isolated from HT-29 cells, stimulated for 
six hours with TNFa (lOOng/ml) having been pre-treated with Th2 cytokines as labelled 
(30ng/ml for one hour), and probed with a specific anti-COX2 antibody (upper panel). 
C. An ELISA for PGE2 (pg/ml) using supernatants from HT-29 cells stimulated with 
TNFa (lOOng/ml) for 24 hours having been pre-treated with Th2 cytokines as labelled 
(30ng/ml for one hour). This is the result of one experiment using triplicate samples 
and is representative of three other experiments. Blots are from single experiments but 
are representative of at least three others. ** represents a significant inhibition of PGE2 
production (p<0 .0 1 ).
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Figure 5.8: Lack o f regulation o f COX2 by Th2 cytokines in Caco-2 cells.
A. Northern analyses of mRNA isolated from Caco-2 cells, which have been 
pre-treated with the Th2 cytokines IL-4, IL-10 or IL-13 (30ng/ml for one hour) 
and stimulated with IL-1 a  (lOng/ml) for two hours (A) and probed for COX2 
(upper panels). The 28S band is shown to demonstrate loading (lower panels). 
Blots are from single experiments but are representative of one other.
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Figure 5.9: Activation o f PKB by Th2 cytokines.
A. Western analyses of protein isolated from HT-29 cells, stimulated over a short 
time course (0-30 mins) with the Th2 cytokines IL-4, IL-10 or IL-13 (30ng/ml). 
Lysates were immunoprecipitated with specific goat anti-PKB antibody and then 
probed with a specific anti-phospho-Ser473 PKB antibody (upper panels). 
Membranes were stripped and reprobed for rabbit anti-PKB to demonstrate equal 
loading. Blots are from single experiments but are representative of one other.
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5.3 Results Summary
• IFNy inhibits the induction of COX-2 mRNA in a concentration dependent 
manner in HT-29 cells. This inhibition of COX-2 mRNA induction by IFNy was 
unaltered by incubation with a JAK2 inhibitor.
• The stability of induced COX-2 mRNA was unaltered by IFNy implying that its 
inhibitory action occurs at the level of decreased transcription.
• IFNy potentiated the induction of COX-2 protein and PGE2 product in a 
concentration dependent manner in HT-29 cells. This potentiation was reversed 
by incubation with a JAK2 inhibitor in a concentration dependent manner.
• The Th2 cytokines IL-4 and IL-13 inhibited the induction of COX-2 mRNA, 
protein and PGE2 product in HT-29 cells, whereas IL-10 had no effect.
• In Caco-2 cells IL-4, IL-10 and IL-13 had no effect on COX-2 mRNA induction.
• In HT-29 cells IL-4 and IL-13 induce the phosphorylation, and presumed 
activation, of the downstream effector of PI 3-Kinase, PKB.
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5.4 Discussion
The work presented here demonstrates the many complexities involved in regulating 
gene expression. The regulatory action of the Thl cytokine IFNy on intestinal COX- 
2 expression has differing effects at the mRNA level when compared with the end 
points of protein and product. The overall effect of IFNy when considering 
functional activity of COX-2 is a synergistic action with TNFa as has been 
previously described in this system (Arias-Negrete et al., 1995; Warhurst et al.,
1998). However the concentration dependent inhibition of COX-2 mRNA gives an 
insight into the many points of regulating COX-2 expression. There is now evidence 
of COX-2 being regulated at the transcriptional level to alter RNA synthesis (Reddy 
et al., 2000), post-transcriptional alteration of RNA stability (Dixon et al., 
2000;Huang et al., 2000), changing the translational rate (Dixon et al., 2000) as well 
as the demonstration of variation between different intestinal cell types of COX-2 
protein stability (Shao et al., 2000). Finally the activity of the protein can be altered 
as is done by specific COX-2 inhibitors.
Looking initially at the level of COX-2 mRNA induction, it can been seen that IFNy 
causes a concentration dependent decrease in both TNFa and IL-1 a  induced COX-2 
mRNA. This does not appear to be JAK2 dependent and this is surprising as current 
theories regarding IFNy signalling always involve JAK2 (Bach et al., 1997; Stark et 
al., 1998). The reason for this does not appear to be due to the ineffectiveness of the 
AG490 compound used as a JAK2 inhibitor as the synergistic activity of IFNy on 
TNFa induced COX-2 protein and PGE2 production was sensitive to this compound.
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Alternatively, there may a second confounding action of AG490. Although it is 
generally regarded as a specific JAK2 inhibitor there is evidence that it may inhibit 
JAK3, STAT and MAP Kinase dependent pathways in some systems (Wang et a l., 
1999). However, the possibility of a novel signalling pathway for IFNy signalling 
can not be ruled out and there is evolving evidence that there are naturally occuring 
variations in these signalling pathways (Dupuis et al., 2001).
The mechanism of action of IFNy inhibiting COX-2 mRNA induction is also 
interesting. As has been stated, much of the regulation of COX-2 at the mRNA level 
is by altering mRNA stability rather than necessarily altering transcription (Dixon et 
al., 2000; Huang et al., 2000). However, in this instance, the presence of IFNy in the 
cell culture medium did not alter the stability of the induced COX-2 mRNA as 
measured by Actinomycin D chase experiments. Other researchers report that IFNy 
can inhibit IL-1 p induced COX-2 transcription (Barrios-Rodiles and Chadee, 1998). 
However, in their system using macrophages, these inhibitory effects were also seen 
at the level of COX-2 protein and PGE2 production. During this work, attempts 
were made to measure COX-2 mRNA transcription rates using nuclear run-on assays 
but unfortunately the assay did not give interpretable results. Thus, the assertion that 
IFNy inhibits TNFa induced COX-2 mRNA transcription in this system cannot be 
proven.
Likely to be of more functional significance is the finding that IFNy acts 
synergistically with TNFa with regards to COX-2 protein and PGE2 production. 
This has been previously demonstrated in HT-29 cells with respect to the induction 
of the chemokines RANTES and MCP-1 (Warhurst et al., 1998). Interestingly, their
144
Results and Discussion: Regulation o f Induced COX-2 by Cytokines
work showed that such synergy was dependent on the end point assessed, as IFNy 
did not potentiate the TNFa induction of IL-8. Such synergy has been demonstrated 
in an alternative intestinal epithelial cell line, T84 cells (Fish et al., 1999), although 
there are models outside of the gastro-intestinal system which show the opposite 
effect (Minghetti et al., 1996; Hewett, 1999). A potential mechanism for the 
synergistic action of TNFa and IFNy in the HT-29 cell line is proposed by Blanch et 
al (Blanch et al., 1999). They demonstrate a role for IRF-1 in the regulation of the 
polymeric immunoglbulin receptor which is coordinately regulated by TNFa/IL-lp 
and IFNy. There is supportive evidence showing that IRF-1 regulates COX-2 
expression in murine peritoneal macrophages although, as is often seen, the details 
do not precisely match in cells of an alternative species and type (Blanco et al., 
2000).
Th2 cytokines are known to have an immunoregulatory role and have been used with 
beneficial effects in therapeutic trials of IBD in humans (Van Deventer et al., 1997; 
Weaver and Robertson, 2000). IL-13 has been shown to down-regulate RANTES 
and iNOS in HT-29 intestinal epithelial cells and the mechanism for the latter was 
demonstrated as being dependent on the activation of PI 3-Kinase by IL-13 (Kolios 
et al., 1999; Wright et al., 1997). In this work we have demonstrated that IL-4 and 
IL-13 inhibit COX-2 expression and activity in HT-29 cells. Indeed, Th2 cytokines 
have been reported to inhibit COX-2 expression in a variety of other systems, 
including osteoblasts (Onoe et al., 1996) and monocytes (Niiro et al., 1998). That 
IL-10 was not demonstrated to have an effect is unsurprising in a system which 
appears to be unable to respond to this cytokine (Bourreille et al., 1999; Kolios et al.,
1999). IL-10 can bind IL-10 receptors in HT-29 cells but they lack IL-10 receptor
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mRNA implying that the IL-10 receptor may be shortened, lacking the intracellular 
portion necessary to mediate cell responses (Bourreille et al., 1999). There is one 
paper in the literature citing an action of IL-10 binding in HT-29 cells but it is 
isolated and is at odds with the apparent deficiencies of the IL-10 signalling pathway 
in these cells (Schottelius et al., 1998).
It is interesting that there was no regulation of COX-2 mRNA expression by any of 
the Th2 cytokines in Caco-2 cells. It is worth noting that a different inducing 
cytokine was used and this may be relevant in this context. However, there is a 
precedent for IL-4 and IL-13 causing a physiological response in HT-29 cells but not 
in Caco-2 cells (Gingras and Simard, 1999). This does not appear to be a uniform 
finding with others reporting that pre-incubation of Caco-2 cells with IL-4 and IL-13 
inhibits the cytokine induction of IL-8, an NFkB dependent gene like COX-2 
(Lugering et al., 1999). Furthermore, the IL-4 and IL-13 receptors have been shown 
to be expressed on both HT-29 and Caco-2 cells (Trejdosiewicz et al., 1998). Thus, 
the reason for the lack of regulation of induced COX-2 mRNA by IL-4 and IL-13 in 
Caco-2 cells remains surprising and unclear.
Finally, it has already been mentioned that IL-13 is known to activate PI 3-Kinase in 
HT-29 cells (Wright et al., 1997). IL-4 has been shown to activate PI 3-Kinase in 
other systems and has similar immunoregulatory effects as IL-13 in intestinal 
systems, probably as a consequence of shared receptors and signalling pathways 
(Ahmad et al., 1999; Mirmonsef et al., 1999; Montaner et al., 1999). This work 
therefore addressed whether the similar responses of HT-29 cells to IL-4 and IL-13 
were reflected in similar activation of PI 3-Kinase. For this work, the
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phosphorylation of PKB, a downstream effector of PI 3-Kinase, was used as a 
marker of its activation. This phosphorylation is generally regarded a being PI 3- 
Kinase dependent and is often used as a marker for PI 3-Kinase activation. In HT-29 
cells IL-4 and IL-13, but not IL-10, resulted in a time dependent increase in the 
phosphorylation of PKB (Figure 5.9). In HT-29 cells there is known to be some 
constitutive PI 3-Kinase activity in keeping with their derivation from a human 
colorectal carcinoma. This explains the basal levels of PKB phosphorylation seen in 
the unstimulated samples. The similarity of response to IL-4 and IL-13 is 
unsurprising but represents the first description of IL-4 activating a PI 3-Kinase 
process, and by inference PI 3-Kinase, in this system. Again IL-10 caused no 
response in HT-29 cells.
Activation of PI 3-Kinase by IL-13 in this system has already been shown to be the 
mechanism by which IL-13 inhibits iNOS expression in HT-29 cells. COX-2 and 
iNOS share many characterisitics and the possibility that PI 3-Kinase may mediate 
the inhibitory action of IL-4 and IL-13 on COX-2 expression in HT-29 cells was 
explored in chapter 6. A variety of other mechanistic pathways having been 
proposed for the effects of Th2 cytokines on COX-2 expression (Niiro et al., 1998; 
Diaz-Cazorla et al., 1999; Paul et al., 1999) but these are not necessarily mutually 
exclusive.
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6 Results - Regulation of Induced COX-2 by PI 3-Kinase
6.1 Introduction
It has been shown in chapter 5 that the Th2 cytokines, IL-4 and IL-13, down-regulate 
cytokine induced COX-2 in HT-29 cells as well as activating the downstream 
effector of PI 3-Kinase, PKB. It is known that both of these cytokines can activate 
the PI 3-Kinase signalling pathway in a variety of cell systems (Mirmonsef et al., 
1999; Montaner et al., 1999). Indeed it has been demonstrated that IL-13 can down- 
regulate iNOS in HT-29 cells and that this effect is mediated by this activation of PI 
3-Kinase (Wright et al., 1997). iNOS shares many biological characteristics with 
COX-2. It is induced in intestinal epithelial cells during inflammation (Singer et al., 
1996; Kolios et al., 1998) and has been shown to be dependent on NFkB for its 
transcription in this cell system (Jobin et al., 1998). This latter point links in with 
recent speculation concerning the findings that activation of NFkB is PI 3-Kinase 
dependent in some, but not all, systems (Ozes et al., 1999; Madge and Pober, 2000). 
It was therefore investigated whether PI 3-Kinase had a regulatory role for cytokine 
induced, and thus NFkB dependent, COX-2 expression. Furthermore, recent work 
has revealed that PI 3-Kinase can be activated by TNFa directly (Hanna et al., 1999; 
Kim et al., 1999) and therefore the activation of PI 3-Kinase by TNFa was 
investigated in intestinal epithelial cells.
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6.2 Resuits
6.2.1 COX-2 Expression and PI 3-Kinase Inhibitors
It was seen in chapter 4 that COX-2 expression can be induced in intestinal epithelial 
cells by both TNFa and IL-la (see table 6.1 below).
Indu ced  COX- 
2
T N F a I L - la
H T-29 mRNA S
Protein s
PGE2 product s X
Caco-2 mRNA X
Protein X s
PGE2 product X X
6.2.1.1 HT-29 cells and wortmannin
TNFa induced COX-2 in HT-29 cells was initially used to investigate the effect of 
the PI 3-Kinase inhibitor wortmannin. Pre-treatment with wortmannin, in the dark 
for 15 minutes, prior to the addition of TNFa resulted in markedly enhanced COX-2 
mRNA expression in a concentration dependent manner (l-100nM) (Figure 6.1 A). 
In the absence of cytokine stimulation, wortmannin had no effect (Figure 6 .IB).
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Having established that TNFa induced COX-2 mRNA expression is markedly up- 
regulated by wortmannin, it was next evaluated whether similar effects were 
observed at the level of protein expression. Indeed, wortmannin enhanced the TNFa 
stimulated COX-2 protein expression in a concentration dependent manner whilst 
having no effect on the constitutive isoform of COX, COX-1 (Figure 6.1C). Next, 
the effect of TNFa on COX-2 enzyme activity was investigated as assessed by 
production of one of its metabolic products, PGE2 . Wortmannin caused a significant 
concentration-dependent up-regulation of TNFa induced PGE2 production 
correlating with the findings for mRNA and protein (Figure 6.ID).
To investigate whether the effects of PI 3-Kinase inhibition with wortmannin on 
induced COX-2 were unique to the TNFa stimulation, these experiments were 
repeated using IL -la  to induce COX-2. As with TNFa, HT-29 cells pre-treated with 
wortmannin for 15 minutes prior to the addition of IL -la  exhibited markedly 
enhanced COX-2 mRNA expression in a concentration dependent manner (0- 
lOOnM) (Figure 6.2A). A similar effect was seen with the potentiation of IL -la  
induced COX-2 protein by wortmannin at lOOnM (Figure 6.2B) but an effect on 
PGE2 could not be assessed as IL -la  does not induce significant measurable PGE2 
production.
The up-regulation of cytokine induced COX-2 in HT-29 cells by wortmannin was 
seen at the level of COX-2 mRNA, as well as the downstream points of protein and 
product synthesis. In view of this, the effect of wortmannin on the stability of COX- 
2 mRNA was investigated to see whether this was the primary point of regulation. 
To assess this an Actinomycin D chase experiment was performed. HT-29 cells, in
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the presence or absence of wortmannin pre-treatment (lOOnM for 15 minutes), were 
stimulated for two hours with either TNFa or IL-la. At two hours Actinomycin D 
was added to give a concentration (5pg/ml) shown to inhibit all new mRNA 
synthesis in the system (Figure 5.2). mRNA was isolated at this point and at one 
hour and two hours thereafter and analysed for COX-2 mRNA by northern blot 
analysis. The decay of signal seen on northern blot analysis allows the calculation of 
a half life for COX-2 mRNA. This was also compared to TNFa or IL -la  
stimulation alone where the cytokine containing media was washed off at two hours 
and replaced with Actinomycin D containing media. This was to check whether 
COX-2 mRNA stability was altered by the cytokines themselves, an effect which has 
been demonstrated in other systems (Huang et ah, 2000). For both TNFa and IL -la  
stimulation, the half life of COX-2 mRNA was approximately one hour (Figure 6.3 A 
and 6.3B). This was not significantly altered by washing off the stimulating 
cytokine at two hours implying that neither TNFa nor IL -la  alters COX-2 mRNA 
stability in HT-29 cells. However the presence of wortmannin caused a significant 
prolongation of COX-2 mRNA stability, induced by either TNFa (p<0.05) or IL- 
l a  (p<0.01)(Figure 6.3A and 6.3B). This would explain the increased COX-2 
mRNA seen in the presence of wortmannin and may contribute to the “downstream” 
increase in COX-2 product and PGE2 product.
6.2.1.2 HT-29 cells and LY294002
Having demonstrated in HT-29 cells that PI 3-Kinase inhibition with wortmannin 
caused a stabilisation of COX-2 mRNA and increased COX-2 protein and PGE2 
product, the effect of a structurally distinct PI 3-Kinase inhibitor, LY294002, was
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investigated. Pre-treatment of HT-29 cells with LY294002 for 30 minutes prior to 
the addition of TNFa resulted in potentiation of induced COX-2 mRNA at 
concentrations <1 pM (Figure 6.4A). Above this concentration there was inhibition 
of COX-2 mRNA with LY294002 alone (1 and 3pM) having no effect on COX-2 
mRNA (Figure 6.4A and 6.4B). To investigate this biphasic concentration response 
further, the effect of LY294002 on COX-2 protein was assessed. Western blot 
analysis showed a similar biphasic concentration response to LY294002 but there 
was no overall potentiation of COX-2 protein as was seen with COX-2 mRNA 
(Figure 6.4C). Indeed, LY294002 caused a partial inhibition of TNFa induced 
COX-2 protein at low (0.3pM) and high (lOpM) concentrations. However, the 
inhibition of COX-2 protein seen at the highest concentration of lOpM was more 
complete than that observed with COX-2 mRNA. To pursue these findings the 
action of LY294002 on the COX-2 product PGE2 was next quantified. This revealed 
a more linear significant concentration dependent inhibition of TNFa induced PGE2, 
in direct conflict with the results seen with wortmannin (Figure 6.4D).
To see whether the observed the biphasic concentration response of TNFa induced 
COX-2 mRNA to LY294002 was dependent on the stimulating cytokine, the 
experiments were repeated with IL -la  as the inducing agent. This supported the 
findings with TNFa induction, showing potentiation of induced COX-2 mRNA by 
LY294002 at concentrations of <3pM with a peak at 0.3pM (Figure 6.5). There was 
similar inhibition of COX-2 mRNA at high inhibitor concentrations.
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6.2.1.3 Caco-2 cells and PI 3-Kinase inhibitors
In order to support the potentially conflicting findings seen using two independent PI 
3-Kinase inhibitors in HT-29 cells, similar experiments were carried out to 
investigate the actions of these inhibitors on the distinct intestinal epithelial cell line, 
Caco-2. Using IL -la  to induce COX-2 mRNA in these cells, the effect of both 
wortmannin and LY294002 pre-treatment was assessed. Wortmannin pre-treatment 
caused a concentration dependent up-regulation of induced COX-2 mRNA in a 
manner supporting the results seen in HT-29 cells (Figure 6.6A). For LY294002 a 
similar biphasic concentration response is seen on induced COX-2 mRNA in Caco-2 
cells as was seen in HT-29 cells, although the regulatory changes are less marked 
(Figure 6.6B). There is minor potentiation of the COX-2 mRNA signal at 0.3 pM 
and minor inhibition at the highest concentration used in this context, 3pM.
6.2.2 Activation of Phosphatidvlinositol 3-Kinase by Thl cytokines
To investigate whether Thl cytokines can activate PI 3-Kinase in intestinal epithelial 
cells two independent sets of experiments were carried out. The first assessed the 
accumulation of PI 3-Kinase products, namely D-3 phosphoinositide lipids as 
measured by High Performance Liquid Chromatography (HPLC). Although any of 
the D-3 phosphoinositide lipids can be used as a marker for PI 3-Kinase activity, 
PtdIns(3,4)/>2 was chosen for use in this work as it was a major product which could 
be clearly and consistently identified allowing easy quantitative measurement 
(Figure 6.7). The second assessed PKB, a downstream effector of PI 3-Kinase, using 
its phosphorylation at Ser473 as a marker of it activation
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6.2.2.1 TNFa induces the accumulation of D-3 phosphoinositide lipids
HT-29 cells were labelled with [32P] and stimulated with TNFa (lOOng/ml for 30 
seconds) with or without wortmannin pre-treatment (lOOnm for 15 minutes in the 
dark). PI 3-Kinase activation was determined by measuring the accumulation of its 
products, the D-3 phosphoinositide lipids, by HPLC as seen on representative 
chromatograms (Figure 6.7). The HT-29 intestinal epithelial cell line is known to 
have some constitutive PI 3-Kinase activity which was reflected in a baseline amount 
of GroPtdIns(3,4)7*2 production in the blank control (Wright et al., 1997)(Figure
6.8). Stimulation with TNFa resulted in a significant (p<0.02) increase of 
GroPtdIns(3,4)7*2 above basal levels, and this was inhibited by wortmannin (Figure
6 .8).
6.2.2.2 Activation of PKB by Thl cytokines
To support the observed activation of PI 3-Kinase by TNFa in HT-29 cells, the 
activation of a downstream effector of PI 3-Kinase, PKB, was assessed. This was 
done by western blot analysis using a specific antibody against the phospho-Ser473 
within the PKB activation loop, which is only phosphorylated in activated PKB. 
HT-29 cells were treated in the presence or absence of wortmannin over a short time 
course (0-30 minutes). Protein was isolated, immunoprecipitated and probed for 
PKB Ser473 phosphorylation as described in Methods. The same blot was stripped 
and reprobed for pan PKB to demonstrate equal loading (Figure 6.9A). As would be 
expected there was some constitutive PKB activation in the control lane which was 
inhibited by the PI 3-Kinase inhibitor wortmannin. TNFa caused a time dependent
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activation of PKB, peaking at 10 minutes, and this could be inhibited by 
wortmannin.
It was then assessed whether IL -la  could activate PKB in a PI 3-Kinase dependent 
manner. This has been reported in the literature in non-gastrointestinal systems but 
without the frequency of that seen with TNFa (Reddy et al., 1997; Reddy et al., 
1998). IL -la  similarly activated PKB, although in a delayed manner with a peak at 
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Figure 6.1: Up-regulation o f TNFa induced COX2 expression by wortmannin.
A and B. Northern analyses of mRNA isolated from HT-29 cells, which have been 
pre-treated with wortmannin (O-lOOnM) alone (B) or stimulated with TNFa 
(lOOng/ml) for two hours (A) and probed for COX2 (upper panels). The membranes 
were stripped and reprobed for p-Actin to demonstrate loading (lower panels). C. 
Western analysis of protein isolated from HT-29 cells, stimulated for six hours with 
TNFa (lOOng/ml) having been pre-treated with wortmannin (O-lOOnM), and probed 
with a specific anti-COX2 antibody (upper panel). The membrane was stripped and 
reprobed with a specific anti-COXl antibody (lower panel). D. An ELISA for PGE2 
(pg/ml) using supernatants from HT-29 cells stimulated with TNFa (lOOng/ml) for 24 
hours having been pre-treated with wortmannin (O-lOOnM). Significant increases in 
PGE2 production by additional wortmannin pre-treatment compared to TNFa alone 
are represented by * (p<0.05) and ** (p<0.01). This is the result of one experiment 
using triplicate samples and is representative of three other experiments. Blots are 
from single experiments but are representative of at least three others.
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Figure 6.2: Up-regulation o f IL - la  induced COX2 expression by wortmannin.
A. Northern analysis of mRNA isolated from HT-29 cells, which have been 
stimulated with IL -la (lOng/ml) for two hours having been pre-treated with 
increasing concentrations of wortmannin (O-lOOnM) and probed for COX2 (upper 
panel). The membrane was stripped and reprobed for p-Actin to demonstrate 
loading (lower panel). B. Western analysis of protein isolated from HT-29 cells, 
stimulated for six hours with IL -la (lOng/ml) having again been pre-treated with 
wortmannin (lOOnM), and probed with a specific anti-COX2 antibody. Blots are 
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Figure 6.3: Stabilisation o f COX2 mRNA by wortmannin
Logarithmic line plots of [Intensity] of COX2 mRNA as measured by Northern 
analyses (arbitrary units where maximum intensity is 1) vs time in hours. HT-29 cells 
were stimulated with TNFa (A) or IL -la (B) for 2 hours in the presence or absence of 
wortmannin (lOOnM). At 2 hours the stimulating cytokine was either washed off or 
remained in the media as labelled and Actinomycin D (5pg/ml) was added to prevent 
new RNA synthesis. The subsequent decay in the mRNA signal was plotted to allow 
calculation of the half life - time at which Intensity is 0.5. The blots shown are 
representative of two experiments. The membranes were photographed to show the 
18S and 28S bands to ensure equal loading (not shown for clarity). * and ** represent 
significant (p<0.05 and p<0.01 respectively) prolongation of COX2 mRNA half life 
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Figure 6.4: Regulation o f TNFa induced COX2 expression by L Y294002.
A and B. Northern analyses of mRNA isolated from HT-29 cells, which have been pre­
treated with LY294002 (0-1 OpM) alone (B) or stimulated with TNFa (lOOng/ml) for two 
hours (A) and probed for C0X2 (upper panels). The membranes were stripped and 
reprobed for p-Actin to demonstrate loading (lower panels). C. Western analysis of 
protein isolated from HT-29 cells, stimulated for six hours with TNFa (lOOng/ml) 
having been pre-treated with LY294002 (0-1 OpM), and probed with a specific anti- 
C0X2 antibody (upper panel). D. An ELISA for PGE2 (pg/ml) using supernatants from 
HT-29 cells stimulated with TNFa (lOOng/ml) for 48 hours having been pre-treated with 
LY294002 (0-1 OpM). * and ** represent significant (p<0.05 and p<0.01 respectively) 
inhibition of PGE2 production by LY294002. This is the result of one experiment using 
triplicate samples and is representative of three other experiments. Blots are from single 
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Figure 6.5: Regulation o f IL-1 a  induced COX2 expression by LY294002.
Northern analysis of mRNA isolated from HT-29 cells, which have been 
stimulated with IL -la (lOng/ml) for two hours having been pre-treated with 
increasing concentrations of LY294002 (0-1 OpM) and probed for COX2 
(upper panel). The membrane was stripped and reprobed for p-Actin to 
demonstrate loading (lower panel). Blots are from single experiments but are 













Figure 6.6: Regulation o f IL-1 a  induced COX2 expression by PI 3-Kinase Inhibitors.
A and B. Northern analyses of mRNA isolated from Caco-2 cells, which have been 
stimulated with IL-la (lOng/ml) for two hours having been pre-treated with increasing 
concentrations of wortmannin (O-lOOnM) (A) or LY294002 (0-10pM) (B) and probed 
for COX2 (upper panels). The membranes were stripped and reprobed for p-Actin to 
demonstrate loading (lower panels). Blots were from single experiments but are 
































Figure 6.7: Activation o f PI 3-Kinase by TNFa.
A representative chromatogram trace, prior to analysis, showing the accumulation 
of the deacylated [32P] labelled PI 3-Kinase product, GroPtdIns(3,4)P2, as isolated 
by HPLC (cpm). [32P] labelled HT-29 cells were stimulated with TNFa 
(lOOng/ml) for 30 seconds. Ptdlns lipids were then extracted and deacylated prior 
to HPLC separation. The control represents unstimulated cells. See Results Figure 
6 . 8  for analysed results
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Figure 6.8: Activation o f PI 3-Kinase by TNFa.
Bar chart representing the accumulation of the [32P] labelled PI 3-Kinase 
product, GroPtdIns(3,4)P2, as isolated and quantified by HPLC (cpm). [32P] 
labelled HT-29 cells were stimulated with TNFa (lOOng/ml) for 30 seconds in 
the presence or absence of pre-treatment for 15 mins in the dark with the PI 3- 
Kinase inhibitor wortmannin (lOOnM). The controls represent unstimulated 
cells and cells treated with wortmannin alone. ** represents significant 


























Figure 6.9: Activation o f PKB by Thl cytokines.
A and B. Western analyses of protein isolated from HT-29 cells, stimulated 
over a short time course (0-30 mins) with TNFa (lOOng/ml) (A) or IL -la 
(lOng/ml) (B) in the presence or absence of wortmannin (lOOnM). Lysates were 
immunoprecipitated with specific goat anti-PKB antibody and then probed with 
a specific anti-phospho473 PKB antibody (upper panels). Membranes were 
stripped and reprobed for rabbit anti-PKB to demonstrate equal loading. Blots 
are from single experiments but are representative of two others.
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6.3 Results Summary
• The PI 3-Kinase inhibitor wortmannin caused a concentration dependent up- 
regulation of induced COX-2. This was seen at the mRNA level in both HT-29 
and Caco-2 cells, and at the level of COX-2 protein and PGE2 product in HT-29 
cells.
• It appears that wortmannin mediated this up-regulation of COX-2 mRNA, 
protein and product by stabilising the COX-2 mRNA and thereby significantly 
prolonging its half life.
• An alternative inhibitor of PI 3-Kinase, LY294002, also caused an up-regulation 
of induced COX-2 mRNA at low concentrations. However at higher 
concentrations LY294002 caused an inhibition of COX-2 mRNA.
• LY294002 did not potentiate induced COX-2 protein, indeed inhibiting COX-2 
protein induction at low and high concentrations.
• LY294002 caused a significant concentration dependent inhibition of induced 
PGE2 production.
• TNFa activated PI 3-Kinase in HT-29 cells as demonstrated by an accumulation 
of D-3 phosphoinositide lipids, and induction of phosphorylation and presumed 
activation of its downstream effector PKB. This activation of PI 3-Kinase was 
inhibited by wortmannin.
• IL-1 a  also caused the phosphorylation and presumed activation of the 
downstream effector of PI 3-Kinase, PKB in a wortmannin sensitive manner.
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6.4 Discussion
The work presented here uses pharmacological inhibitors of PI 3-Kinase to provide 
evidence for a regulatory role for this signalling cascade on induced intestinal 
epithelial COX-2 expression. Such a role has already been demonstrated in this 
system with iNOS expression and activity as well as chemokine expression (Wright 
et al., 1997; Kolios et al., 1999). Indeed, in those contexts, PI 3-Kinase mediates the 
inhibitory effects of Th2 cytokines, such as IL-4 and IL-13, which were shown in 
chapter 5 to phosphorylate and presumably activate the downstream effector of PI 3- 
Kinase, PKB (Wright et al., 1997). However the use of two pharmacological 
inhibitors of PI 3-Kinase, especially when they reveal at times contrasting and 
complex effects, necessitates further discussion.
Wortmannin is a PI 3-Kinase inhibitor derived from a metabolite of the fungus 
Penicillium funiculosum Thom (Wiesinger et al., 1974; Park et al., 1997). It 
covalently attaches to the pi 10 catalytic subunit and causes irreversible inhibition 
with a Kj of 1-1 OnM and a similar I C 5 0 .  In this work it caused a concentration 
dependent up-regulation of TNFa or IL -la  induced COX-2 mRNA in both HT-29 
and Caco-2 cells, as well as of protein and PGE2 production in HT-29 cells, at 
concentrations correlating well with its Kj.
This work also provides some evidence as to the mechanism of action of
wortmannin. As its effects are seen at the point of mRNA assessment, it implies that
it mediates its actions either by increasing transcription or increasing the stability of
the induced COX-2 mRNA. The Actinomycin D chase experiments show that
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incubation with wortmannin causes a significant stabilisation of COX-2 mRNA 
which would result in the marked increase seen on northern analysis. It is interesting 
to note that the continued presence or absence (by washing) of the stimulating 
cytokine does not alter COX-2 mRNA stability, as has been reported in other 
systems (Huang et al., 2000). If PI 3-Kinase inhibition stabilises COX-2 mRNA, it 
implies that PI 3-Kinase pathways either act actively to destabilise COX-2 mRNA, 
or conversely prevent its stabilisation which is an important part of increasing COX- 
2 expression (Huang et al., 2000). However, in this emerging area, the precise 
mechanisms for the effects of the PI 3-Kinase signalling cascade remain speculative. 
Taken overall, these results with wortmannin would strongly point to a negative 
regulatory role for PI 3-Kinase on induced intestinal epithelial COX-2 expression 
seen across two in vitro models. The evidence using a second pharmacological 
inhibitor of PI 3-Kinase is not completely supportive of this hypothesis.
LY294002 is a structurally distinct, competitive inhibitor for the adenosine 
triphosphate binding site of PI 3-Kinase and has been shown to cause specific 
inhibition with a Kt of 1.6pM and an IC5o of 1.4pM (Vlahos et al., 1994). At 
concentrations of 1 pM or less, LY294002 also had an up-regulatory effect on COX- 
2 mRNA expression in both HT-29 and Caco-2 cells. However at higher 
concentrations LY294002 inhibited TNFa and IL -la  induced COX-2 mRNA. 
Furthermore, it did not potentiate induced COX-2 protein in HT-29 cells, although it 
maintained a biphasic dose response curve with inhibition of induced COX-2 protein 
at low (0.3 pM) and high (lOpM) concentrations. Finally, LY294002 caused a 
significant concentration dependent inhibition of induced PGE2 production in HT-29
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cells in contrast to the action of wortmannin. There are a number of possible 
explanations of this difference between the two inhibitors.
Firstly, when regarding the actions of LY294002 on induced COX-2 mRNA in both 
HT-29 and Caco-2 cells, it can be seen that the initial potentiation occurred at 
concentrations consistent with the Kj and IC50. The inhibition of induced COX-2 
mRNA seen at higher concentrations may be due to non-specific actions of 
LY294002 at concentrations above those needed to inhibit PI 3-Kinase. Against 
this, however, are the results seen at the level of COX-2 protein and PGE2 
production.
A second possible explanation of the different response profiles for the two 
inhibitors may be as a result of disparate effects on different classes of the PI 3- 
Kinase family of enzymes. For example, wortmannin is a poor inhibitor of Class II 
PI 3-Kinases (Domin et al., 1997). Such effects of specific classes may well be 
important in HT-29 cells where differential class effects of PI 3-Kinase enzymes are 
involved in controlling macroautophagy (Petiot et al., 2000) and this may also 
explain why wortmannin only partially inhibits the TNFa induction of PI 3-Kinase 
(Figure 6.8).
Thirdly, wortmannin and LY294002 may not be as specific at inhibiting PI 3-Kinase 
as they claim. Although there are reports demonstrating the specificity of their 
actions (Wiesinger et al., 1974; Vlahos et al., 1994; Davies et al., 2000), there are 
isolated reports suggesting other actions of these pharmacological compounds. 
Wortmannin has been reported as inhibiting phospholipase A2 (Cross et al., 1995),
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although if this resulted in less arachidonic acid as substrate for COX-2 one might 
expect inhibition of PGE2 production rather than potentiation. Reports that 
wortmannin can inhibit PI 4-Kinase (Nakanishi et al., 1995) are more difficult to 
interpret, as is the finding that LY294002 can inhibit casein kinase (Davies et al., 
2000).
Finally, although disparity between results obtained using wortmannin and 
LY294002 are rare, there is a precedent (Salh et al., 1998). This group were 
studying PI 3-Kinase and iNOS activation in a macrophage cell line and showed that 
activation of PI 3-Kinase by LPS was sensitive to both wortmannin and LY294002. 
However, nitric oxide generation was sensitive only to LY294002 and not to 
wortmannin. They proposed an FKBP12-rapamycin-associated protein (FRAP) 
dependent pathway which was more sensitive to LY294002 than to wortmannin. 
Supporting their proposition is evidence from a second group demonstrating that 
both wortmannin and LY294002 can inhibit FRAP at higher concentrations than 
those necessary to inhibit PI 3-Kinase (Brunn et al., 1996).
To summarise the use of these pharmacological inhibitors of PI 3-Kinase, one must 
be aware of the potential pitfalls regarding the interpretation of the results. There are 
other methods of inhibiting PI 3-Kinase such as molecular methods like micro­
injection of antibodies or transferring dominant negative forms of PI 3-Kinase into 
cells (Benistant et al., 2000; Sasaki et al., 2000; Stein and Waterfield, 2000; Weaver 
and Ward, 2001). Similar transfer methods can be used to manipulate PI 3-Kinase 
by causing its over-expression, and these may be placed under the control of an 
environmental agent such as an antibiotic in the culture media (Craddock et al.,
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1999). Evidence should be gathered from different models using different 
mechanisms of manipulating PI 3-Kinase and from the resulting evidence a 
consensus should be drawn.
With the knowledge that Th2 cytokines activate PI 3-Kinase and inhibit COX-2 
(chapter 5), supported by the consistent results with wortmannin, there is evidence 
supporting the hypothesis that PI 3-Kinase activity inhibits COX-2 expression in 
intestinal epithelial cells. Indeed, one interpretation of the results presented here is 
that basal PI 3-Kinase activity known to be present in HT-29 cells may be regulating 
COX-2 expression. Against this, however, is the fact that neither PI 3-Kinase 
inhibitor used here had any effect on COX-2 mRNA or protein expression or on 
PGE2 production when used in the absence of cytokine stimulation. The results with 
LY294002 do bring an inhibitory role of PI 3-Kinase on COX-2 in to question. So 
too does work by Shao et al using tranfer of constitutively active or dominantly 
negative forms of PKB, the downstream effector of PI 3-Kinase, into HCA-7 and 
LS-174 human intestinal epithelial cells (Shao et al., 2000). This work can be 
summarised as indicating a role for PKB in stabilising a COX-2 3'-UTR construct. 
This is at odds with the results presented here, but used a different method of 
inhibiting PI 3-Kinase as well as looking at a marker of COX-2 mRNA stability 
rather than its actual stability as used here.
The possibility that PI 3-Kinase, a signalling cascade with a known pro-proliferative 
action, could be inhibiting COX-2, which is also known to promote carcinogenesis, 
is surprising. However, PI 3-Kinases are a complex family of enzymes which may
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have conflicting actions. Also, more evidence is needed to confirm the exact inter­
relationship between PI 3-Kinases and COX-2 expression.
One aspect of conformity involving the use of these inhibitors should be commented 
on. There have been reports in epithelial cells that the TNFa induced activation of 
NFkB, known to be crucial to COX-2 expression, is dependent on PI 3-Kinase 
activation (Ozes et al., 1999; Reddy et al., 2000). Work by collaborating colleagues 
in University of North Carolina -  Chapel Hill demonstrated that the activation of 
NFkB by TNFa or IL-1 was not affected by incubation with either of the inhibitors 
of PI 3-Kinase (Appendix A) (Weaver et al., 2001). This implies that any effect seen 
using either PI 3-Kinase inhibitor does not appear to be mediated via alteration of 
NFkB activation. It also implies that activation of NFkB is not PI 3-Kinase 
dependent in this system, something which has been shown in endothelial cells 
(Madge and Pober, 2000). Other investigators have shown that PI 3-Kinase 
inhibition does alter NFkB activity in this system, but over a much longer time 
period and with a much higher inhibitor concentration (Wang et al., 2000).
The next subject addressed in this chapter was whether Thl cytokines could activate 
PI 3-Kinase directly. This follows on from the work mentioned above concerning 
TNFa activation of NFkB being PI 3-Kinase dependent in some systems. Recent 
research has shown that TNFa can activate PI 3-Kinase in HeLa cells (Pastorino et 
al., 1999), rat fibroblasts (Hanna et al., 1999), cervical epithelial cells (Ozes et al., 
1999) and embryonic kidney cells (Ozes et al., 1999), although the biological 
implications of this are uncertain. We have also shown that TNFa does activate PI 
3-Kinase directly, beyond the constitutive activity that these cells are known to
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demonstrate, as well as inducing the phosphorylation and presumed activation of the 
downstream effector of PI 3-Kinase, PKB. Furthermore, the other Thl cytokine 
shown to induce COX-2 in HT-29 cells, IL-la, also induces the phosphorylation of 
PKB implying activation of PI 3-Kinase as has been seen in other systems 
(Donaldson et al., 1996; Reddy et a l., 1997; Madge and Pober, 2000).
In intestinal epithelial cells TNFa is now known to activate pro-apoptotic pathways 
and the NFkB signaling pathway as well as the pro-proliferative PI 3-Kinase as 
demonstrated here (Papadakis and Targan, 2000). Making sense of these conflicting 
intracellular signals highlights the multiple controls of cellular responses with the 






Figure 7A: Schematic representation o f the possible involvement o f PI 3-Kinase 
in the regulation o f cytokine induced COX-2
If PI 3-Kinase does inhibit COX-2 expression and mediate the inhibitory action of 
Th2 cytokines, as much of the evidence presented here supports, then the TNFa 
activation of PI 3-Kinase will act as a negative autoregulatory pathway on the TNFa
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activation of NFkB dependent COX-2 expression. Such autoregulatory feedback 
loops are likely to be repeated many times in the cell with the apparent redundancy 
of mechanisms allowing better controlled and smoother cellular responses (see 
Figure 7A).
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7 Mitogen Activated Protein Kinases -  their activation.
interactions and role in COX-2 expression
7.1 Introduction
The Mitogen Activated Protein Kinases (MAP Kinases) represent a family of 
signalling pathways which are important in the propagation of inflammation and 
developmental regulation (Tibbies and Woodgett, 1999). In some systems they are 
known to regulate COX-2 transcription and mRNA stability (Dean et al., 1999), and 
are also known to mediate the regulatory effects of cytokines on COX-2 expression 
(Niiro et al., 1998). Indeed, there is increasing evidence that they are involved in 
“cross-talk” with other signalling pathways known to be important in COX-2 
regulation, namely NFkB and PI 3-Kinase (Yamaki et al., 2000). Therefore, this 
work aimed to address whether MAP Kinases were activated by the pro- 
inflammatory cytokines TNFa and IL -la  which have already been shown to induce 
COX-2, activate PI 3-Kinase and known to activate NFkB. Secondly, specific 
inhibitors of MAP Kinases were used to investigate whether MAP Kinases had a 
regulatory role for COX-2 in this gastrointestinal system. Thirdly, the issue of MAP 
Kinase activation being mediated by PI 3-Kinases was addressed. Finally, the 
inactivation by phosphorylation of a downstream substrate of PKB, Glycogen 
Synthase Kinase 3a/p, was assessed to determine the relative contributions of PI 3- 
Kinase and ERK1/2 and possible synergistic action of these two signalling pathways.
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7.2 Results
7.2.1 MAP Kinase activation
7.2.1.1 TNFa and MAP Kinase activation
To investigate activation of MAP Kinases in intestinal epithelial cells TNFa was 
first assessed since it is known to activate NFkB and PI 3-Kinase in HT-29 cells. 
Confluent monolayers of HT-29 cells were stimulated over a short time course of up 
to thirty minutes with TNFa at lOOng/ml and then protein was isolated for western 
blot analysis. Whole cell lysates were run on western blots and probed with specific 
rabbit antibodies against the phosphorylated (activated) MAP Kinases -  phospho180, 
182 p38, phospho183, 185 JNK or phospho202, 204 ERK1/2. Membranes were then 
stripped and reprobed for the respective un-phosphorylated isoforms (Figure 7.1). 
TNFa was shown to activate p38 and JNK transiently, whilst ERK activation was 
more sustained. All three MAP Kinases were optimally phosphorylated at 10 
minutes.
7.2.1.2 IL -la  and MAP Kinase activation
Having demonstrated that TNFa activates p38, JNK and ERK1/2 MAP Kinases in 
HT-29 intestinal epithelial cells, activation by IL -la  was next investigated. Using 
similar experimental protocols, HT-29 cells were stimulated with IL -la  (lOng/ml) 
over a short time course up to 30 minutes. Protein was isolated for western blot
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analysis as previously, probing for the activated forms of p38, JNK and ERK1/2 
showed IL -la  also activated these MAP Kinases (Figure 7.2). This was 
qualitatively different from MAP Kinase activation by TNFa as the activation was 
still increasing at 30 minutes rather than peaking at 10 minutes. Stripping and 
reprobing the membranes, with the respective un-phosphorylated isoforms, 
demonstrated equal loading (Figure 7.2).
7.2.1.3 ERK1/2 and p38 activation in the presence of their specific inhibitors
Understanding of the role of MAP Kinases in cell physiology has been improved by 
the growing use of specific inhibitors. A variety of specific inhibitors exist for the 
ERK1/2 and the p38 pathways although not for the JNK pathway. It was planned to 
use inhibitors of ERK1/2 and p38, PD98059 and SB203580 respectively, to 
investigate the role of these signalling components in COX-2 expression. Prior to 
doing this, these compounds were first used to determine their effect on activation of 
their respective MAP Kinase pathways.
Firstly, the effect of PD98059 on ERK1/2 was determined since PD98059 is known 
to inhibit the upstream kinases, MEK1/2, which control ERK1/2 phosphorylation. 
HT-29 cells were stimulated with TNFa over a short time course of 30 minutes, in 
the presence or absence of pre-treatment with PD98059 at 10pM for one hour. 
Protein was isolated and analysed by western blot analysis with a specific antibody 
against the active form of ERK1/2 (Figure 7.3). The presence of PD98059 caused a 
significant but not complete abrogation in ERK1/2 phosphorylation when compared
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to TNFa alone. Stripping and reprobing the membranes, with the respective un- 
phosphorylated isoforms, demonstrated equal loading (Figure 7.3).
The situation with the selected p38 inhibitor, SB203580, proved to be more complex. 
This is a reversible inhibitor of the ATP binding site of p38 with conflicting 
evidence regarding its action on activation of p38 by phosphorylation (Young et al., 
1997). HT-29 cells were stimulated over a short time course of 30 minutes with 
TNFa in the presence or absence of pre-treatment with SB203580 at lOpM for one 
hour. Protein was isolated and analysed by western blot analysis with a specific 
antibody against the active form of p38 (Figure 7.4A). The presence of SB203580 
had little effect on phosphorylation status, and by inference activation, of p38 when 
compared to TNFa alone. Stripping and reprobing the membranes, with the 
respective un-phosphorylated isoforms, demonstrated equal loading (Figure 7.4A).
In view of the fact that there is evidence that SB203580 effectively binding the ATP 
site may not alter the phosphorylation of p38, an in vitro kinase assay for p38 
activity was next performed. HT-29 cells were stimulated as previously with TNFa 
in the presence or absence of pre-treatment with SB203580. Protein was isolated 
and the p38 kinase assay was performed as described in methods. The functional 
readout of this assay was p38 dependent in vitro phosphorylation of a known p38 
substrate, namely the transcription factor ATF-2 (Figure 7.4B). It can be seen that 
the presence of SB203580 did not alter the TNFa stimulated p38 activity, as 
assessed by ATF-2 phosphorylation. TNFa stimulated p38 activity peaked at 20 
minutes, approximately 10 minutes after peak p38 phosphorylation seen in the
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associated blot of whole cell lysate. Stripping and reprobing for unphosphorylated 
p38 demonstrated equal loading.
This lack of inhibition of p38 activity by SB203580 may be due to the reversible 
nature of the inhibitor and it being washed off in the immunoprecipitation steps of 
the kinase assay. In this case it should be possible to reintroduce SB203580 after the 
washing steps and see an inhibition of p38 activity. Such data has been discussed 
but not shown in the literature (Young et al., 1997). However, an attempt to 
reintroduce SB203580 to the kinase assay for 15 minutes after the washing steps 
failed to demonstrate significant inhibition of p38 kinase activity (Figure 7.4C).
7.2.2 MAP Kinase inhibition and COX-2 expression
7.2.2.1 PD98059 and COX-2 expression
Having demonstrated that the specific MEK1/2 inhibitor does inhibit activation of 
ERK1/2, this compound was then used to assess whether ERK1/2 activation had a 
role in the induction of COX-2 expression. HT-29 cells were stimulated with TNFa 
in the presence or absence of PD98059 (0-3OpM) for 2 hours and then RNA was 
isolated and probed for COX-2 mRNA by Northern blot analysis (Figure 7.5A). 
Surprisingly, PD98059 caused an increase in stimulated COX-2 mRNA production 
at concentrations of 10 and 30pM.
In light of the knowledge that there can be opposing regulatory effects at different 
points in the RNA to protein to product pathway, as seen with IFNy (chapter 5), the
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effect of ERK1/2 inhibition was investigated at the level of COX-2 protein and 
product expression. Protein isolated from HT-29 cells pre-treated with PD98059 and 
then stimulated with TNFa for six hours, showed that COX-2 protein is partially 
inhibited at higher concentrations (lOpM) of this inhibitor (Figure 7.5B). When 
looking at cells stimulated for 72 hours, and where supernatants were collected for 
PGE2 assay, PD98059 caused a significant concentration dependent inhibition of 
PGE2 generation with an IC50 of approximately 1.5pM (Figure 7.5C). This is a far 
lower concentration than those causing the effects on COX-2 mRNA and protein.
1.22.2 SB203580 and COX-2 expression
Having shown that ERK1/2 appear to play a part in inducing COX-2 expression in 
HT-29 cells, a similar range of experiments were planned using the p38 inhibitor 
SB203580. As seen previously, this compound did not inhibit p38 phosphorylation 
or indeed activity in the context of an in vitro p38 kinase assay. However, there 
were possible molecular and methodological reasons for this and the action of this 
compound, which is widely used as a p38 inhibitor in the literature, was explored on 
COX-2 mRNA and protein expression as well as PGE2 production.
HT-29 cells were stimulated as previously with TNFa for two hours, in the presence 
or absence of one hour pre-treatment with SB203580 at 0-3OpM, with COX-2 
mRNA expression being assessed by Northern blot analysis (Figure 7.6A). p38 
inhibition caused a slight decrease of COX-2 mRNA expression at high 
concentrations (10 and 30pM). A similar effect of p38 inhibition was seen at 
slightly lower concentrations on COX-2 protein induced by TNFa stimulation for six
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hours (Figure 7.6B). At 3 and 10pM there was slight inhibition of COX-2 protein 
induction. Finally, SB203580 was seen to have a similar significant inhibitory 
action to PD98059 on TNFa induced PGE2 production, at similar concentrations 
(IC50 approximately 1.5pM).
1,2.23 Combined p38 and ERK1/2 inhibition on COX-2 expression
The demonstration of both p38 and ERK1/2 inhibition individually causing a 
concentration dependent inhibition to COX-2 functional activity raised speculation 
that there may be a greater effect if used in combination as has been shown in other 
systems (LaPointe and Isenovic, 1999; Rutault et al., 2001). This was explored in 
HT-29 intestinal epithelial cells at the level of TNFa induced COX-2 protein 
expression and PGE2 production. As is seen in Figure 7.7A, combined pre-treatment 
with both inhibitors at 3pM did not cause a greater inhibition of COX-2 protein at 
six hours as seen by western blot, with there being no alteration of the constitutive 
isoform of COX, COX-1. Similarly, TNFa induced PGE2 production by HT-29 
cells at 72 hours was inhibited by both compounds as previously described, but there 
was no additive effect of the inhibitors used in combination (Figure 7.7B).
7.2.3 MAP Kinase activation in the presence of PI 3-Kinase inhibition
7.2.3.1 MAP Kinase activation in the presence of wortmannin
It has been previously shown in chapter 6 that the PI 3-Kinase inhibitor wortmannin 
caused a concentration dependent up-regulation of induced COX-2 mRNA and
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protein expression as well as PGE2 production. In combination with the findings 
regarding the role of p38 and ERK1/2 in COX-2 expression, this led to the 
possibility that wortmannin may be exerting its effects by promoting MAP Kinase 
activation. In contrast, published literature reports that the activation of MAP 
Kinases may be PI 3-Kinase dependent, although this has not been shown in a 
gastro-intestinal system (Yamaki et al., 2000; Jiang et al., 2000; Yamboliev et al., 
2000).
The previously described activation of p38, ERK1/2 and JNK by TNFa was 
therefore assessed in the presence or absence of wortmannin pre-treatment at lOOnM 
for 15 minutes. Figure 7.8 shows this comparison with it being seen that the addition 
of wortmannin pre-treatment does not alter TNFa induced phosphorylation of p38, 
ERK1/2 or JNK.
7.2.3.2 Cytokine induced GSK-3a/p inactivation
Glycogen Synthase Kinase-3a/p (GSK-3a/p) is an example of an enzyme which is 
known to be phosphorylated by PI 3-Kinase dependent mechanisms (Cross et al., 
1995; Stein and Waterfield, 2000). GSK-3a/p is a constitutively active enzyme that 
is inactivated by phosphorylation. HT-29 cells were incubated with TNFa or IL -la 
over a 30 minute time course, protein was isolated for western blot analysis and the 
membranes were probed for GSK-3a/p. Figure 7.9 shows that IL -la  and TNFa can 
both induce the phosphorylation and therefore presumably inactivation of GSK- 
3 a/p in a time dependent fashion. IL-13 stimulation for 10 minutes, as a known 
activator of PI 3-Kinase, is shown as a known positive control, which is abrogated
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by wortmannin pre-treatment (lOOnM for 15 minutes). As with MAP Kinases, IL- 
l a  induced phosphorylation occurs later than that seen with TNFa, which peaks at 
10 minutes.
HT-29 cells were then stimulated with TNFa over a 30 minute time course, having 
been pre-treated with wortmannin at lOOnM for one hour, and the subsequently 
generated western membranes were probed for phospho-GSK-3a/p. Wortmannin is 
shown to partially abrogate the TNFa induced phosphorylation of GSK-3a/p (Figure 
7.10A) as would be expected given the documented involvement of PI 3-Kinase in 
this pathway. However, as the effect of wortmannin was only partial abrogation, it 
was combined with the MEK1/2 inhibitor of the ERK1/2 pathway, PD98059. With 
this combination of wortmannin (lOOnM) and PD98059 (lOpM), there is complete 
inhibition of the TNFa induced phosphorylation of GSK-3a/p (Figure 7.1 OB). 
PD98059 alone, like wortmannin, had a partial effect. This clearly demonstrates that 
the reagents used were active, and that there is a role for activation of both ERK1/2 






















Figure 7.1: Activation o f MAP Kinases by TNFa in HT-29 cells.
A to C. Western analyses of protein isolated from HT-29 cells stimulated with 
TNFa (lOOng/ml) over a 30 minute time course and then probed with specific 
antibodies against: phospho180’ 182 p38 (A), phospho183’ 185 JNK (B) or phospho202’ 204 
ERK1/2 (C) (upper panels). Membranes were then stripped and reprobed with the 
respective antibodies against the unphosphorylated protein to show equal loading 















Figure 7.2: Activation o f  MAP Kinases by IL-1 a  in HT-29 cells.
A to C. Western analyses of protein isolated from HT-29 cells stimulated 
with IL -la  (lOng/ml) over a 30 minute time course and then probed with 
specific antibodies against: phospho180’ 182 p38 (A), phospho183’ 185 JNK (B) 
or phospho202’ 204 ERK 1/2 (C) (upper panels). Membranes were then 
stripped and reprobed with the respective antibodies against the 
unphosphorylated protein to show equal loading (lower panels). Blots are 











Figure 7.3: Inhibition o f TNFa induced ERK1/2 activation by PD98059.
Western analyses of protein isolated from HT-29 cells stimulated with TNFa 
(lOOng/ml) over a 30 minute time course in the presence or absence of the specific 
MEK1/2 inhibitor PD98059 (lOpM for one hour) and then probed with a specific 
antibody against phospho202, 204 ERK 1/2 (upper panel). The membrane was then 
stripped and reprobed with the antibody against the unphosphorylated protein to 
show equal loading (lower panel). Blots are from single experiments but are 
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Figure 7.4: The action o f SB203580 on phosphorylation and in vitro kinase activity o f p38.
A. Western analyses of protein isolated from HT-29 cells stimulated with TNFa (lOOng/ml) 
over a 30 minute time course in the presence or absence of the specific p38 inhibitor 
SB203580 (lOpM for one hour) and then probed with a specific antibody against phospho180’ 
182 p38 (upper panel). The membrane was then stripped and reprobed with the antibody 
against the unphosphorylated protein to show equal loading (lower panel). B. In vitro kinase 
assay of p38 activity in HT-29 cells stimulated with TNFa (lOOng/ml) over a 30 minute time 
course in the presence or absence of SB203580 (lOpM for one hour). Activity of p38 is 
relative to amount of p38 dependent ATF-2 phosphorylation as shown by the intensity of the 
phospho71 ATF-2 band in the samples immunoprecipitated with p38 (upper panel). The 
whole cell lysates of the same samples were analysed by western blot and probed for 
phospho180’ 182 p3 8  (middle panel) or unphosphorylated p38 (lower panel). C. In vitro kinase 
assay of p38 activity in HT-29 cells stimulated with TNFa (lOOng/ml) over a 30 minute time 
course in the presence or absence of SB203580 (lOpM for one hour) and with SB203580 
being again added to the kinase assay after the washing associated with immunoprecipitation. 
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Figure 7.5: Regulation o f TNFa induced COX2 expression by PD98059.
A. Northern analyses of mRNA isolated from FIT-29 cells, which have been stimulated 
with TNFa (lOOng/ml) for two hours having been pre-treated with increasing 
concentrations of PD98059 (0-30pM for one hour) and probed for COX2 (upper panel). 
The 28S band is shown to demonstrate loading (lower panels). B. Western analysis of 
protein isolated from HT-29 cells, stimulated for six hours with TNFa (lOOng/ml) 
having been pre-treated with increasing concentrations of PD98059 (0-1 OpM), and 
probed with either a specific anti-COX2 (upper panel) or anti-COXl antibody (lower 
panel). D. An ELISA for PGE2 (pg/ml) using supernatants from HT-29 cells stimulated 
with TNFa (lOOng/ml) for 24 hours having been pre-treated with increasing 
concentrations of PD98059 (0-1 OpM). Significant inhibition of PGE2 production by 
additional PD98059 pre-treatment compared to TNFa alone are represented by * 
(p<0.05) and ** (p<0.01). This is the result of one experiment using triplicate samples 
and is representative of two other experiments. Blots are from single experiments but 
are representative of at least two others. Some of these results were obtained 
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Figure 7.6: Regulation o f TNFa induced COX2 expression by SB203580.
A. Northern analyses of mRNA isolated from HT-29 cells, which have been 
stimulated with TNFa (lOOng/ml) for two hours having been pre-treated with 
increasing concentrations of SB203580 (0-30pM for one hour) and probed for COX2 
(upper panel). The 28S band is shown to demonstrate loading (lower panels). B. 
Western analysis of protein isolated from HT-29 cells, stimulated for six hours with 
TNFa (lOOng/ml) having been pre-treated with increasing concentrations of SB203580 
(0-1 OpM), and probed with a specific anti-COX2 antibody. D. An ELISA for PGE2 
(pg/ml) using supernatants from HT-29 cells stimulated with TNFa (lOOng/ml) for 24 
hours having been pre-treated with increasing concentrations of SB203580 (0-1 OpM). 
Significant inhibition of PGE2 production by additional SB203580 pre-treatment 
compared to TNFa alone are represented by * (p<0.05) and ** (p<0.01). This is the 
result of one experiment using triplicate samples and is representative of three other 
experiments. Blots are from single experiments but are representative of at least two 
others. Some of these results were obtained supervising Miss K.M. Patel in her final 
year project.
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Figure 7.7: Regulation o f TNFa induced COX2 expression by PD98059 and SB203580 
A. Western analysis of protein isolated from HT-29 cells, stimulated for six hours with 
TNFa (lOOng/ml) having been pre-treated with increasing concentrations of PD98059 
(3pM) and SB203580 (3pM) both alone and together, and probed with a specific anti- 
COX2 antibody (upper panel) or a specific COX1 antibody (lower panel). B. An ELISA 
for PGE2 (pg/ml) using supernatants from HT-29 cells stimulated with TNFa (lOOng/ml) 
for 24 hours having been pre-treated with increasing concentrations of PD98059 (0-3 pM) 
and SB203580 (0-3 pM) both alone and together. This is the result of one experiment using 
triplicate samples and is representative of two other experiments. Blots are from single 






































Figure 7.8: Activation o f MAP Kinases by TNFa is unaltered by PI 3-Kinase inhibition.
A to C. Western analyses of protein isolated from HT-29 cells stimulated with TNFa 
(lOOng/ml) over a 30 minute time course in the presence or absence of pre-treatment with 
the PI 3-Kinase inhibitor wortmannin (lOOnM for 15 mins) and then probed with specific 
antibodies against: phospho180’ 182 p38 (A), phospho183’ 185 JNK (B) or phospho202’ 204 
ERK 1/2 (C) (upper panels). Membranes were then stripped and reprobed with the 
respective antibodies against the unphosphorylated protein to show equal loading (lower 






o  ©I © o
r r \  r r \













Figure 7.9: Activation o f GSK-3a/pby TNFa or IL -la  in HT-29 cells.
A and B. Western analyses of protein isolated from HT-29 cells stimulated with 
TNFa (lOOng/ml) (A) or IL -la  (lOng/ml) (B) over a 30 minute time course and 
then probed with a specific antibody against phospho21’ 9 GSK-3a/p (upper 
panels). Membranes were then stripped and reprobed with the respective 
antibody against the unphosphorylated protein to show equal loading (lower 
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Figure 7.10: Combined inhibition o f GSK-3a/(3by PD98059 and wortmannin
A and B. Western analyses of protein isolated from HT-29 cells stimulated with 
TNFa (lOOng/ml) over a 30 minute time course in the presence or absence of pre­
treatment with the PI 3-Kinase inhibitor wortmannin (lOOnM for 15 mins) (A), or 
the MEK1/2 inhibitor PD98059 (10pM for one hour) (B) or both combined (B), and 
then probed with a specific antibody against phospho21,9 GSK-3a/p (upper panels). 
Membranes were then stripped and reprobed with the respective antibody against 
the unphosphorylated protein to show equal loading (lower panels). Blots are from 
single experiments but are representative of at least two others.
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7.3 Results Summary
• TNFa and IL -la  induced the phosphorylation and presumed activation of the 
three MAP Kinases, p38, ERK1/2 and JNK in HT-29 cells.
• PD98059, a specific inhibitor of MEK1/2, the enzymes which activate ERK1/2, 
inhibited the induced phosphorylation of ERK 1/2.
• PD98059 also demonstrated a regulatory role for ERK1/2 on induced COX-2. 
Incubation with this inhibitor of the ERK pathway caused an up-regulation of 
induced COX-2 mRNA. In contrast, PD98059 caused an inhibition of induced 
COX-2 protein and PGE2 production.
• A specific inhibitor of p38, SB203580, does not prevent the induced 
phosphorylation of p38. Furthermore, SB203580 did not inhibit p38 activity as 
measured by an in vitro kinase assay.
• Despite its apparent lack of measured inhibition of p38, SB203580 did inhibit 
induced COX-2 mRNA, protein and PGE2 production.
• There was no evidence of combinatorial inhibition of COX-2 dependent PGE2 
product using both PD98059 and SB203580.
• Inhibition of PI 3-Kinase with wortmannin did not alter the TNFa induced 
phosphorylation of p38, ERK1/2 or JNK.
• Both TNFa and IL -la  induced the phosphorylation and presumed inactivation of 
GSK-3a/p. This could be partially abrogated by inhibition of both PI 3-Kinase 
and the ERK1/2 pathways although complete inhibition of phosphorylation was 
only possible using a combination of PI 3-Kinase and ERK 1/2 pathway 
inhibitors.
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7.4 Discussion
The work presented here demonstrates that TNFa and IL -la  induce the 
phosphorylation, and thus the presumed activation, of the three main MAP Kinases, 
p38, ERK and JNK, in HT-29 intestinal epithelial cells. This is a novel, although not 
unexpected finding, as pro-inflammatory stimuli such as TNFa and IL -la  are known 
to induce MAP Kinase activity in a number of systems (Saklatvala et al., 1998; 
Tibbies and Woodgett, 1999; Cario et al., 2000). The MAP Kinase cascades are 
activated at times of stress and inflammation, and in this model, TNFa and IL -la  
promote an apparently classical inflammatory response. It is worth pointing out the 
difference in the kinetics of activation of the MAP Kinases by TNFa and IL-la. IL- 
l a  causes a slightly later and more prolonged phosphorylation of all three MAP 
Kinases when compared to that seen by TNFa. This highlights the existence of 
differing pathways downstream of their respective receptors despite the perceived 
similarity of their induced responses (Saklatvala et al., 1998; Toshina et al., 2000).
Of more interest is the functional outcome of MAP Kinase activation with regards to 
COX-2 expression in this system. To investigate this, well known inhibitors of the 
ERK signalling pathway (PD98059) and the p38 pathway (SB203580) were used. 
PD98059 is an inhibitor of MEK1/2 which is the kinase upstream of ERK1/2 and 
which activates it by catalysing its phosphorylation. It is regarded as a specific 
inhibitor (Davies et al., 2000) and in this work behaved in a predictable way. Pre­
incubation with lOpM PD98059 significantly abrogated the TNFa induced
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phosphorylation of ERK1/2 (Figure 7.3) as would be expected. The results with the 
inhibitor of the p38 pathway were more complex.
SB203580 is a pyridinyl imidazole compound which inhibits p38 by competitively 
binding to the ATP binding site (Young et al., 1997; Cuenda et al., 1995). It is 
termed a specific inhibitor although there is evidence that it can inhibit lymphocyte 
kinase and GSK-3P, although at IC50S two orders of magnitude higher than their 
effects on p38 (Davies et al., 2000). Of greater relevance are reports demonstrating 
the inhibition of PKBa (Davies et al., 2000; Lali et al., 2000) and some members of 
the JNK family (Dean et al., 1999) at concentrations similar to those needed to 
inhibit p38. Such findings make it necessary to interpret with care results using this 
compound.
A second note of caution concerns the mechanism of action of SB203580. Most 
papers just use the assumption that SB203580 is a specific p38 inhibitor, but the 
literature reveals heterogeneity in the results of a variety of assays used to document 
its inhibition of p38 when this is assessed (see Table 8.1). Firstly, regarding using 
phosphorylation of p3 8 as a marker of its activity, as SB203580 binds to the separate 
ATP binding site on p38 and not to its phosphorylation site, there is no apparent 
reason why it could not bind and prevent activity without preventing 
phosphorylation. Such a mechanism would support the results presented here where 
SB203580 does not alter phosphorylation of p38 at a concentration subsequently 
shown to inhibit COX-2 expression and PGE2 production. However, although there 
is support for this hypothesis in the literature (Cuenda et al., 1995; Young et al., 
1997), it is not universal (Frantz et al., 1998).
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E ffec t o f SB203580 on 
m a rk e r  o f p38 








(Young et al., (Dean et al., pff|
1997) 1999)
...........
Phosphorylation of p38 Yes No
p38 Kinase assay






Phosphorylation ofhsp27 Yes .  . .  : ^ j
Inhibition of “p38 
dependent” event
Yes Yes Yes Yes
Table 8.1: Table demonstrating the heterogeneity o f results concerning the effect 
o f the p38 inhibitor, SB203580, on markers o f p38 activation
The second potential marker of p38 activity is a direct in vitro kinase assay 
employing a specific action of p38. Two assays are commonly used; the 
phosphorylation and activation of MAPKAP2, and the phosphorylation and 
activation of ATF-2. Again there is heterogeneity of the published results -  see 
Table 8.1. Young et al found that SB203580 pre-incubation did not inhibit p38 
kinase activity, although the addition of the compound to the kinase assay after the 
necessary washes did cause inhibition (Young et al., 1997). In the work here, neither
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pre-incubation with SB203580 alone, or pre-incubation with subsequent repeated 
addition of SB203580 to the kinase assay resulted in inhibition.
The third potential marker of p38 activity was phosphorylation of hsp27, a reaction 
catalysed by MAPKAP2 which in turn has been activated by p38. In all instances 
this demonstrated inhibition by SB203580, even in conditions of sole pre-incubation 
with SB203580 and no subsequent addition to the kinase assay reaction mixture, 
conditions which had shown apparent absence of inhibition of p38 kinase activity 
(Young et al., 1997; Paul et al., 1999).
Why is there such heterogeneity in results concerning p38 activity? Primarily, it is 
apparent that experimental conditions and techniques, as well assays used, make a 
significant difference to the results obtained. SB203580 is a competitive inhibitor 
which can be washed off. Therefore, in kinase assays, it may need to be added to the 
final reaction in some, although not all, circumstances. In these kinase assays, the 
broken cell lysates may not represent accurately the normal physiological function of 
the cell, with the natural milieu of the cell being significantly altered by the 
phosphatase inhibitors in lysis buffer. Secondly, there is some general consensus, 
and mechanistic logic, that the phosphorylation state of p38 is not necessarily altered 
by effective SB203580 binding.
In this work, SB203580 caused inhibition of COX-2 expression and marked 
inhibition of PGE2 production although inhibition of p38 activity could not be 
demonstrated. This was not due to the SB203580 vehicle (DMSO) (Figures 5.2, 
5.4C and 5.6) but may be due to other actions of SB203580. However, there is
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evidence to support the statement that SB203580 was still likely to be inhibiting p38, 
despite that not being clearly demonstrated, because of the technicalities of the 
assays used.
As already mentioned, both p38 inhibition with SB203580 and ERK1/2 inhibition 
with PD98059, altered COX-2 expression and functional activity. Starting with the 
actions of presumed p38 inhibition by pre-incubation with SB203580, this caused a 
minor concentration dependent inhibition of TNFa induced COX-2 mRNA and 
protein. It did however cause a significant inhibition of TNFa induced PGE2 
production with an IC50 of 1.5pM. This is in agreement with other published work 
showing that cytokine induced COX-2 expression was decreased by p38 inhibition in 
renal (Cheng et al., 2000), HeLa (Ridley et al., 1998), macrophage (Hwang et al., 
1997; Paul et al., 1999) and cardiac (LaPointe and Isenovic, 1999) cell lines. The 
site of this regulatory effect has been investigated with it being demonstrated that, 
for IL-1 stimulation of HeLa cells, SB203580 inhibits induced PGE2 production but 
not induced arachidonic acid release, implying a COX-2 dependent mechanism 
(Ridley et al., 1998). This group have gone on to show that p38 dependent pathways 
regulate COX-2 at the point of its mRNA stability in their model (Ridley et al., 
1998; Lasa et al., 2000). Indeed, they demonstrate that a 123 nucleotide fragment of 
the COX-2 3'-UTR was necessary and sufficient for this regulation and identified a 
protein similar to the AU-rich element/poly(U) binding factor 1 (AUF-1) (Lasa et al., 
2000). Such a mechanistic action of p38 inhibition would explain the observation 
that SB203580 can inhibit cytokine induced COX-2 expression but over-expression 
of p38 alone does not cause COX-2 induction as, in the absence of constitutive 
expression, there would be no COX-2 mRNA to stabilise (Hwang et al., 1997). It
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also provides a mechanism for the well documented inhibition of COX-2 by 
dexamethasone (Lasa et al., 2001).
It was shown in chapter 6 how wortmannin can regulate COX-2 using mRNA 
stability in this intestinal epithelial cell system. However, in that case and in the 
work cited here (Ridley et al., 1998; Lasa et al., 2000), the responses to the 
regulatory element (wortmannin and SB203580 respectively) showed similar 
concentration dependent reponses for the actions on COX-2 mRNA, protein and 
PGE2 production. For the regulatory action of SB203580 on TNFa induced COX-2 
in HT-29 cells, the inhibition is much more marked at the level of PGE2 production. 
This implies a predominantly post-translational effect of SB203580, while not ruling 
out an alteration of COX-2 mRNA stability to account for the slight decrease seen in 
COX-2 mRNA at higher concentrations of SB203580. Although there are many 
possible sites of potential post-translational regulation, one proposed by LaPointe et 
al is that of substrate availability (LaPointe and Isenovic, 1999). They demonstrated 
that IL-ip induces both COX-2 and CPLA2 in cardiac myocytes and that the latter is 
also inhibited by p38 inhibition. This would potentially decrease the substrate pool 
available for the induced COX-2 resulting in a disproportionate decrease in PGE2 
production compared to the amount of COX-2 protein present on western blot 
analysis. These workers make a similar point for ERK1/2 inhibition with PD98059 
which would also seem appropriate for the results presented here.
Regarding ERK1/2 inhibition, there is generally less literature than that with p38 
inhibition. This is probably because p38 represents a better potential anti­
inflammatory target for new drugs than does ERK1/2 which is intrinsically involved
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in cell proliferation (Saklatvala et al., 1998; Herlaar and Brown, 1999). However 
there is evidence that ERK1/2 inhibition does inhibit COX-2 expression and 
functional activity (Hwang et al., 1997; LaPointe and Isenovic, 1999). This work 
has similar results as for p38 inhibition, with PD98059 having a marked effect at the 
level of PGE2 production which seems disproportionate to its effects on COX-2 
protein and implies a post-translational mechanism. Furthermore, there is a 
paradoxical increase in TNFa induced COX-2 mRNA, similar to the opposing 
effects of IFNy on COX-2 at mRNA as opposed to protein and product levels 
(chapter 5).
Finally, with respect to the use of ERK1/2 and p38 inhibitors, there is evidence in the 
literature that there can be a combinatorial effect with their use (LaPointe and 
Isenovic, 1999; Rutault et al., 2001). However, in this work, such effects were not 
observed. This is somewhat surprising as it might be expected if the MAP Kinase 
pahways were running in parallel as is classically proposed.
Regarding the results investigating the effect of PI 3-Kinase inhibition and MAP 
Kinase activation, there were two hypotheses being considered. Firstly, there is 
evidence in some, but not all cell lines, that MAP Kinase activation is PI 3-Kinase 
dependent (Jiang et al., 2000; Yamaki et al., 2000; Yamboliev et al., 2000). In this 
case wortmannin would be expected to inhibit TNFa induced MAP Kinase 
activation. Alternatively, if the effect of wortmannin at increasing COX-2 
expression and activity is mediated via a MAP Kinase dependent pathway, it would 
be expected that wortmannin would potentiate the activation of MAP Kinases by 
TNFa. The results presented here demonstrate no alteration of TNFa induced MAP
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Kinase activation in the presence of pre-incubation with wortmannin. This would 
apparantly negate both hypotheses and implies that, in HT-29 intestinal epithelial 
cells, PI 3-Kinase and MAP Kinase pathways are running parallel to each other. It 
also seems unlikely that PI 3-Kinase activation is MAP Kinase dependent as PI 3- 
Kinase activation is seen within 30 seconds of TNFa stimulation. This would be 
supported by other work which always shows PI 3-Kinase to be upstream in models 
where MAP Kinase is PI 3-Kinase dependent with no evidence of the converse 
relationship.
The final piece of work in this chapter concerns the phosphorylation and inactivation 
of GSK-3a/p by TNFa and the signalling pathways involved. As mentioned in the 
introduction, the GSK signal is involved in colorectal carcinogenesis where it is an 
anti-oncogenic signal resulting in p-catenin degradation as part of the Wnt pathway. 
GSK is inactivated by phosphorylation and this phosphorylation has been shown to 
be PI 3-Kinase dependent (Cross et al., 1995), thus further supporting the pro- 
proliferative actions of PI 3-Kinase (Roymans and Siegers, 2001). Figure 7.9 
demonstrates that TNFa and IL -la  phosphorylate GSK-3a/p in a time dependent 
manner with the phosphorylation caused by IL -la  being more prolonged, as seen 
with the MAP Kinases. IL-13, which is known to activate PI 3-Kinase in HT-29 
cells, acts as a wortmannin sensitive positive control (Wright et al., 1997). 
Interestingly, wortmannin only caused a partial abrogation of the TNFa induced 
GSK-3a/p phosphorylation, which was surprising and implied a second pathway 
mediating the TNFa signal. Work using the ERK1/2 inhibitor PD98059 showed that 
it too caused a partial abrogation of the GSK-3a/p phosphorylation caused by 
TNFa. When combined, TNFa induced GSK-3a/p phosphorylation was completely
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inhibited. This implies that this process is dependent on PI 3-Kinase and ERK1/2 
dependent signals which run in parallel. This supports the previous conclusion that 
the MAP Kinases, and in this case ERK1/2, are not downstream of PI 3-Kinase but 
are independent signalling pathways in this context. Furthermore it highlights a role 
for ERK1/2 in GSK-3ot/p inactivation by phosphorylation which has not previously 
been demonstrated. This is, however, perhaps unsurprising given the known 




A number of general points are briefly made below concerning the work presented 
here. They represent general issues raised by the work, rather than specific points 
which have already been discussed.
8.1 Experimental Model
The experimental model used in this work was in vitro culture of transformed 
intestinal epithelial cell lines and the assessment of pro-inflammatory cytokine 
induction of COX-2 expression as well as intra-cellular signalling responses. In this 
context COX-2 appears to be behaving as an acute pro-inflammatory agent -  induced 
by pro-inflammatory cytokines, inhibited by Th2 immunoregulatory cytokines and 
having its expression regulated by the MAP Kinases and NFkB. Although allowing 
detailed manipulation of the regulatory pathways involved, the experimental model 
lacks the ability to pursue the more complex points concerning COX-2 such as a 
potential anti-inflammatory role in chronic disease. The system may also over­
estimate the signalling pathways activated by TNFa and IL -la  as transformed cell 
lines are believed to be more sensitive for activation of signalling cascades 
(Saklatvala et al., 1998).
8.2 Drawing Conclusions and Making Comparisons
One feature of the literature that is obvious is the heterogeneity in results between 
different models and cell types. It is therefore important that, although much can be
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learnt from work in other systems, results must be confirmed in a system relevant to 
the physiological system of interest -  in this case the gastro-intestinal tract. 
Furthermore, because of the limitations of transformed cell lines, albeit human ones, 
work should ideally be repeated and validated in similar systems. There may be a 
common theme in the literature, such as TNFa or IL -la  inducing COX-2 which is 
shared in many systems. Other points, such as the regulatory actions of IFNy, are 
extremely system dependent. The conclusions outlined in Figure 8.1 are therefore 
from this work and similar work in gastro-intestinal systems, rather than using other 
models which may not be relevant.
On a similar note, conclusions from this work are strongest when using a variety of 
techniques, such as the TNFa activation of PI 3-Kinase, or when consistent results 
are obtained using similar inhibitors. As is seen with the PI 3-Kinase inhibitors, 
wortmannin and LY294002, this is not always the case making the drawing of clear 
conclusions more difficult.
8.3 Complex Interactions of Signalling Pathways
As seen in Figure 8.1 there are many regulatory elements in an important gene such 
as COX-2 with the possibility that there may be interactions between them. There is 
also an element of redundancy and the possibility that stimulation may activate 
opposing signals. Such complexities make drawing detailed conclusions difficult. 
They also make the teasing out of the individual pathway effects challenging and 
often limited by the available molecular tools.
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8.4 Similarities Between TNFa and IL -la
In all of the work presented here, TNFa and IL -la  have the same biological 
outcome, albeit at times with differing kinetics. However in human disease the 
targeting of TNFa for therapies has proved far more successful than targeting IL -la  
and the reasons for this have not been particularly clear. The two cytokines may 
share targets, but have differing pathways for activating them, and thus the reason 
for one being a superior therapeutic target may lie in the complexities of intra­
cellular signalling.
8.5 Application to Gastroenterological Diseases
In the detailed discussions associated with each chapter there has been little 
comment on the implications for gastro-intestinal diseases. This is partly because 
work in such a model is quite separated from the complex physiological systems in 
the human body. However there are some general points that can be made:
1 Firstly, in acute inflammation all the results here continue to support a pro- 
inflammatory role for COX-2 in the gut although this may not be true for 
chronic inflammation.
2 Secondly, as it is likely that COX-2 inhibition is likely to be beneficial in the 
chemoprevention of colorectal carcinoma, this work identifies more potential 
methods of COX-2 inhibition including the p38 and ERK1/2 MAP Kinases.
3 Thirdly, from the point of view of possible therapeutic targets of the future, 
there is the question of specificity. Basic science research, when applied to a 
clinical speciality such as gastroenterology, often states as its aims the 
gaining of a more precise understanding of molecular pathophysiology and
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the subsequent development of specific therapeutic modalities. Although the 
former is most definitely true, the latter point needs to be developed. 
Therapy involving inhibition of TNFa in Crohn’s disease is regarded as a 
specific molecular therapy. However, it can be seen here that TNFa results 
in the activation of multiple and potentially conflicting pathways in the 
intestinal epithelium alone, disregarding the infiltrating immune cells seen in 
IBD. Such therapies are not as isolated and precise as is often stated and it is 
worth pointing out that drugs such as 5-ASA, with multiple and not fully 
understood mechanisms of action, still provide a mainstay of management of 
IBD. Thus, although it is vital to fully understand the molecular processes of 
disease, it is not always necessary for a therapy to be precise with only one 
mechanism of action.
4 The COX pathway is highly complex with multiple points of external and 
auto-regulation. Downstream prostaglandins, as well as upstream 
arachidonic acid liberation by phospholipases, will play a physiological role. 
Thus, isolating the precise function of COX expression in complex 











Figure 8.1: Schematic representation o f results concerning C0X2 
regulation in intestinal epithelial cells 
This schema draws predominantly on results from this work with 
relevant other results from other work being in dotted boxes. Red 
represents a positive activation and blue an inhibitory inactivation.
Conclusions and Future Work
9 Conclusions
• COX-2 can be induced in intestinal epithelial cells by the pro-inflammatory 
cytokines TNFa and IL-1 a  or p
• This induction is regulated at many points including transcription and stability of 
mRNA, translation into protein and subsequent activity, and the prostaglandins 
produced. Regulation at these different points may be contrasting at each level.
• The products of COX-2 regulate its expression in opposing ways, as can IFNy.
• Th2 cytokines, IL-4 and IL-13, down-regulate induced COX-2 as well as 
activating PI 3-Kinase
• PI 3-Kinase has a regulatory role on induced COX-2, which appears to be 
inhibitory, although the evidence is conflicting.
• There is strong evidence that TNFa activates PI 3-Kinase in intestinal epithelial 
cells. This is supported by data that IL -la  has a similar action.
• Both TNFa and IL -la  also activate the three major MAP Kinases in a PI 3- 
Kinase independent manner. They both also inactivate GSK-3a/p which is 
partially sensitive to PI 3-Kinase inhibition or ERK1/2 inhibition and completely 
inhibited when these inhibitors are used in combination.
• ERK1/2 and p38 have a post-transcriptional inhibitory role on induced COX-2 
expression.
• In intestinal epithelial cells the activation of multiple signalling pathways by Thl 
cytokines, and the complex regulation of induced COX-2, have important 
implications for gastro-intestinal disease which are only beginning to be 
understood.
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10 Future Work
This work has been fortunate to coincide with a great expansion of interest in intra­
cellular signalling in clinically relevant conditions. In making some novel findings 
regarding the role of signalling pathways, and PI 3-Kinase in particular, as well as 
pointing out the complexities of COX-2 expression and regulation within the gastro­
intestinal tract, it mirrors reasonably accurately the current state of this area of 
research. However, there is much to be done to convert these initial findings in a 
simple system into a more cogent understanding of the role of signalling and COX-2 
expression in gastrointestinal physiology and disease. This includes:
• Persevering with methods to study COX-2 expression, and the activation of 
signalling pathways, in fresh human tissue as opposed to transformed cell lines.
• Supporting the work presented here with work in other models using other 
techniques. In particular, regarding the work based on PI 3-Kinase inhibition, 
other techniques should be used such as molecular inhibition using dominant 
negative or constitutively active transfected constructs.
• This area of COX-2 research concentrates on the enzyme rather than its products, 
which are the focus of its functional activity. Prostaglandins, and their 
differential synthesis and regulation, warrant more research.
• Models need to be developed which differentiate acute inflammation from 
chronic inflammation, and these need to be specific to the gut. It is highly likely 
that the functional role of COX-2 in the acute and chronic situation is different.
• Clinical research gastroenterologists need to be aware of research into intra­
cellular signalling as it is likely to provide future therapeutic options, albeit not 
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Appendix A: Cytokine induced N F kB binding activity is not altered by
PI 3-Kinase inhibition
HT-29 cells were stimulated with TNFa or IL-1 (both at 5ng/ml for 30 
mins) with or without 30 mins pre-treatment with two independent PI 3- 
Kinase inhibitors, wortmannin (lOOnM) or LY294002 (25pM). Nuclear 
extracts (5pg) were tested for NFkB binding activity by EMSA. Pre­
treatment with PI 3-Kinase inhibitors did not alter cytokine induced 
activation of NFkB binding activity. Blot is from a single experiment 
but is representative of at least three others. This work was carried out 
by Maria Pia Russo and Christian Jobin at the University of North 
Carolina, Chapel Hill as part of a collaborative study.
